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Introduction
In the Netherlands, approximately 74.500 patients will be diagnosed with cancer every 
year. Hence, 2.5% of the Dutch population will be treated for cancer1. Many types of 
cancer can be treated effectively with chemotherapy, radiotherapy or a combination of 
both. Unfortunately such therapy affects all rapidly dividing cells whether neoplastic or 
not. Consequently, the lining of the oral cavity is at high risk of side effects. Mucositis 
is the medical term that is used to refer to oral complaints that can range in severity 
from a red, sore mouth to open sores that can be severe enough to prevent eating and 
drinking. A basic definition of mucositis is the development of erythema and ulceration 
of the mucosa following chemotherapy with or without irradiation for treating cancer2. 
Oral mucositis markedly influences the physical and psychosocial wellbeing of patients 
undergoing cancer therapy. As oncology nurses play a critical role in improving patient 
outcomes related to oral mucositis 3, knowledge and research regarding oral mucositis 
forms a crucial part of their activities.
Managing oral mucositis is as important as managing, fatigue, nausea and vomiting, 
and many other side effects that affect patients with cancer. Oral mucositis is one of the 
most frequent causes of treatment delay and dosage reductions in cancer therapy2. 
Patients’ quality of life can also be affected markedly by pain, infection, altered nutri-
tion, and decrease in oral function4, 5. 
Incidence
The incidence of oral mucositis varies widely based on the specific type of cancer and 
the modality used for treatment. Mucositis often is associated with radiotherapy of 
head and neck cancer and with high-dose cytostatic chemotherapy regimens, espe-
cially those used in haematopoietic stem cell transplantation. According to Elting and 
colleagues6 mucositis also occurs with the use of myelosuppressive chemotherapy for 
solid tumours. Epstein and Schubert7 found that 30%–75% of chemotherapy patients 
experienced oral mucositis. The frequency associated with head and neck radiotherapy 
and haematopoietic stem cell transplantation exceeds 90%8.
Pathology
Sonis9 postulated that the pathobiology of oral mucositis consists of five phases (see 
Figure 1).
The first phase is initiation which occurs immediately after radiotherapy or chemothe-
rapy is delivered. Direct damage to the epithelial cells injures the DNA and results in the 
death of a small fraction of cells. 
The second phase of the oral mucositis model is upregulation and message generation. 
During this phase of oral mucositis, multiple events are known to occur simultaneously. 
Chapter 1            General  introduction 
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Inflammatory cytokines are released that cause further tissue injury and cell death. The 
mucosa starts to thin, and erythema may be present. Tumour necrosis factor-alpha 
(TNF-α), a proinflammatory cytokine, is a protein produced by monocytes and macro-
phages that is increased because of inflammation. TNF-α has the ability to cause necro-
sis by interfering with blood flow, it induces cytotoxic inflammation, and regulates the 
immune responses.
The third phase is signalling and amplification, which consists of direct damage to cells 
and escalation of the process initiated by proinflammatory cytokines. In this phase, 
TNF-α activates additional cytokines, creating a feedback loop that enlarges the biolo-
gical effects. Most of the damage occurs below the level of the mucosa.
During the fourth phase, the ulceration of oral mucositis is the most significant to both 
patient and caregiver. Loss of mucosal integrity produces lesions that can be extremely 
painful. Breaks in the mucosal epithelium may provide portals of entry for bacteria, vi-
ruses, and fungi located on the surface. Bacterial cell wall products induce immune cells 
to produce cytokines, leading to further inflammation and apoptosis. 
Healing forms the final phase when the epithelial cells that border the ulcer begin to 
migrate into the wound bed where they proliferate. The tissue will start to form layers, 
and the normal oral microbial flora will re-establish itself. 
 
Figure 1:  Phases of Mucositis
Based on Sonis 2004
Clinical presentation of oral mucositis
Some patients treated for cancer never develop oral mucositis, and not every treatment 
causes oral mucositis. Patterns of oral mucositis vary with the type and dosage of can-
cer therapy10. 
The dose, intensity, duration, and frequency of chemotherapy administration increase 
the risk for oral mucositis. Ulceration among patients who develop oral mucositis follo-
wing stomatotoxic chemotherapy tends to become clinically apparent about one week 
after treatment and severity generally progresses to a peak roughly 14 days after the 
start of therapy. Healing will occur within 2-3 weeks after chemotherapy is ended7. 
After chemotherapy, mild erythema and oedema of the oral mucosa develops first, fol-
lowed by dryness of the mouth and a burning sensation in the lips. Ulcerations occur 
at the lateral and ventral tongue, buccal mucosa, and soft plate. The ulcerative stage is 
painful and affects nutritional intake while speaking becomes difficult 11. Severe pain 
often requires opioid intervention12. Chronic pseudomembrane can also be present, 
with dry, red buccal mucosa and a reddened, swollen, shiny, dry, cracked tongue13. 
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The degree and duration of oral mucositis in patients who receive head and neck ra-
diation therapy are influenced by the radiation source, cumulative dose, dose inten-
sity, and volume of radiated tissue or fractionation14. Patients who receive head and 
neck radiation therapy tend to develop erythema during the second week of therapy in 
conjunction with a total dose of approximately 2,000 cGy and symptoms peak around 
the fifth or sixth week of radiation therapy. Severity increases as the dose increases, 
with the worst mucosal reactions associated with total doses ranging from 5,000–6,000 
cGy15. Healing then takes approximately 2-3 weeks16. It is not uncommon for patients 
receiving radiotherapy for cancer of the month to have severe ulcerative oral mucosi-
tis for 5-7 weeks12. As with chemotherapy-induced mucositis, that seen with radiation 
therapy initially presents as redness and swelling. The mucosa then becomes denuded, 
ulcerated, and covered with a white pseudomembrane. Lesions are limited to tissues in 
the field of radiation 11. Pain, burning, and discomfort are felt, swallowing and speaking 
become difficult. Reduction in salivary flow is related to the dose and duration of radi-
ation therapy13. 
An oral assessment is an important first step in the management of oral mucositis and 
objective (erythema, lesions, oedema), subjective (pain or sensitivity, dryness), and 
functional aspects (voice, swallowing, chewing) need to be taken into account.
A major obstacle to mucositis research has been the lack of an objective scoring system 
for mucositis that is universally accepted. Instead, individuals and groups have develo-
ped a variety of different scoring systems, often with different objectives. 
The management of oral mucositis 
Nurses are the primary advocates for patients, and play a central role in preventing and 
managing oral mucositis and reducing its burden on patients. Oral care is an essential 
component of an oral mucositis management programme. 
Assessment
Assessment of oral mucositis is the first step in the nursing process. The primary goal 
of the nursing assessment of the oral cavity is to identify changes in the oral mucosa, 
recognize the presence of infection, and describe the effect that oral mucositis has on 
patients’ functional status. Using systematic, regularly scheduled oral assessments with 
a reliable and valid rating scale specifically designed to assess oral mucositis among 
patients with cancer will allow oncology nurses to better recognize, monitor, and do-
cument the progression of oral mucositis and institute nursing interventions to ease 
patients’ discomfort3. The scale adopted by the World Health Organization (WHO) is 
the most widely used and was developed to describe toxicities associated with a par-
ticular chemotherapeutic regimen or radiation therapy. The WHO scale addresses all 
three components of oral mucositis: objective signs (such as ulceration), subjective 
  15
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Grade 1: 
Soreness and erythema 
Grade 2: 
Erythema and or lesions; patient can swallow solid diet 
Grade 3: 
Lesions with or without extensive erythema; patient is able 
to swallow liquid but cannot swallow  solid diet. 
Grade 4: 
Mucositis to the extent that patient is not able to tolerate 
even liquid diet. 
http://www.cdc.gov/nchs/ppt/icd9/att_mucositis_sep05.ppt
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symptoms (such as soreness), and functional disturbances (such as inability to eat). This 
scale is often used to describe the different stages of oral mucositis. The WHO scale is 
widely regarded as the gold standard despite the fact that the instrument was never 
tested for its reliability. Indeed there are many other tools described in the literature. 
The severity of oral mucositis is graded from 0, no mucositis, to 417 and grade 1 and 2 
of the WHO can be compared with the upregulation and message generation phases 
while WHO grade 3 and 4 signal the ulceration phase.
To assess the development and severity of oral mucositis nurses need a valid and relia-
ble assessment tool which is easy to interpret and with clearly understood parameters, 
an instrument that is comfortable for the patient and feasible in practice. Assessment 
should include thorough examination of the oral cavity, including lips, tongue, oral mu-
cosa, gingival and palate evaluating the presence of erythema, oedema and lesions. 
Pain is one of the most distressing symptoms experienced by patients hence the use of 
a pain scale is an essential element of oral mucositis assessment.
However, insight into the validity and reliability of the large number of instruments 
available in the literature is incomplete and assessment tools are often not used in nur-
sing care thus undermining the quality of assessment and preventive care18. 
Management
Systematic provision of oral care is probably more effective than any specific agents 
or devices in ameliorating the distress caused by oral complications.  A vast number 
of agents have been studied for their potential usefulness in the prevention and treat-
ment of mucositis, but none is highly effective. A 2006 Cochrane review of 29 interven-
tions for the prevention of cancer treatment-related mucositis indicated some evidence 
of benefit for 8 agents including amifostine, antibiotic pastillea or paste, benzydamine, 
hydrolytic enzymes, vitamin E, cryotherapy, povidone iodine and, last but by no means 
least, oral care19. However most interventions involved medicines which require pres-
cription and only few, specifically oral care, cryotherapy and several mouthwashes, can 
be incorporated into daily nursing practice. 
Frequency, consistency, and quality are important factors in oral care 20-24. Yet, published 
reports on the use and efficacy of oral care guidelines and protocols do not offer detai-
led guidance because the agents used and the frequency of administration vary widely 
and evidence for recommendations is often not provided. Assessment and criteria used 
to measure efficacy of oral care have been inconsistent. There is a lack of evidence for 
the current care given by nurses not only in terms of effective assessment, but also with 
respect to prevention and non-pharmacological treatments. Despite of the availability 
of various guidelines and systematic reviews, their place in practice is limited and their 
quality remains to be determined. 
Moreover it is not clear which care nurses actually provide to patients at risk for oral mu-
cositis nor which knowledge and skills they have in relation to the available evidence. 
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Finally, only a few studies have investigated what nurses actually know about oral care 
and none were found that reported practice improvement projects or whether know-
ledge and skills improve with oral care education sessions. In other areas such as pain 
management for patients with cancer, educational programmes designed to update 
knowledge in order to change pain management practices and patient outcomes were 
offered to nurses and were effective25.
Aim of the thesis
The aim of this thesis was to make an inventory of, and to evaluate, different aspects of 
current nursing practice in the management of oral mucositis.
More specifically, we aimed to: 
•	 describe	 current	 nursing	 practice	 and	 practice	 improvement	 in	 relation	 to	 oral
 mucositis directed care in haematology nursing 
•	 evaluate	available	evidence	for	preventive	care	and	treatment	of	oral	mucositis	and
 to evaluate guidelines in general oncology care.
The outline of the thesis 
Part 1
Chapters 2 to 5 describe current nursing practice and practice improvement in haema-
tology nursing.
A survey was undertaken of European transplant centres to gain a better insight into 
current nursing practice for the management of oral mucositis. The responses of 46 
haematopoietic stem cell transplantation centres in 16 countries to this survey are re-
ported in Chapter 2. To observe signs and symptoms of oral mucositis nurses need a 
valid, reliable and use-friendly assessment instrument. In Chapter 3 a systematic review 
was undertaken to summarize the scoring instruments that were available in the lite-
rature, and the development of a new instrument Oral Mucositis Nursing Instrument 
(OMNI)* was undertaken. To test the reliability of the OMNI, pairs of experienced nurses 
assessed the oral cavity of patients. The usability of the instrument was evaluated with 
a questionnaire. Chapter 4 investigated the responsiveness of the OMNI using the Guy-
att’s Responsiveness Index and the Receiver Operating Characteristic.
Chapter 5 investigated whether knowledge and skills about oral care improve when 
education is provided for nurses in charge of patients who are at risk for oral mucosi-
tis. This intervention study consisted of a baseline test on the knowledge and skills of 
nurses in the haematology wards of two different hospitals. Oral care education ses-
sions were given in one hospital and follow-up tests were performed in both hospitals. 
* The OMNI was originally christened the Nijmegen Nursing Mucositis Scoring System, (NNMSS). 
 For purpose of readability, we used ONMI throughout the text of this manuscript. 
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Part 2
To investigate evidence and guidelines of oral mucositis in general oncology care se-
veral studies were carried out.
A number of reliable instruments are available to assess oral mucositis, but none is 
universally acceptable. A collaboration of multi-disciplinary experts from Europe was 
formed to formulate recommendations on oral mucositis assessment, based on a syste-
matic literature review and expert experience. The results are presented in Chapter 6.
Chapter 7 describes a systematic review of the effectiveness of mouthwashes for the 
prevention of chemotherapy-induced oral mucositis and reports a meta-analysis on the 
effectiveness of chlorhexidine. 
To investigate the evidence for oral mucositis nursing care, the quality of guidelines and 
systematic reviews for the prevention and treatment of oral mucositis was assessed, and 
reported in Chapter 8. The Appraisal of Guidelines for Research and Education (AGREE) 
instrument was used to assess the quality of the guidelines and the Overview Qua-
lity Assessment Questionnaire (OQAQ) was used for the quality of systematic reviews.
The appendix presents the development and testing of the national guideline “Oral 
Mucositis of Patients with Cancer”.
Finally, in Chapter 9, the main findings, strengths and limitations of this thesis are sum-
marised and recommendations for future research are given.  
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Abstract
Oral mucositis (OM), which occurs in many patients with hematologic malignancies tre-
ated with high-dose therapy and stem cell transplantation, is associated with substan-
tial clinical, economic, and quality-of-life (QOL) consequences. It has been associated 
with an increased need for total parenteral nutrition and opioid analgesics, prolonged 
hospital stays, and increased risk of infection. The research subgroup of the European 
for Blood and Marrow Transplantation Nurses Group surveyed nurses at transplantation 
centres for their thoughts about the clinical, QOL, and economic consequences of OM; 
tools for assessing OM; strategies for preventing and treating OM; and the need for the 
development and implementation of treatment guidelines. The responses from 46 cen-
tres, in 16 countries, indicated that most nurses (91%) believe OM has a large effect on 
patients' QOL. Nurses are not highly satisfied with current treatments for OM, but they 
believe the discomfort is reduced with oral care protocols and mouthwashes. Oral mu-
cositis is routinely and frequently assessed, however there are inconsistencies in how it 
is managed. Most centres used unpublished, centre-specific guidelines, and the survey 
found that most nurses agreed that published national guidelines would be valuable 
for standardising the assessment and management of OM.
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 Introduction
Oral mucositis (OM) is a major focus of nursing care in bone marrow transplantation 
(BMT) centres. Its incidence varies, depending on the chemotherapy regimen and the 
treatment modality, but it is especially common and severe in patients who undergo 
haematopoietic stem cell transplantation (HSCT), because of the high-dose, myeloabla-
tive chemotherapy used for conditioning. The rate of severe OM (grade 3 or 4) exceeds 
60% in most reports on patients who receive total body irradiation, and it is 30% to 
50% even without total body irradiation1. Early data from the Prospective Oral Mucosi-
tis Audit indicate that OM requiring treatment (grades 2-4) occurs in more than 60% of 
patients with haematologic malignancies who undergo HSCT2.
Oral mucositis can range in severity from soreness and erythema to severe ulceration, 
which penetrates to the submucosal lining. Healthcare professionals tend to focus on 
the strict clinical definition of OM, which refers to erythema and ulceration; however, 
patients tend to express most concern about symptoms such as pain and xerostomia, 
and other oral cavity changes3. In a series of interviews of 38 patients with haematologi-
cal malignancies who underwent BMT, 79% reported oropharyngeal changes, most fre-
quently oral pain, sores, tender or sensitive mouth, and thick mucus4. Among all study 
participants, 42% rated OM as the single most debilitating complication of their trans-
plant, far ahead of the second most troublesome complication, nausea or vomiting.
Because it disrupts the function and integrity of the oral cavity, OM can substantially 
decrease quality of life (QOL) and may also increase morbidity5. OM can be associated 
with severe pain, which can lead to cachexia, anorexia, dehydration, and severe mal-
nutrition. It is estimated that a large proportion of adults undergoing haematopoietic 
stem cell transplantation (HSCT) require feeding tubes and narcotic analgesics5. Severe 
OM causes impairment in functional activities such as eating, swallowing, and talking, 
which affect social interactions and emotional well-being6, 7. In addition, patients have 
attributed increased depression and sleep disturbances to OM8. Oral mucositis may 
also affect the risk of death in the transplant setting. In the first multicentre study to 
consider the impact of OM, Sonis et al. analyzed data on 92 patients undergoing BMT 
and found that each 1-point increase in OM severity on the Oral Mucositis Assessment 
Scale was associated with a nearly 4-fold increase in 100-day mortality9. More recently, 
Fanning et al. showed that in patients who underwent autologous HSCT for haematolo-
gical malignancies, severe mucositis was a significant risk factor for all-cause mortality 
and relapse mortality10. 
The multicentre study by Sonis et al. also showed that increasingly severe OM was as-
sociated with progressively worse morbidity and economic outcomes. Each 1-point in
crease in OM severity on the Oral Mucositis Assessment Scale was associated with a 2-fold 
increase in the risk of significant infection, 3 additional days of total parenteral nutrition, 
3 additional days of injectable narcotic analgesia, and 3 additional days in the hospital 
resulting in additional hospital charges9. There was a statistically significant association 
between the severity of OM and each of these outcomes. The mean hospital charge was 
higher among patients with ulceration than among those without OM (P = 0.06).
26
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Patients treated with myelosuppressive chemotherapy are already at increased risk of 
infection due to neutropenia, and breakdown of the mucosal barrier due to OM exa-
cerbates the incidence of bacteraemia and sepsis5, 11. For these and other reasons, OM 
is increasingly being recognised as a major dose-limiting toxicity. It can disrupt cancer 
treatment by requiring breaks in radiation therapy, reductions or delays in chemothe-
rapy, modifications in the selection of chemotherapeutic agents, or discontinuation of 
optimal cancer therapy5, 12.
Nurses are in a prime position to perform the day-to-day assessment of OM, and as 
such are integral to its management; moreover, they are the primary source of informa-
tion for patients concerning treatment options. In an effort to understand practice pat-
terns across Europe, in 2004 we surveyed nurses at European BMT centres to learn more 
about how they prevent and treat OM. This paper presents the results of the survey and 
their implications for improving nursing care of OM in the transplant setting.
Materials and methods
The research subgroup of the European for Blood and Marrow Transplantation Nurses 
Group (EBMT-NG) used a questionnaire to assess nurses' impressions of the manage-
ment of OM in adult patients with haematological malignancies who are undergoing 
either autologous or allogeneic bone marrow or peripheral stem cell transplant. This 
questionnaire was developed by adapting a survey of practices in oral care in children 
who are treated for cancer13. The questionnaire, which was distributed in October 2004, 
addressed:
•	Nurses'	impressions	of	the	QOL,	clinical,	and	economic	consequences	of	OM
•	Tools	for	assessing	OM
•	Strategies	for	preventing	and	treating	OM
•	Need	to	implement	and	use	guidelines	for	OM
Nurses at 100 European BMT centres were invited to participate. These centres were 
selected because they performed the most stem cell transplantations in 2004 and were 
members of EBMT. The research sub-group of the EBMT-NG encouraged participation 
and followed up with any nonresponders.
Results
There were responses from nurses from 46 centres in 16 countries: Italy (9), United King-
dom (6), Germany (5), Spain (5), Belgium (3), Sweden (3), Switzerland (3), Czech Repu-
blic (2), the Netherlands (2), Poland (2), Austria (1), Denmark (1), Finland (1), France (1), 
Ireland (1), and Slovenia (1). Most of the nurses (74%) surveyed had between 6 and 15 
years experience in caring for BMT recipients.
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Figure 2  Nurses’ perceptions of the effects of oral mucositis on patients’ quality of life (QOL).  
 
 
 
 
 
Table 1.  Treatment of oral mucositis (not including prevention measures) across centres by severity 
of oral mucositis  
 
 Centres that treat (%) 
Patients treated for OM WHO grade 1 or 2 WHO grade 3 WHO grade 4 
100% 33 54 70 
80%–99% 4 2 — 
60%–79% 2 13 — 
40%–59% 11 4 — 
20%–69% 9 2 4 
1%–19% 7 4 7 
0% 24 9 9 
No response 11 11 11 
 
Strategies for managing OM 
Nurses' impressions of QOL, clinical, and economic consequences of OM
Most nurses believed that OM affects the length of time that patients are unable to per-
form daily activities such as eating, drinking, talking, and receiving visitors (Figure 1). 
A majority (91%) also believed that OM has a major negative effect on patients' QOL 
(Figure 2). 
Figure 1: Nurses’ perceptions of the mean length of time patients were unable to perform everyday activities
 because of oral mucositis.
Figure 2:  Nurses’ perceptions of the effects of oral mucositis on patients’ quality of life (QOL).
 
Most respondents did not believe that OM influences the success of cancer therapy but 
did believe that it has clinically significant effects on the risk of secondary infections, 
the length of hospitalisations, and the costs of care (Figure 3).
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of oral mucositis  
 
 Centres that treat (%) 
Patients treated for OM WHO grade 1 or 2 WHO grade 3 WHO grade 4 
100% 33 54 70 
80%–99% 4 2 — 
60%–79% 2 13 — 
40%–59% 11 4 — 
20%–69% 9 2 4 
1%–19% 7 4 7 
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No response 11 11 11 
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Figure 3: Nurses’ perceptions of the effects of oral mucositis on patients’ clinical and economic outcomes. 
Assessment of OM by nurses and centres
Most nurses reported that they assess for OM routinely and often at their centres; 91% 
of centres assessed patients at least once a day, with 31% assessing them 3 or more 
times a day. Eighty-four percent of centres began their assessments at the start of tre-
atment, regardless of the condition of the patient’s mouth, and the others assessed pa-
tients only after OM had developed or they had had difficulty in swallowing or eating. 
Most nurses (70%) reported that they do not increase the frequency of assessments in 
patients with an increase in the severity of OM, possibly because the additional assess-
ments might add to the patient's pain.
Fifty-nine percent of nurses used standardised scales for assessing OM. The most com-
monly used scales are the World Health Organization Oral Mucositis scale, the Oral Mu-
cositis Assessment Scale, and the Oral Assessment Guide 14-16. Of the nurses surveyed 
for this study, 74% used the World Health Organization Oral Mucositis scale, 4% used 
the Oral Mucositis Assessment Scale, and another 4% used the Oral Assessment Guide. 
Almost all nurses agreed that the grade of OM has an effect on the initiation of both 
parenteral nutrition (94%) and narcotic analgesics (98%).
Inconsistent treatment across centres
Preventive care was routinely used in more than 90% of all patients who underwent ei-
ther allogeneic or autologous BMT, however, there was substantial variation on the tre-
atment of OM between centres. Only 70% of centres routinely implemented treatment 
for all patients with grade 4 OM, while 9% of centres reported that patients with grade 
4 OM were not treated at all (Table 1). A modest number of centres (33%) reported that 
they used early intervention and routine treatment at the first sign of oral ulcers in all 
patients with less severe OM.
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Table 1.: Treatment of oral mucositis (not including prevention measures) across centres by severity of oral 
 mucositis 
Strategies for managing OM
In the absence of effective measures for preventing OM at the time of this survey, oral 
hygiene methods were recommended to 87% of patients who underwent transplan-
tation; dental gels, antimicrobial rinses, and antibiotics were also frequently used. 
Methods for preventing and treating OM are shown in Table 2. Nurses identified that 
treating OM differed from preventing it, mainly with respect to the use of more fre-
quent rinsing, as well as greater use of narcotic analgesics and other pain management 
methods. Sixty-nine percent of nurses believed that controlling pain was an adequate 
means of treating OM, and 96% reported that they used narcotic or other analgesics for 
treating the pain. The duration of treatment with narcotic analgesics that was reported 
varied by the severity of the OM, with mild OM (grade 1) and moderate OM (grade 2) 
being treated for a mean of 2.4 days, grade 3 for 6.5 days, and grade 4 for 9.5 days.
Fewer than half of the nurses surveyed were aware of newer treatment options for OM. 
Keratinocyte growth factor was the best known, with 44% of nurses having heard of it, 
even though at the time of the survey it was only available in clinical trials. A third of 
nurses were familiar with Gelclair, a bioadherent gel, and L-glutamine, with 2% aware of 
the use of vitamin E in the management of OM.
Table 2.: Strategies for managing oral mucositis
1Satisfaction was rated on a scale of 1 to 5, with 1 being “not satisfied at all” and 5 being “extremely satisfied.” 
The mean score reflects the nurses’ satisfaction with both the prevention strategies and the treatment strate-
gies.
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Table 2.  Strategies for managing oral mucositis 
 
 Nurses using strategy (%)  
Strategy For prevention For treatment Mean satisfaction score1 
Oral hygiene 96 96 4.1 
Chlorhexidine 61 65 3.1 
Rinses-antimicrobial 46 63 3.1 
Antibiotics 41 50 3.3 
Rinses-bland 30 43 3.4 
Ice chips 22 35 3.3 
Granulocyte or granulocyte-macrophage 
colony-stimulating factor 
13 26 2.5 
Sucralfate 9 22 3.1 
Benzydamine 7 17 2.1 
Prednisone 7 15 3.6 
1Satisfaction was rated on a scale of 1 to 5, with 1 being “not satisfied at all” and 5 being “extremely satisfied.” 
The mean score reflects the nurses’ satisfac ion with both the prevention strategies and the tre ment 
strategies. 
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Guidelines for assessing, preventing, and managing OM
Most of the nurses (78%) surveyed thought that they, not physicians, have primary res-
ponsibility for implementing centre-specific guidelines. More than two thirds of the 
nurses agreed that national guidelines would be valuable in managing OM at their cen-
tre (Figure 4). 
Figure 4: Nurses’ perceptions of the value of national guidelines for managing oral mucositis. 
The key benefits cited included; standardisation of care (18%), implementation of evi-
dence-based guidelines in their practice (11%), and potential for common standards 
for comparative trials (7%). Eighty-eight percent of the nurses and centres routinely 
and consistently used guidelines or protocols for oral care; of these, 90% (78% overall) 
used centre-specific guidelines for managing OM and 15% used published guidelines. 
The survey questionnaire did not address whether the centre specific guidelines were 
adapted from or incorporated parts of the published guidelines. The 13% of nurses and 
centres that did not consistently use guidelines cited one or more of the following rea-
sons: little staff awareness of the existing guidelines (50%), current guidelines are out-
dated (50%), and current guidelines are impractical (25%).
Discussion and conclusions
Oral mucositis is a painful and debilitating complication in many patients treated with 
myeloablative conditioning therapy and BMT, and it can have serious clinical, economic, 
and QOL consequences. To gather information about current practice across Europe, 
we surveyed nurses about their perceptions of oral care at European BMT centres. The 
nurses agreed that OM has major effects on the QOL and the costs of care of patients 
who undergo BMT. The survey also found inconsistencies in the treatment of OM across 
centres and the need for a more standardised approach. Not all centres treated patients 
with grade 4 OM, a debilitating condition, while in contrast some centres used early 
intervention and initiated treatment at the first appearance of oral ulcers.
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These findings confirm observations by McGuire et al. about the need for a consistent 
and unified approach to performing OM assessments and the need for updated gui-
delines for assessment and treatment17. The survey respondents agreed that national 
evidence-based guidelines can help standardise the assessment, prevention, and treat-
ment of OM in European BMT centres. In 2004, the Multinational Association of Suppor-
tive Care in Cancer/International Society of Oral Oncology published evidence-based 
guidelines for preventing and treating chemotherapy-induced OM, which were based 
on a review by 36 panellists of the literature published between 1996 and 2002 1. In the 
absence of effective strategies for preventing and treating OM, the guidelines recom-
mended oral hygiene as the preferred strategy for managing the condition. The 2005 
update of the guidelines now recommend the use of palifermin (Kepivance®, recombi-
nant human keratinocyte growth factor-1) in patients with haematological malignan-
cies who receive myeloablative therapy and HSCT18. Our survey found that fewer than 
half of the nurses who responded were aware of palifermin or other newer therapies for 
OM. It is important that nurses educate themselves about the guidelines and keep up 
with novel therapies, innovative mechanisms of action, new concepts about pathobio-
logy, and future trends in the management of OM. 
It should be noted that this article is based on nurses' perceptions of the management 
of OM in European transplant centres. There are several limitations to this approach. 
The results of this study may not be generalisable since the sample was small. The po-
tential bias in responses should also be considered because of the response rate of 
46%. It is also possible that the respondents may not have answered questions accu-
rately or honestly, even though confidentiality was assured. Further, reports were not 
independently verified, although this may not be important because the study focused 
on the nurses' perceptions. Despite these limitations, we believe that these results pro-
vide useful insight into the management of OM in European transplant centres.
Most nurses surveyed believe that OM is a debilitating condition in patients who un-
dergo transplantation and that European BMT centres lack uniform methods and pro-
tocols for assessing, preventing, and treating it. Once uniform evidence-based national 
guidelines are established, they can be implemented into clinical practice, followed by 
continuous quality improvement programs to evaluate changes in practice patterns 
and potential improvements in outcomes. The expert oral mucositis assessment group, 
made up of nurses, physicians, and dentists from EBMT and the European Oncology 
Nursing Society, is currently working to prepare guidelines to support the practice of 
oral assessment. Greater awareness of potential new therapies for OM can be expected 
to help nurses improve the QOL of their patients who have OM.
32
Management of oral mucositis             Chapter 2
References
 1  Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and
  treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100
  (9 Suppl): 2026-2046.
 2  Blijlevens NA, McCann S, Bacon P, Cinnéide R, Quinn B, Roosaar A, et al., on behalf of the EBMT
  Mucositis Advisory Group, 2006. Prospective Oral Mucositis Audit (POMA): occurrence and conse-
  quences of severe oral mucositis in high dose melphalan and BEAM conditioning. Poster presen-
  ted at: Annual meeting of  the American Society of Hematology; 9-12, 2006; Orlando, Florida
 3  Eilers J, Epstein JB. Assessment and measurement of oral mucositis. Semin Oncol Nurs 2004;20(1): 
  22-29.
 4  Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone
  marrow transplantation. Support Care Cancer 2000;8(1): 33-39.
 5  Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: patho-
  genesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100(9 Suppl): 
  1995-2025.
 6  Borbasi S, Cameron K, Quested B, Olver I, Evans D. More than a sore mouth: patients' experience of 
  oral mucositis. Oncol Nurs Forum 2002;29(7): 1051-1057.
 7  Peterman A, Cella D, Glandon G, Dobrez D, Yount S. Mucositis in head and neck cancer: economic
  and quality-of-life outcomes. J Natl Cancer Inst Monogr 2001;29: 45-51.
 8  Rose-Ped AM, Bellm LA, Epstein JB, Trotti A, Gwede C, Fuchs HJ. Complications of radiation therapy
  for head and neck cancers. The patient's perspective. Cancer Nurs 2002;25(6): 461-467.
 9  Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hema-
  topoietic stem-cell transplantation. J Clin Oncol 2001;19(8): 2201-2205.
 10  Fanning SR, Rybicki L, Kalaycio M, et al. Severe mucositis is associated with reduced survival after
  autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 2006;135(3):
  374-381.
 11  Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of can-
  cer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer
  2003;98(7): 1531-1539.
 12  Eilers J. Nursing interventions and supportive care for the prevention and treatment of oral muco-
  sitis associated with cancer treatment. Oncol Nurs Forum 2004;31(4 Suppl): 13-23.
 13  Glenny AM, Gibson F, Auld E, et al. A survey of current practice with regard to oral care for children
  being treated for cancer. Eur J Cancer 2004;40(8): 1217-1224.
 14  World Health Organization. WHO Handbook for Reporting results of cancer treatment. Geneva,
   WHO, 1979.
 15  Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical
  trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group.
  Cancer  1999;85(10): 2103-2113.
 16  Eilers J, Berger AM, Petersen MC. Development, testing, and application of the oral assessment 
  guide. Oncol Nurs Forum 1988;15(3): 325-330.
 17  McGuire DB, Rubenstein EB, Peterson DE. Evidence-based guidelines for managing mucositis.
  Semin Oncol Nurs 2004;20(1): 59-66.
  33
Chapter 2            Management of oral mucositis 
 18  Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology,
  2005. Summary of evidence-based clinical practice guidelines for care of patients with oral and 
  gastrointestinal mucositis (2005 update). Available online at: http://www.mascc.org/media
  Resource_ centers/Guidelines_mucositis.doc. Accessed, 2006.
34
3Chapter 3A scoring system for the assessment of oral mucositis
in daily nursing practice
Carin M.J. Potting
Nicole M.A. Blijlevens
J. Peter Donnelly
Ton Feuth
Theo van Achterberg
European Journal of Cancer Care 2006; 15: 228-234
Chapter 3            A scoring system 
14
A scoring system             Chapter 3
  37
Abstract
Nurses take care of patients around the clock, so they are in an ideal position to ob-
serve and record the signs and symptoms of oral mucositis. This requires a valid, reliable 
scoring instrument that is easy to use. The objectives of this study were to summarize 
the scoring instruments that are available, to develop a new Oral Mucositis Nursing 
Instrument (OMNI) and to evaluate this new instrument. A systematic review was un-
dertaken in which 21 scoring instruments were reviewed and compared. None of the 
instruments studied satisfied the criteria that were established beforehand. The six 
most common items from the systematic review were selected for the new instrument. 
To test the OMNI, pairs of experienced nurses assessed the oral cavity of 26 patients in-
dependently. Inter-observer reliability (Kappa), correlation between items (Spearman’s 
rank–order correlations) and internal consistency of the instrument (Cronbach’s alpha) 
were calculated. The usability was evaluated with a questionnaire. Cohen’s weighted 
Kappa was within an acceptable range. Almost all correlations were statistically signi-
ficant and in the predicted direction. The Cronbach’s alpha coefficient indicated suf-
ficient internal consistency. All nurses found the OMNI user-friendly and suitable for 
day-to-day care. The OMNI can be used as a valid, reliable and usable instrument in 
daily nursing practice.
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Introduction
Mucositis is an important and frequent complication of patients after treatment with 
cytostatic chemotherapy. Up to 40% of patients are affected by oral mucositis following 
cytostatic chemotherapy1, as are almost all those who have undergone a haematopoie-
tic stem cell transplant (HSCT), with 67% developing severe oral mucositis2.
Oral pain associated with oral mucositis is the most common complaint reported by pa-
tients3, and results in difficulties in chewing, swallowing and speaking4. Other symptoms 
include inflammation, oedema and lesions in the mouth. There is also a serious risk of 
infection which can lead to fulminant sepsis of patients with reduced immunity4-6.
It is essential that mucositis is recognized at an early stage, so that adequate measures 
can be taken and the results of these interventions can be evaluated.
One of the tasks of nurses is to observe changes in the patients’ condition, including 
those involving the oral mucous membranes. Scoring mucositis is therefore within the 
remit of nurses.
A valid and reliable instrument for evaluating oral mucous membranes is essential, and 
a number of scoring instruments have been described. However, these instruments 
were developed for various purposes. For example, instruments have been developed 
from the perspective of dentistry e.g Hickey et al.7, radiotherapy e.g. Lievens et al.8, 
oncology e.g. World Health Organization9 and nursing e.g. Eilers et al.10. Most of these 
instruments were designed to evaluate the effects of a particular intervention. Others 
have been specifically designed to measure oral mucositis and monitor its progress, in-
cluding one developed in our own department Donnelly et al.11. Inter-rater reliability of 
the instruments was not important as they were frequently used by a few researchers. 
However, this may make them less suitable for a daily nursing practice, which requires 
a reliable validated instrument that is robust enough to remain reproducible despite 
the steady change over of staff with each shift. The instrument also has to be usable in 
daily nursing practice employing items that are clearly described, requiring the fewest 
possible number of aids and affording assessment that is as comfortable as possible for 
the patients and convenient for the nurses.
The current study had three objectives: first to perform a literature review to summarize 
the scoring systems available, second to select an instrument comprising those items 
best suited to daily nursing practice and third, to evaluate the validity, reliability and 
usability of this instrument.
Methods
Systematic review
A systematic literature review was undertaken to find a validated, reliable and a useful 
scoring instrument for daily nursing practice.
To identify relevant scoring instruments, the databases Medline and Cinahl were sear-
ched for literature up to June 2004, with the keywords neoplasm, cancer, radiation 
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therapy, chemotherapy, nursing, mucositis, stomatitis in combination with grading sys-
tem, rating scale, measurement, index scoring. Articles were included in this study if the 
scoring instrument was completely described. A total of 17 instruments were found. In 
addition, two instruments were found using references of relevant articles. Finally, two 
instruments (graduation papers) were found via the network. This resulted in a total 
of 21 widely varied instruments (see Figure 1). Data were collected for all instruments 
concerning domains of oral mucositis, reliability, validity and the usability.
Figure 1:  Selection of articles
Development of the instrument
Based on the systematic literature review of scoring instruments, a new scoring instru-
ment for daily nursing practice was developed. The development began with a selec-
tion of descriptive items to encompass the range of changes in the oral cavity classically 
appearing in patients treated with cytostatic chemotherapy. The six most prevalent 
items of 21 scoring instruments are used for the composition of the new instrument. 
This new instrument was then presented to a panel of experts (nurses and physicians) 
for their comment. Finally, the instrument was then tested in daily nursing practice.
Evaluation of the instrument
The OMNI was tested in February and March of 2004 in the haematology ward of the 
Radboud University Nijmegen Medical Centre in the Netherlands. The haematology 
ward has 28 patient beds admitting patients for cytotoxic chemotherapy, and autolo-
gous and allogeneic HSCT.
Patients participating in this study had to be ≥ 16 years of age, able to read and com-
prehend Dutch, and estimated to be hospitalized for 21 days. Patients were nursed in 
rooms supplied with air under positive pressure. All patients participating in the stu-
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dy received a standardized oral care protocol, consisting of four times a day rinsing 
and brushing the oral cavity, to use a soft toothbrush and toothpaste of choice and 
to renew the toothbrush every week and if necessary, to moisturize lips with Vaseline. 
Twenty-six successive either allogeneic or autologous HSCT recipients were included 
in this study. 
Eight certified nurses with experience in haematology care participated in this study.
Each patient was examined by two nurses; within ½ hour the nurses assessed patient 
cavity independently. The assessment took place in a systematic manner, a penlight 
and a spatula was used for good inspection.
After examining the patient’s oral cavity, nurses had to fill out the form of the OMNI.
Analysis procedures
The internal consistency of an instrument is the degree to which the items of an instru-
ment are all measuring the same attribute or dimension. Cronbach’s alpha was compu-
ted for the new instrument and Spearman’s rank–order correlations were calculated for 
all items. The reliability evaluation furthermore included the inter-observer reliability. 
Cohen’s weighted Kappa12  was calculated for all observations. 
The usability of OMNI was evaluated with a questionnaire for the nurses involved.
Results
Systematic review
The origin and purpose of the instruments largely determine their structure and con-
tents. There were four instruments originating from oncology, two from radiotherapy, 
seven each from dentistry and nursing, and one instrument was designed in a multi-
disciplinary setting.
Roughly speaking, two stereotypical scoring instruments emerged from the literature: 
ordinal and numeric instruments. Ordinal instruments classify the symptoms into pre-
viously described categories, where the severity of the mucositis is determined and 
graded. An example of these instruments is the World Health Organization9 grading 
scale. The categories are broad and subject to interpretation: thus, the WHO instrument 
is not useful for assessing small changes over time.
Numerical instruments are those where the severity of the symptoms is measured and 
where a numerical system defines the status of the mucositis; this may or may not be 
followed by classification into categories. Examples of these instruments are the Oral 
Assessment Guide (OAG) developed by Eilers10 and the Oral Mucositis Assessment Sca-
le (OMAS) developed for testing the effects of intervention13, and the Daily Mucositis 
Score (DMS) developed in our own department to monitor the progress of mucositis in 
relation to infectious complications11. Most of the instruments based their validation on 
the result of consensus statements from cooperative groups or a small number of ex-
perts in the field. Only nine scoring systems of the 21 found in the literature evaluated 
the reliability of the instrument under study.
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Objective changes (erythema, lesions, oedema), subjective changes (pain or sensitivity, 
dryness) and functional changes (voice, swallowing, chewing) are all used in the va-
rious instruments. Figure 2 shows the most prevalent items and/or symptoms of 21 
scoring instruments. Obviously, the origin of the instrument plays a role in the selection 
of the items. 
Figure 2:  Most prevalent items/symptoms of 21 scoring instruments
For example, gums and teeth are items that play a role especially with instruments 
that have their origin in dentistry. Seven instruments have their origin in nursing (see 
Table 1). Only one instrument, the Western Consortium for Cancer Nursing Research
Table 1:  Overview of the nursing scorings instruments
* No later publication could be found that showed the reliability
OAG: Oral Assessment Guide; OCAF: Oral Cavity Assessment Form; OMI:Oral Mucositis Index;
WCCNR: Western Consortium for Cancer Nursing Research stomatitis staging system
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Table 1  Overview of the nursing scorings instruments 
 
 Validity Reliability Usability Scale Items/symptoms 
WCCRN 14 Expert, 
construct 
No No 3 stages Per stage extended 
description of the 
oral cavity 
OAG 10 Expert, content Inter-Observer 
range 70% - 100% 
No 3 point 8 
OCAF 15 Yes (adaptation 
OAG) 
No still on research* No 4 total=severity 
mucositis 
5 items in 13 
locations in the oral 
cavity 
McDibbs 16 Expert Inter- Observer: 13 
items 100% lesions 
85% 
No 7 items. 3 point 
1 item score in mm and 
3 item present-/absent 
11 items 
OMI-20 17 Construct  Test-retest: range 0.38- 
0.86 p=0.001 
Inter-Observer: range 
0.80 - t0.90  
No 4 2 in 9 locations in 
the oral cavity  
1 location 1 in the 
oral cavity 
1 location 1 in the 
oral cavity 
Nieweg18 Expert  Inter-Observer: 63% -
53% 
No 3 point for each item 
differ value 
12 
MSS19 Expert  Inter-Observer: Kappa 
range 0.62-0.96 
No 4 6 from which 3 in 7 
locations in the oral 
cavity 
 
* No later publication could be found that showed the reliability 
OAG: Oral Assessment Guide; OCAF: Oral Cavity Assessment Form; OMI:Oral Mucositis Index; WCCNR: Western 
Consortium for Cancer Nursing Research stomatitis staging system 
 
 
Table 2 Oral Mucositis Nursing Instrument 
 
Objective characteristics of oral mucositis (Mouth inspection by the nurse) 
 0 point 1 point 2 points 3 points 
Erythema Pink and moist Mild/moderate Severe  
Oedema Absent Mild 
-Print of teeth in tongue 
edge 
-Gingival swollen and red 
Moderate 
-Print of teeth in tongue 
-Gingival swollen and 
white 
Severe 
-Swollen tongue 
-Gingival swollen and 
shining white 
Lesions Absent 1 to 4 > 4 Elapse ulceration 
Subjective characterises of oral mucositis (Information from the patient) 
 0 point 1 point 2 points 3 points 
Pain None VAS score < 3 VAS score 4,5,6, VAS score >6 
Dryness mouth Normal Mild Moderate Severe 
Viscosity saliva  Normal Slimy Thick  
 
VAS, visual analogue scale 
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(WCCNR) stomatitis staging system 14  is compound in a ordinal scale. It consists of three 
stages of extended descriptions of the oral cavity. For daily nursing practice, this is im-
practical, because it requires nurses to memorize the three stages in order to classify 
patients’ cavity into a stage. Six nursing scoring instruments use a numeric structure.
The number of items or symptoms varies from four Oral Mucositis Index (OMI)-2017 to 12 
Nieweg18. The OAG10 is the only instrument that does not measure pain as a symptom of 
oral mucositis20. Oral pain rise and fall predictably during the course of oral mucositis. 
Three nursing scoring instruments15, 17, 19 are complicated in the assessment of the oral 
cavity. They require the assessment of several items or symptoms on specific locations 
in the oral cavity, and items or symptoms vary per location. This requires nurses to me-
morize all aspects of the complete instrument during the assessment of the oral cavity 
and for patients with severe pain to open their mouth for sufficient time.
In a number of instruments, different tools are necessary to correctly inspect the oral 
cavity. A penlight or a spatula are practical tools for mouth inspections, but a perio-
dontal probe16 to measure the length of a lesion is too complicated for daily nursing 
practice and requires a significant amount of training. Some of the instruments require 
arithmetic methods to calculate the total scores. Sometimes, different items must be 
multiplied with definite values or mathematical formulae to score the patient’s oral 
cavity into a category or grade18. This procedure is susceptible to miscalculations.
In general, the ordinal scales require the stages to be memorized in order to classify 
patients cavity. As these stages are defined using complex combinations of symptoms, 
mistakes in classifying can easily occur. Therefore, numerical instruments appear to be 
better suited for daily nursing practice, as they require the evaluation of one symptom 
at a time. If measurements take place on a daily basis, the total scores provide an over-
view of the progression of the mucositis. 
None of the instruments studied satisfied the criteria that were established beforehand: 
valid, reliable and usable in daily nursing practice.
Development of the Oral Mucositis Nursing Instrument (OMNI)
The systematic literature review of scoring instruments showed that the most prevalent 
items (see Figure 1) used in the various scoring instruments were erythema, oedema, 
lesions, pain and saliva production, which is mostly expressed by dryness of the mouth 
and saliva viscosity.
These six items were added together to generate a mucositis score, which was used 
to monitor the development, progression and course of mucositis on a daily basis (see 
Table 2). A 4-point scale was used for four items – oedema, lesions, pain and dryness of 
the mouth and, a 3- point scale for two items – erythema and saliva viscosity. For each 
item, a score of 0 was assigned to the normal or desirable condition. The degree of oral 
pain was gauged with the help of a visual analogue scale (VAS), a 10-mm line with 0 in-
dicating no pain and 10 representing the worst possible pain. Patients were required to 
indicate the dryness of their mouth into normal, mild, moderate and severe, scored as 
0, 1, 2 or 3. The viscosity of the saliva is required to be scored as normal, slimy or viscous 
with a score of 0, 1 or 2.
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The overall oral assessment score is the sum of the six scores. 
The scoring system was then presented to a panel of five experts (nurses and physici-
ans) in the area of oral problems of oncology patients. The panel did not recommend 
any major change.
Table 2:  Oral Mucositis Nursing Instrument
VAS, visual analogue scale
Testing the Oral Mucositis Nursing Instrument (OMNI)
According to the newly devolved instrument, nurses were instructed to examine pa-
tient’s oral cavity in a systematic manner. The lips, tongue and oral mucosa of the gingi-
val, palate, uvula and tonsillar crypts were evaluated for the presence of erythema, oe-
dema and lesions, and patients were required to indicate the degree of oral pain using 
the VAS and to indicate the dryness of their mouth and the viscosity of the saliva.
There were 15 male and 11 female patients aged 16– 70 years, with a mean age of 
47 years. All had been admitted for an HSCT, 14 received an allogeneic HSCT and 12 
an autologous HSCT. Eleven of the patients had acute myelogenous leukaemia (AML), 
eight had acute lymphocytic leukaemia (ALL), four Non-Hodgkin’s lymphoma and three 
patients had multiple myeloma (MM). All patients admitted to the haematology ward 
were eligible to this study.
Individual mucositis scores ranged from 0 to 13, with 50% of the patients having a total 
mucositis score <4, 15.4% of the patients having a score 5–8, only 3.8% of the patient
having a total mucositis score 9–12 and 7.7% of the patients score>13. Eight nurses 
participated (four men and four women), all of whom were graduates and six had spe-
Table 3:  Spearman’s rank-order correlations (n=26)
* Correlation is significant at the 0.01 level (1-tailed).
** Correlation is significant at the 0.05 level (1-tailed).
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Table 1  Overview of the nursing scorings instruments 
 
 Validity Reliability Usability Scale Items/symptoms 
WCCRN 14 Expert, 
construct 
No No 3 stages Per stage extended 
description of the 
oral cavity 
OAG 10 Expert, content Inter-Observer 
range 70% - 100% 
No 3 point 8 
OCAF 15 Yes (adaptation 
OAG) 
No still on research* No 4 total=severity 
mucositis 
5 items in 13 
locations in the oral 
cavity 
McDibbs 16 Expert Inter- Observer: 13 
items 100% lesions 
85% 
No 7 items. 3 point 
1 item score in mm and 
3 item present-/absent 
11 items 
OMI-20 17 Construct  Test-retest: range 0.38- 
0.86 p=0.001 
Inter-Observer: range 
0.80 - t0.90  
No 4 2 in 9 locations in 
the oral cavity  
1 location 1 in the 
oral cavity 
1 location 1 in the 
oral cavity 
Nieweg18 Expert  Inter-Observer: 63% -
53% 
No 3 point for each item 
differ value 
12 
MSS19 Expert  Inter-Observer: Kappa 
range 0.62-0.96 
No 4 6 from which 3 in 7 
locations in the oral 
cavity 
 
* No later publication could be found that showed the reliability 
OAG: Oral Assessment Guide; OCAF: Oral Cavity Assessment Form; OMI:Oral Mucositis Index; WCCNR: Western 
Consortium for Cancer Nursing Research stomatitis staging system 
 
 
Table 2 Oral Mucositis Nursing Instrument 
 
Objective characteristics of oral mucositis (Mouth inspection by the nurse) 
 0 point 1 point 2 points 3 points 
Erythema Pink and moist Mild/moderate Severe  
Oedema Absent Mild 
-Print of teeth in tongue 
edge 
-Gingival swollen and red 
Moderate 
-Print of teeth in tongue 
-Gingival swollen and 
white 
Severe 
-Swollen tongue 
-Gingival swollen and 
shining white 
Lesions Absent 1 to 4 > 4 Elapse ulceration 
Subjective characterises of oral mucositis (Information from the patient) 
 0 point 1 point 2 points 3 points 
Pain None VAS score < 3 VAS score 4,5,6, VAS score >6 
Dryness mouth Normal Mild Moderate Severe 
Viscosity saliva  Normal Slimy Thick  
 
VAS, visual analogue scale 
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Table 3  Spearman’s rank-order correlations (n=26) 
 
 Erythema Oedema Lesions Pain Dryness Viscosity Total score 
Erythema 1.000 .364** .520** .255*    .475** .137 .704** 
Oedema  1.000 .389** .262* .183 .195 .612** 
Lesions   1.000  .330**     .405** .177 .653** 
Pain    1.000   .266* .215 .595** 
Dryness     1.000 .052 .680** 
Viscosity      1.000 .435** 
Total score       1.000 
 
* Correlation is si ificant at the 0. 1 level (1-tailed). 
** Correlation is si ificant at the 0.05 level (1-tailed). 
 
 
Table 4  Item-Total Statistics (n=26) 
 
 
Scale Mean if 
Item Deleted 
Scale Variance if Item 
Deleted 
Corrected Item-Total 
Correlation 
Cronbach's Alpha if 
Item Deleted 
Erythema 3.85 9.544 .642 .656 
Oedema 3.46 9.351 .454 .695 
Lesions 4.00 7.882 .690 .615 
Pain 4.04 9.097 .455 .695 
Dryness 3.56 8.879 .437 .704 
Viscosity 4.17 11.597 .157 .760 
 
 
Table 5  Inter-observer reliability for nurses (n=8) 
 
Items Inter-observer N  
Erythema 0.60 
Oedema 0.26 
Lesions 0.73 
Pain 0.83 
Dryness 0.78 
Viscosity 0.72 
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cialized training in oncology. They had worked in the haematology for 1–5 years, and 
were familiar with daily mouth inspection.
Spearman’s rank–order correlations were calculated between all items and the total 
scores of the OMNI (Table 3). Almost all correlations were statistically significant and in 
the predicted direction. Only viscosity of the saliva correlated negatively with the total 
instrument.
The internal consistency using Cronbach’s alpha coefficient for the OMNI was 0.729, 
indicating modest, but sufficient internal consistency. Deletion of viscosity improved 
the instrument (Table 4). 
Table 4:  Item-Total Statistics (n=26)
The inter-observer reliability was assessed by comparing the measurements of pairs of 
nurses (Table 5). The reliability is considered very good for values >80, good for values 
61–80, and moderate for values 41–60.
With exception of oedema, the Cohen’s weighted Kappa of all the items of the new 
instrument was in the acceptable range.
The examination of the patient’s oral cavity took 2–5 min, and all nurses found the 
OMNI use-friendly. Erythema and oedema were the most difficult to assess, according 
to 63% and 72% of the nurses respectively.
Table 5:  Inter-observer reliability for nurses (n=8)
Discussion
This study describes the development and testing of a new instrument. The OMNI was 
developed as a result of the need to find an instrument that accurately assesses the 
patient’s oral cavity in daily nursing practice. Validity of the OMNI, based on the syste-
matic review, appears to be strong, and the internal consistency analysis indicates good 
internal consistency of the scale. Viscosity contributed little to the OMNI and was there-
fore deleted. The reliability of the OMNI was in acceptable ranges, although difficulties 
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were encountered with scoring erythema and oedema. In spite of what nurses reported 
concerning the symptom erythema, the Cohen’s weighted Kappa coefficient shows op-
posite values. Probably, nurses feel uncertainty, but assess this symptom more accurate 
than they themselves expect. The weighted Cohen’s Kappa coefficient for the symptom 
oedema underlined the nurses’ expectations. Despite of the sufficient clinical experi-
ence nurses had, assessment of the symptom oedema should be trained and described 
in more detail to increase the reliability of the OMNI. The teaching and training of the 
nursing staff in the use of the OMNI is necessary to guarantee a reliable and correct as-
sessment of the oral cavity.
The instrument was tested in a group of HSCT recipients. To enlarge the use and avai-
lability of the OMNI, it should also be tested in a group of patients who receive other 
cancer therapies. Another limitation of this study is the small sample size, a larger study 
will provide more information about the instrument and its use. The OMNI was tested 
for validity, reliability and usability; future studies need to involve the testing of respon-
siveness. Responsiveness refers to the extent that instruments are capable of differen-
tiating among clinically relevant changes. In daily nursing practice, patient allocation 
is the most common operating procedure. Often, the same nurse cares for the same 
patient for a specific period of time. Therefore, it would be interesting to know the in-
traobserver reliability of the OMNI. 
The importance of an instrument to assess oral mucositis is based on the premise that 
nurses should be able to identify chemotherapy-induced mucositis early, so that they 
can intervene to help minimize its severity and enable them to evaluate the effective-
ness of oral mucositis treatment with various oral care protocols.
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Abstract
Oral mucositis is a burdensome and potentially dangerous side effect of chemotherapy 
and radiotherapy. Oral assessment is an important first step when identifying manage-
ment strategies for oral mucositis. The Oral Mucositis Nursing Instrument (OMNI) is a 
valid, reliable and user-friendly instrument to assess oral mucositis in patients treated 
with chemotherapy and/or radiotherapy. However, to evaluate the results of nursing 
interventions an instrument should also be able to detect clinical relevant changes.
This study investigated the responsiveness of the OMNI. 
The oral mucositis data came from a cohort of 32 recipients of a haematopoietic stem 
cell transplant unit who had participated in a prospective trial of parenteral glutamine. 
Evaluations of oral mucositis began between day 7 and 28 after conditioning. Responsi-
veness was investigated using two approaches: Guyatt’s Responsiveness Index and the 
Receiver Operating Characteristic (ROC) curves. 
Guyatt’s responsiveness index for the OMNI instrument is 2.2, indicating good sensiti-
vity for detecting changes in oral mucositis over time. The ability of the OMNI to detect 
day-to-day deterioration (or improvement) was further expressed by the areas under 
the two corresponding ROC curves of 0.89 and 0.92 respectively. 
The adequate responsiveness of the OMNI suggests it is a good instrument for measu-
ring oral mucositis on a daily basis.
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Introduction
Oral mucositis is a common complication of chemotherapy and radiotherapy and can 
be a significant complication for patients undergoing cancer treatment or haemato-
poietic stem cell transplant (HSCT)1.
It is essential that mucositis is recognised at an early stage so that adequate interven-
tions can be taken and the results of these interventions can be evaluated. One of the 
tasks of nurses is to observe changes in the patient’s condition including those invol-
ving the oral mucous membranes. A valid and reliable instrument for evaluating oral 
mucous membranes is essential. In the literature, a number of scoring instruments have 
been described. However, these instruments were developed for various purposes for 
example research into the relationship between bacteraemia and mucositis2, day-to-
day care3 and from different perspectives for example dentistry 4, oncology 5 and nur-
sing3. Most of these instruments were designed to evaluate the effects of a particular 
intervention. Others were designed to measure oral mucositis and monitor its progress. 
Roughly speaking, two typical scoring instruments emerged from the literature: ordinal 
and numeric instruments. Ordinal instruments classify the symptoms into predefined 
categories, where the severity of the mucositis is determined and graded. Numerical 
instruments are instruments where the severity of component signs and symptoms is 
assigned a score and the individual scores are summed together to produce an overall 
score that defines the degree of the mucositis; this may or may not be followed by clas-
sification into categories. The numerical instruments appear to be better suited for daily 
nursing practice. If measurements take place on a daily basis, the total scores provide 
an overview of the progression of the mucositis. Most of the instruments based their 
validation on consensus statements from co-operative groups or a small number of 
experts in the field. Objective changes (erythema, lesions, oedema), subjective changes 
(pain or sensitivity, dryness) and functional changes (voice, swallowing, chewing) are 
all used in the various instruments. Some instruments are complicated as they require 
the assessment of several items or symptoms at specific locations in the oral cavity and 
items or symptoms vary for each location. In a number of instruments, different tools 
are necessary to correctly inspect the oral cavity. Also, some of the instruments require 
arithmetic methods to calculate the total scores. This procedure is susceptible to mis-
calculations.
Given the problems outlined above, the Oral Mucositis Nursing Instrument (OMNI) was 
developed and validated. The quality of an instrument in general relates to three con-
cepts: validity, reliability and usability. Responsiveness (or sensitivity to changes) is the 
ability to detect change over time6. Though seldom seen as a separate aspect of the 
quality of an instrument, since it could be argued that responsiveness relates to the 
validity of the instrument, a responsive instrument allows closer monitoring which may 
be important for deciding to intervene and also for determining when a response oc-
curs. 
The literature is unclear about what is an adequate approach for evaluating responsive-
ness7. According to Husted  et al.8 two major aspects of responsiveness can be described, 
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namely internal and external responsiveness. Internal responsiveness characterizes the 
ability of a measure to change over time when change would be expected. External 
responsiveness is the extent to which change in a measure relates to corresponding 
change in a reference measure of clinical health status. One method for assessing inter-
nal responsiveness is to evaluate change in a measure which has been assessed using a 
single group repeated measures design, where patients are assessed before and after a 
known treatment. In oral mucositis, responsiveness implies that the instrument should 
correlate with known patterns of mucositis progression. The changes in scores should 
then reflect this pattern.
The aim of the present study was to establish the responsiveness of the OMNI in a lon-
gitudinal study design. 
Patients and Methods
The data for this assessment originated from a cohort of 32 patients of a haematopoietic 
stem cell transplant unit who had participated in a prospective randomised placebo-
controlled study which failed to show any benefit of parenteral nutrition supplemented 
with glutamine-dipeptide on oral mucositis 9.
The patients who had participated were all adults of 18 years of age or older and had 
received the same myelablative conditioning therapy namely idarubicin at a dose of 
42 mg/m2 by continuous infusion over 48 h starting 12 days before transplant (SCT day 
−12), 120 mg/kg cyclophosphamide (60 mg/kg per day on SCT days −6 and −5) and 9 
Gy of total body irradiation (4.5 Gy per day on SCT days−2 and −1)10.
All were nursed in rooms supplied with air under positive pressure and had followed 
the same supportive care protocol which included prophylactic antimicrobial agents. 
Oral care consisted of rinsing and brushing the teeth four times a day using a soft 
toothbrush and the toothpaste of choice and renewing the toothbrush every week. 
The patients’ lips were moisturised with Vaseline when necessary. Morphine was given 
on demand to control pain related to oral mucositis.
Mucositis assessment
Assessment of oral mucositis was performed daily by a trained nurse who inspected the 
mouth in a systematic manner with a penlight and a spatula. 
OMNI
The Oral Mucositis Nursing Instrument (OMNI) was develop in a previous study that 
included a systematic review of the literature, expert validation and testing of its relia-
bility and usability in a group of hematopoietic stem cell transplant (HSCT) patients. Six 
items commonly found in other oral mucositis assessment instruments were selected 
for the new instrument. These included erythema, oedema, lesions, pain, dryness of the 
mouth and salvia viscosity. The salvia viscosity item was deleted from the initial instru-
ment after initial testing, as it contributed little to the scale.
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Erythema, oedema and lesions are observed by nurses, while patients’ self assessments 
are used for pain and dryness of the mouth. A three point scale is used for the erythema 
item, whereas four point scales are used with all other items. The four point scale for 
pain is a transformation of a visual analogue scale where patients are asked to select 
a number from a 0 to 10 range, 0 representing no pain and 10 representing the worst 
possible pain. As with pain, 0 represents a normal or most desirable condition for every 
OMNI item. The total oral assessment score from the instrument is calculated by adding 
the scores for each of the items (0-14 range). 
From the previous study, the validity of the OMNI appeared to be strong, its reliability 
was acceptable and nurses found the instrument user friendly11.
DMS
The Daily Mucositis Score (DMS)2 was routinely used at the study ward and was the refe-
rence instrument for testing the responsiveness of the OMNI. As with all oral mucositis 
instruments currently used, a substantial overlap in OMNI and DMS items exists (table 1). 
The DMS involves scoring the presence of lesions, erythema, oral oedema, pain and 
dysphagia individually as 0 if absent, 1 if mild, 2 if moderate and 3 if severe. 
Important differences between the two instruments are the use of a visual analogue 
scale for pain in the OMNI, and inclusion of an item on dryness of the mouth in the 
OMNI versus an item on dysphagia in the DMS. Also, the scale used for the erythema 
item differs for the two instruments. 
Unlike the OMNI, the DMS allows for a transformation of the total score (range 0-15) 
into four oral mucositis grades to convey the severity of oral mucositis in a more acces-
sible manner as has previously been reported by Donnelly et al.2. Hence the absence of 
oral mucositis was allocated an overall grade 0, while a score o 1-7, 8-14 and ≥15 was 
labeled respectively as grade 1 or mild mucositis, grade 2 or moderate mucositis and 
grade 3 or severe mucositis. These grades were used in our study and are referred to as 
the ‘oral mucositis grades’ in the analyses. 
Table 1: Oral Mucositis Nursing Instrument versus Daily Mucositis Score
Statistical analysis
Responsiveness was analysed using two strategies: Guyatt’s Responsiveness Index and 
the Receiver Operating Characteristic (ROC) curves. Clinically important deterioration 
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Table 1 Oral Mucositis Nursing Instrument versus Daily Mucositis Score 
 
Item OMNI Levels  DMS Levels  
Lesions Yes 0,1,2,3 Yes 0,1,2,3 
Erythema Yes 0,1,2 Yes 0,1,2,3 
Oedema Yes 0,1,2,3 Yes 0,1,2,3 
Pain Yes VAS 1-10; 0,1,2,3 Yes 0,1,2,3 
Dryness Yes 0,1,2,3 No - 
Dysphagia No  Yes 0,1,2,3 
Score - Sum 0 - 14 - Sum 0 - 15 
Grades No Absence of oral mucositis is 0 
1–7 is grade I or mild mucositis 
8–14 for grade II or moderate mucositis 
≥15 for grade III or severe mucositis 
 
 
Table 2 Effect of reducing the number of OMNI items on the responsiveness with five possible combinations.  
 
Instrument Ind x of 
Responsiveness 
(Guyatt) 
AUC ROC    
(Deterioration) 
AUC ROC   
(Improvement) 
P+D+E+L+O * 2.2 0.89 0.92 
Four items 
P+D+E+L 2.0 0.86 0.87 
P+D+E+O 2.2 0.88 0.90 
P+D+L+O 2.1 0.87 0.90 
P+E+L+O 1.8 0.85 0.90 
D+E+L+O 2.2 0.87 0.90 
mean 2.1 0.87 0.89 
One item 
Pain 0.9 0.71 0.73 
Dryness  1.0 0.68 0.70 
Erythema 1.3 0.70 0.68 
Lesions 1.0 0.66 0.71 
Oedema 1.1 0.72 0.75 
mean 1.1 0.69 0.71 
 
P: pain; D: dryness; E: erythema; L: lesions; O: oedema 
*: The original OMNI instrument. 
Values of <0.20, 0.50, and >0.80 indicate small, moderate, and large responsiveness. 
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or improvement in mucositis was assumed to have occurred if the oral mucositis grade 
increased or decreased respectively, by one grade, representing a shift from absent to 
mild, from mild to moderate, and from moderate to severe mucositis or the converse. 
Accordingly, a minimal clinically important change in the OMNI was defined as the 
mean change in the OMNI of patients who experienced a change in a single grade on 
the DMS. The Guyatt Responsiveness Index (GRI) i.e. the ratio of the minimally clinically 
important change in the OMNI and the standard error of this change was estimated6. 
We calculated three ‘single step’ GRI’s for the transition between grade 0 and grade I, 
between grade I and grade II and between grade II and grade III.  The standard errors 
with respect to the transition between grades I and I+1 are given by  √MSEi + MSEi+1 in 
which MSEi is the mean squared error of the OMNI obtained from one way analysis of 
variance (ANOVA) one repeated observations in patients with oral mucositis grade I. 
We defined the average of these three ‘single step’ GRI’s as the final Gyuatt responsive-
ness index.  
Values of <0.20, 0.50, and >0.80 representing respectively, slight, moderate, and large 
responsiveness,8, 12 were used as references.
The second strategy to assess responsiveness of the OMNI instrument made use of the 
Receiver Operating Characteristic curves (ROC)13, 8. Briefly, responsiveness to improve-
ment was described in terms of the sensitivity and specificity which were used to plot a 
ROC curve so as to assess the ability of the OMNI to reflect day-to-day improvement or 
deterioration. The area under the ROC curve represents the probability that the OMNI 
correctly classifies patients as improved or not when compared to the foregoing day. 
A second ROC analyses was performed to assess the responsiveness of the OMNI to 
deterioration.  
The development of mean OMNI scores and mean grades between day 7 and 28 after 
conditioning were studied using linear mixed models with the aim of excluding possible 
delays in the OMNI response compared to the mucositis profile over time as expressed 
by the grade. The responsiveness per item was calculated and values of <0.20, 0.50, and 
>0.80 were again used to indicate slight, moderate, and large responsiveness. 
Finally, Guyatt’s index and AUC, and the ROC were calculated for all five resulting com-
binations of OMNI to explore the effect of simplifying the instrument by omitting a 
single item on the responsiveness.
Results 
The onset and duration of oral mucositis of 32 patients is shown in Figure 1. The spread 
of the OMNI scores shows the variation in the severity of oral mucositis experienced 
by patients. Although most of the patients suffered from moderate mucositis between 
day 17 and 21 some had only mild mucositis whereas others suffered severe mucositis 
in the same period.
Guyatt’s responsiveness index for the OMNI was 2.2 indicating a high sensitivity for de-
tecting the change in oral mucositis over time. The ability of the OMNI to detect day-
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to-day deterioration (or improvement) was also expressed by the areas under the two 
corresponding ROC curves which were 0.89 and 0.92 respectively. The development 
over time of the mean OMNI scores between the day of conditioning and the 14th day 
after HSCT was best described by a fourth-degree polynomial of the variable 'time from 
transplantation' (Figure 2). Mucositis began around day 7, becoming progressively more 
severe and reached a maximum on day 19. Thereafter the mucositis score decreased. 
The mean grade is conspicuously flatter than is the OMNI line showing the instrument 
to be highly sensitive to changes on a day to day basis. 
Table 2 shows the responsiveness of Guyatt’s index and the AUC ROC per item. Guyatt’s 
index indicated large responsiveness per item whereas the AUC ROC values indicated 
a moderate responsiveness. The responsiveness of pain also contributed least to the 
OMNI compared to the other items. 
Reducing the instrument by one item had no marked influence on the responsiveness 
of the instrument as all values were ≥ 80 indicating greater responsiveness.
Figure 1: Actual mean score
The scatter plot shows the actual scores of the daily OMNI per day. The spreading of the OMNI score 
shows the variation of the severity of oral mucositis experience by patients.  The box plots shows pattern 
of the daily OMNI scores
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Figure 2: The development of OMNI and the DMS over time
Mean OMNI profile (__) with 95% confidence bands (---) and mean DMS grade (line with dots) as mode-
led with 4th degree polynomials using linear mixed models. 
Day 0 is the day of hematopoietic stem cell transplantation.
Day –7 start of conditioning.
Table 2: Effect of reducing the number of OMNI items on the responsiveness with five possible combinations. 
P: pain; D: dryness; E: erythema; L: lesions; O: oedema
*: The original OMNI instrument.
 Values of <0.20, 0.50, and >0.80 indicate small, moderate, and large responsiveness.
 
 
 
Table 1 Oral Mucositis Nursing Instrument versus Daily Mucositis Score 
 
Item OMNI Levels  DMS Levels  
Lesions Yes 0,1,2,3 Yes 0,1,2,3 
Erythema Yes 0,1,2 Yes 0,1,2,3 
Oedema Yes 0,1,2,3 Yes 0,1,2,3 
Pain Yes VAS 1-10; 0,1,2,3 Yes 0,1,2,3 
Dryness Yes 0,1,2,3 No - 
Dysphagia No  Yes 0,1,2,3 
Score - Sum 0 - 14 - Sum 0 - 15 
Grades No Absence of oral mucositis is 0 
1–7 is grade I or mild mucositis 
8–14 for grade II or moderate mucositis 
≥15 for grade III or severe mucositis 
 
 
Table 2 Effect of reducing the number of OMNI items on the responsiveness with five possible combinations.  
 
Instrument Index of 
Responsiveness 
(Guyatt) 
AUC ROC    
(Deterioration) 
AUC ROC   
(Improvement) 
P+D+E+L+O * 2.2 0.89 0.92 
Four items 
P+D+E+L 2.0 0.86 0.87 
P+D+E+O 2.2 0.88 0.90 
P+D+L+O 2.1 0.87 0.90 
P+E+L+O 1.8 0.85 0.90 
D+E+L+O 2.2 0.87 0.90 
mean 2.1 0.87 0.89 
One item 
Pain 0.9 0.71 0.73 
Dryness  1.0 0.68 0.70 
Erythema 1.3 0.70 0.68 
Lesions 1.0 0.66 0.71 
Oedema 1.1 0.72 0.75 
mean 1.1 0.69 0.71 
 
P: pain; D: dryness; E: erythema; L: lesions; O: o dema 
*: The original OMNI instrument. 
Values of <0.20, 0.50, and >0.80 indicate small, moderate, and large responsiveness. 
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Figure 2 The development of OMNI and the DMS over time 
 
 
 
 
Mean OMNI profile (ʊ) with 95% confidence bands (---) and mean DMS grade (line with dots) as modeled 
with 4th degree polynomials using linear mixed models.  
Day 0 is the day of hematopoietic stem cell transplantation. 
ay –7 start of conditioning. 
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Discussion
In this study the responsiveness of the OMNI was shown to be good according to Guy-
att’s Responsiveness Index and the Receiver Operating Characteristic curves. These fin-
dings indicate that the OMNI is a good scale for measuring oral mucositis on a daily 
basis between day 7 and 28 after transplantation. Progression of mucositis is clear from 
figure 2, but this does not necessarily mean that the score for each individual patient 
can be predicted.
We explored the possibility of downsizing the instrument by a single item without loss 
of responsiveness and the results showed that four items are necessary to attain the 
most sensitive assessment of oral mucositis. Moreover, not one item could be omitted 
since each combination yielded a good responsiveness score. 
However, there may be compelling arguments for simplifying the instrument. The usabi-
lity of the OMNI was tested in a previous study and showed erythema and oedema to be 
the most difficult to assess among 63% and 72% of the nurses respectively. The weigh-
ted Cohen’s Kappa coefficients were 0.60-0.26 underlining the nurses’ expectations11.  
The validity of scoring pain is compromised when analgesia is used. None the less, pain 
is the most direct guide to the severity of oral mucositis and the consequent require-
ment for analgesia. In spite of the fact that erythema, oedema or pain could be deleted 
from the instrument without compromising responsiveness, there are no good argu-
ments in terms of content validity to delete any one of these items. Each contributes 
to the total picture of oral mucositis and is consistent with the findings in a systematic 
review11 which showed that experts generally include these items in instruments for 
monitoring oral mucositis. Therefore we propose not to change the instrument in our 
hospital, at least for the time being. However, those centres with nurses who are unfa-
miliar with assessing oral mucositis could choose to reduce the instrument by leaving 
out the more troublesome items erythema or oedema without seriously compromising 
the responsiveness of the instrument, as the quality of assessment depends on experi-
ence and nurses' training.
Our instrument was tested in a group of HSCT recipients admitted to a specialist ward. 
Therefore it should be tested in other settings before being generally adopted for pa-
tients who receive other cancer therapies.
Ideally, responsiveness is assessed by comparing the results of the test under conside-
ration to the results of an instrument that is known to be responsive6. In the present 
study, such an approach was not feasible simply because there is no gold standard for 
measuring oral mucositis.
Until now, most attention concerning responsiveness has been devoted to following 
changes indicating improvement. The OMNI is able to monitor the course of oral muco-
sitis which gets worse before it gets better as the score gradually increased reaching a 
maximum in the 2nd week after stem cell infusion declining thereafter as oral mucositis 
improved.  
Investigators using instruments that are not responsive could falsely draw negative 
conclusions from the results of their clinical research. Therefore it is important to have 
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an instrument that is capable of detecting small but relevant and important changes 
especially when the outcome of interest is also the primary outcome measure for a trial 
14, 15. Furthermore, in the design of a clinical trial on oral mucositis, researchers must be 
confident that the score used is responsive enough to detect the minimal important 
difference that is hypothesized16.  In the literature only two studies have reported the 
responsiveness of their instrument. Sonis et al.17 concluded that his instrument was res-
ponsive over time, but a definition of responsiveness and how it was quantified was not 
reported whilst Stiff et al.18 calculated responsiveness extensively and found the daily 
questionnaire administered by the patients themselves was responsive.
In conclusion, we have shown that the OMNI is responsive to alterations in oral mucosi-
tis and encourage other researchers to evaluate their instruments in the same manner.
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Abstract
In the international literature, the most commonly recommended intervention for ma-
naging oral mucositis is good oral care, assuming that nurses have sufficient know-
ledge and skills to perform oral care correctly. 
The aim of the present study was to investigate if knowledge and skills about oral care 
improve when education in oral care is provided to nurses in charge of patients who 
are at risk of oral mucositis.
This intervention study consists of a baseline test on the knowledge and skills of nurses 
of the haematology wards of two different hospitals. Oral care education sessions were 
given in one hospital and follow-up tests were performed in both hospitals. Nursing 
records were examined and observations of nurses performing oral care were made at 
baseline as well as at follow-up. 
The results show significant differences in the scores for knowledge and skills before 
and after the education, whereas there was no difference in scores at the two points 
in time for the comparison hospital, where no education had taken place. The records 
test showed no differences at baseline or follow-up for the two groups. Observations 
showed that nurses who followed the education session implemented the oral care 
protocol considerably better than those who did not attended.
Education in oral care has a positive influence on the knowledge and skills of nurses 
who care for patient at risk of oral mucositis, but not on the quality of oral care docu-
mentation. 
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Introduction
Patients who receive chemotherapy to treat malignant disease, often experience oral 
mucositis as the most debilitating side effect 1, 2. As a result of oral mucositis, patients' 
quality of life can be affected by pain, infection, altered nutrition and impaired oral 
function 3, 4. Oral mucositis is one of the most common causes of treatment delay and 
dosage reductions in cancer therapy 5. 
Prevention and treatment are as important to oral mucositis as they are to fatigue, nau-
sea and vomiting and many other side effects affecting patients with cancer. 
Nurses play a central role in preventing and managing oral mucositis and reducing its 
debilitating effects on patients. In fact they have 3 main tasks in managing oral muco-
sitis: (1) assessing and monitoring changes in the oral cavity; (2) providing appropriate 
oral care; and (3) offering patient education 6.
Nurses give oral care of patients with cancer a high priority 7, but very little is known on 
day -to -day practice 8.
In the international literature, regular oral care is most commonly mentioned for ma-
naging oral mucositis 9-11 though the standards for oral care are not consistently im-
plemented and advice on the frequency of oral care frequency varies from 'once every 
shift' to ‘only if patient requests it’. 
Furthermore, obstacles to providing oral care have been little investigated. McGuire 12 
outlined barriers to implementing oral care standards and proposed strategies to over-
come them. In a study by Wallace et al. attitudes and subjective norms predicted 39% 
of the behaviour of nurses in providing oral care 13.
Simple lack of knowledge about oral care is a major barrier to providing optimal oral 
care 12. A first and necessary step in the process of change is to identify the educatio-
nal needs that exist in order to be able to offer adequate education and support, both 
theoretically and practically. However, knowledge deficits are not the only barriers. To 
manage oral care effectively, nurses require more and continuing education 7, 8.
An important part of daily oral care is to assess the oral cavity of each patient at risk for 
oral mucositis. To this end, nurses should be trained in the use of standardised tools 
for screening and assessment 14 in order to be proficient in using such instruments 15. 
Besides this, training increases the inter-observer reliability of the oral assessment and 
improves the evaluation of mucositis 16.    
The aim of the present study was to investigate whether knowledge and skills regar-
ding oral care improve when education is provided to nurses caring for patients who 
are at risk for oral mucositis. 
Methods
Study design
Baseline tests on the knowledge and skills of nurses in haematology wards of two diffe-
rent hospitals were conducted. Oral care education sessions were given in one hospital 
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and follow-up tests were performed in each hospital (Figure 1).
The baseline and follow-up consisted of performance observations as well as the nur-
sing record tests. A knowledge test was also employed to investigate nurses’ familiarity 
with the key principles of oral care. Oral care education sessions were tailored to the 
baseline scores. The follow-up tests were performed one month after the last education 
session in the intervention hospital.
Figure 1: study plan
Setting and sample
The study population consisted of nursing staff of the haematology wards of two uni-
versity hospitals in the Netherlands. The intervention group was made up of qualified 
nurses experienced in nursing on the haematology ward of the Radboud University 
Nijmegen Medical Centre (RUNMC). The ward has 28 patient beds and admits 100 pa-
tients a year for autologous and allogeneic HSCT. The Daily Mucositis Score (DMS) 17 
was used to assess oral mucositis on a daily basis. Briefly, this requires the nurse to score 
erythema, oedema, dysphagia, lesions and pain assigning a score of 0 to 3 on a specially 
designed chart containing each day of the week. 
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Nursing staff developed an oral mucositis care plan when the first signs of oral mucosi-
tis appeared which consisted of brushing the teeth four times daily using a soft tooth-
brush and using oral rinses with normal saline (0.9% NaCl) or water. 
The control group consisted of experienced nurses from the haematology/oncology 
ward of the Academic Medical Centre of Amsterdam (AMC). The ward has 18 haema-
tological beds and admits 60 patients a year for autologous and allogeneic HSCT. Pa-
tients admitted to this ward received an oral care regime similar to that included in 
the RUNMC care plan. Oral inspection was done every day for patients at risk for oral 
mucositis without employing a specific assessment instrument. Signs of oral mucositis 
were recorded, though not in a standardised manner and a checklist was used to mo-
nitor daily oral care. 
The protocols of both wards were based on published guidelines including those of the 
MASCC 11, 18.
The intention was to examine 60% of the nurses per ward at both baseline and follow-
up. All nurses were informed that participation was voluntary, and their anonymity was 
guaranteed.
Instruments and procedures
Demographic data were collected on gender, age, years of nursing experience and ba-
sic nursing degree.
 
Knowledge test
The knowledge test was a 32-item questionnaire including open-ended and multiple-
choice questions and 8 photographs of the mouth illustrating different stages of oral 
mucositis. A team of experts including a haematologist (NB), nurse specialist (CP), den-
tal hygienists (AO, MO) and an oncology nurse (AM) developed the test from existing 
protocols, the international literature and their own specialized knowledge. 
Topics included: 
•	 Anatomy	and	pathology	of	the	oral	cavity	(10	open	questions,	max.	score	123	points).
•	 Oral	hygiene	(10	open	questions,	3	multiple-choice	questions,	max.	score	166	points).
•	 Oral	mucositis	(4	questions,	max.	score	45	points).
•	 Patient	education	(5	open	questions,	max.	score	76	points).
•	 Assessment	of	oral	mucositis	in	8	photographs,	(max.	score	40	points).
The overall maximum score was 450 points. On average, 30-45 minutes were needed to 
complete the test. In the intervention hospital, only the nurses who had received these 
sessions were asked to participate in the follow-up test.
Observation of skills
The observations were designed to evaluate nurses’ oral care skills.  A list consisting of 
44 observations points (OP) was developed to audit these activities and each was ans-
wered with 'yes' (done) or 'no' (not done). The OP were grouped into 5 subsections; 
•	 Checking	patient’s	oral	status	of	the	previous	days	(3	OP)
•	 Assessment	of	the	patient’s	oral	cavity	according	to	the	protocol	(12	OP)
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•	 Assisting	with	or	performing	oral	hygiene	for	the	patient	(23	OP)
•	 Patient	directed	advice	for	oral	care	(3	OP)
•	 Documentation	of	findings	in	the	nursing	record	(3	OP)
The maximum score was 44 points. The list was a mix of the standardised protocols of 
both hospitals, though some questions were not relevant for both settings (e.g. locally 
standardised preventive or treatment prescriptions). 
The observations at both baseline and follow-up were done during the day by exa-
mining the mouths of patients known to have oral complaints. Two dental hygienists 
observed the nurses while they assessed the oral cavity and delivered oral care.  
Nursing record test 
Correct and adequate reporting of findings and interventions is essential to nursing 
care. The nursing record test consisted of six questions derived from the hospital pro-
tocols:
•	 The	status	of	the	oral	cavity	is	recorded	daily;
•	 Results	of	oral	assessment	are	reported;
•	 The	patient’s	oral	pain	is	recorded;
•	 In	case	of	signs	of	oral	mucositis,	the	oral	care	protocol	is	started;
•	 Advice	concerning	oral	care	is	provided	to	the	patient	and	documented;
•	 Interventions	are	started	and	documented.
 Ten nursing records from each ward were reviewed in retrospect, both at baseline and 
follow-up. Each question was assigned a maximum of 4 points and the completeness of 
the records was given up to 24 points.
Oral care education sessions
The oral care education sessions were offered to the nursing staff of the RUNMC only. 
The results of the baseline knowledge tests directed the content of these sessions.
The training was given by two dental hygienists who provided theoretical education 
on the anatomy of the oral cavity, relevant pathology, oral hygiene, oral mucositis and 
options for prevention and treatment. Oral assessment training was achieved with the 
help of slides. A second component of the training consisted of nurses cleaning each 
other’s teeth, which helped them rehearse their skills and experience the process from 
the patient’s perspective. The education session took 1½ hours. Four identical sessions 
were offered to enable as many nurses as possible to attend.
Statistical analyses
The tests on the nursing record, nurses’ knowledge and the skills performance obser-
vations resulted in summary scores and were analysed using the Statistical Package for 
the Social Science (SPSS version 14.0) using simple descriptive statistics. A total score 
for both tests was used to give a final analysis of nurses’ knowledge, skills and perfor-
mance in documentation.
The effect of the intervention (education sessions), compared to no intervention was 
analyzed using two-way independent 22 ANOVA. A significant (alpha=0.05) interaction 
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of the main effects for time point (baseline versus follow-up) and group (intervention 
versus control) was to indicate a positive effect of the education sessions.
Results
Knowledge test
Thirty-one and 29 nurses participated in the knowledge test at base line and at follow-
up respectively. Two nurses of the control group started the knowledge test but did not 
finish it. Their tests results were not analysed.  Nurses were predominantly females, with 
a mean age of 34.9 years (range 24-54) and a mean number of 6.2 years (range 1-15) of 
experience in care of oncology patients (Table 1).
Table 1: Nurses’ age and experience for both nursing teams at both time points
At baseline, only 30% of the nurses knew all the characteristics of mild mucositis, 
whereas 60% of the nurses were able to describe severe mucositis. Most of the nurses 
knew the most important risk factors for development of oral mucositis. On the other 
hand, only half of the nurses gave correct answers to the questions on anatomy and pa-
thology. Knowledge about oral hygiene varied, with more than 50% of the nurses being 
unable to offer advice to a patient with dental prostheses and oral mucositis. Three out 
of eight photographs showing various stages of oral mucositis were assessed correctly 
by 75% of the nurses. The test was a revelation to some nurses as it showed how little 
they knew about aspects of oral mucositis.
 
Table 2: Knowledge test mean score and standard deviation per group and time point 
The difference in mean increase is 56.9, 95%CI: [15.7; 98.0], p = 0.008
Table 2 shows the means and standard deviations on the knowledge test for the two 
groups and both points in time. There was a significant interaction effect (illustrated 
in figure 2) between time (baseline versus follow-up) and group (control versus inter-
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Table 1. Nur es’ age and exp rience for both nursing teams at both time points 
 Intervention group 
baseline 
Intervention 
follow-up 
Control group 
baseline 
Control group 
follow-up 
Total
N 20 20 11 9 60 
Mean age (years) 36.4 34.9 36.6 31.9 34.9 
Mean experience 
(years) 
7.6 5.9 5.7 5.6 6.2 
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Table 1. Nurses’ age and experience for both nursing teams at both time points 
 Intervention group 
baseline 
In ervention 
follow-up 
Control group 
baseline 
Control group 
follow-up 
Total
N 20 20 11 9 60 
Mean age (years) 36.4 34.9 36.6 31.9 35.3 
Mean experience 
(years) 
7.6 5.9 5.7 5.6 6.8 
 
 
 
Table 2. Knowledg  test mean score and standard deviation per group and time point  
 Intervention group
baseline 
Intervention group 
follow-up 
Control group 
baseline 
Control group  
follow-up 
     
N 20 20 11 9 
Mean 212.3 276.2 200.3 207.3 
Std. deviation 36.9 35.5 43.2 34.9 
     
The difference in mean increase is 56.9, 95%CI: [15.7; 98.0], p = 0.008 
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vention): p = 0.008. The difference in the increase in mean knowledge was 56.9, 95%CI: 
[15.7; 98.0], indicating a relevant positive effect of education on knowledge (Figure 2).
Figure 2: Esimated marginal means of total score knowlegde test.
Observation of skills performance
The results of the observation test are shown in Table 3 (to facilitate the interpretation 
of the results, the maximal score per section is presented next to the actual scores).
At baseline, almost half of the nurses assessed the patient’s oral cavity without kno-
wing the previous oral status. Many mistakes (50%) were made with oral inspection The 
equipment required was not always used, and the floor of the mouth was overlooked 
in two-thirds of cases. However, 65% of the nurses gave at least some advice about oral 
care to the patients.
Table 3: Observations mean scores per item and overall mean score and standard deviation per group
The difference in mean increase is 12.3, 95%CI: [2.1; 22.5],  p = 0.019
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 Intervention 
baseline 
 N=10 
Mean  
Intervention 
follow-up  
N=10 
Mean 
Control 
baseline 
N=10 
Mean 
Control 
follow-up 
N=10 
Mean 
     
Checking patient’s oral status of 
previous days before oral 
assessment. 
4.5 5.6 5.0 2.7 
Assessment of patient's oral cavity 
according to the protocol. 
15.8 21.9 15.2 15.3 
Assisting with- or performing oral 
hygiene for the patient. 
32.4 39.5 29.8 34.2 
Patient directed advice for oral care 5.2 5.8 4.4 5.1 
Documentation of findings in the 
nursing record. 
2.7 2.7 2.6 2.3 
     
     
Overall Mean  
St. deviation 
60.6 
9.0 
75.5 
5.6 
57.0 
7.9 
59.6 
8.8 
Figure 1 study plan 
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 Nurses who attended the oral care sessions implemented the oral care protocol signifi-
cantly better than those who did not attend (p = 0.019). The difference in mean increase 
in total score was estimated at 12.3, 95%CI: [2.1; 22.5].
Nursing record test
Only records of patients at risk for oral mucositis were included in the nursing record 
test. Each record was carefully studied by two dental hygienists with the help of the 
checklist (Table 4). There were no significant overall differences between the groups 
p = 0.367. The difference in mean increase in total score was estimated at 2.3, 95%CI: 
[- 2.9; 7.5].
Table 4: Record tests mean scores per item
The difference in mean increase is 2.3, 95%CI: [- 2.9; 7.5],  p = 0.376.
Discussion
The aim of this study was to investigate whether knowledge and skills in oral care im-
prove when education is offered to the nurses who care for patients at risk for oral mu-
cositis. Nursing skills were assessed by reviewing nursing records and observing nurses 
while they were providing oral care. Furthermore, knowledge tests at baseline and at 
follow-up provided a clear impression of the effect of oral education sessions.
To our knowledge, this particular study design has not been used previously, though 
there are a number of studies in other areas that used educational interventions to 
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Table 4. Record tests mean scores per item 
 
 
 Intervention 
group baseline 
 
N= 10 
Intervention 
group follow-up 
 
N=10 
Control 
group 
baseline 
N=10 
Control 
group 
follow-up 
N=10 
     
A daily notation concerning the 
status of the oral cavity is 
written 
1.2 0.9 1.3 1.9 
Results oral assessments are 
reported.  
1.2 2.7 2.4 1.9 
Patient’s oral pain is recorded.  0.8 0.8 1.0 0.8 
If there are signs of oral 
mucositis, the oral mucositis 
protocol is started. 
2.6 2.3 1.7 1.3 
Advice concerning oral care is 
given to the patient and is 
recorded.  
1.1 2.4 1.7 1.6 
Interventions are started and 
recorded.  
 
1.4 1.1 1.0 1.2 
 
Overall Mean 
St. Deviation 
 
8.3 
4.3 
 
10.2 
4.0 
 
9.1 
4.5 
 
8.7 
3.3 
 
 
 
The difference in mean increase is 2.3, 95%CI: [- 2.9; 7.5],  p = 0.376. 
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change knowledge and skills. For example, Dalton et al. 19 designed an educational 
program to improve knowledge in order to change pain management practices and 
patient outcomes. This program was offered to nurses who provided day-to-day care 
for patients with cancer. A quasi-experimental design was used to measure the effec-
tiveness of the program in changing nurses' knowledge, attitude and behaviour. Data 
were collected from nurses and patient charts before and after the program. Nurses' 
knowledge improved, but the change was not statistically significant. 
In contrast with the study by Dalton and similar studies on the effects of education in 
nurses, our study added observations on performance, a less common element in this 
type of study. 
Knowledge tests
In our study, we tested the actual knowledge of nurses in the area of oral care. This is in con-
trast to other studies that investigated nurses’ self-reported knowledge or personal views 
on oral care by means of questionnaires or interviews 7, 8, 20, 21. Nevertheless, the results are 
similar; baseline data revealed that nurses have gaps in their knowledge of oral care, parti-
cularly in their knowledge and assessment of the different stages of oral mucositis. 
Observation of performance
At baseline, observations of nurses carrying out oral care revealed mistakes in assessing 
the oral cavity as well as in assisting with- or providing oral hygiene. Moreover, even 
though oral assessment had become a daily routine, procedures that were wrongly 
learned, persisted.
Observations by dental hygienists during the daily nursing routine are not common 
for nurses or their patients, which will alter their behaviour as they know that they are 
being watched. This could have resulted in more favourable scores for nurses. However, 
as observations were used at both points in time, the changes from baseline identified 
in our study are likely to be genuine. Follow-up data showed significant improvement 
of oral care given by nurses who attended the oral care sessions indicating that quality 
of oral care will likely be improved by refreshing existing knowledge and providing new 
knowledge.
Nursing records
The purpose of the nursing record is to have an easily accessible reference that descri-
bes the patient's needs and wishes. Also, nursing interventions can be documented 
and evaluated in the record22. The records are the main source of information on each 
patient's oral care.
At baseline, the results for the record test showed inadequacies in the documentation 
of oral care. Most of the records were incomplete and sometimes oral assessment was 
documented but the accompanying intervention was not described. Although special 
attention was given to this during the education sessions, the follow-up test showed 
no improvement in the quality of the records. This likely reflects a more general at-
titude of nurses towards reporting. To improve the quality of nursing records, a more 
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comprehensive training should be provided, together with continuous feedback based 
on regular evaluations 23. The development of electronic nursing records might pos-
sibly improve accuracy and make them a more useful source for information on patient 
outcomes 24.
Oral care education session
The effects of  educational sessions showed the impact of education and training. Trai-
ning in oral assessment is necessary, even for experienced nurses, to prevent mistakes 
when inspecting the oral cavity and to ensure the results are judged correctly 15, 16. 
During the education sessions, slides of photographs of the mouth showing different 
stages of oral mucositis were used. In future studies, videotaped demonstrations 25 and 
guided practice in assessing patients’ mouth under supervision of an experienced nur-
se or a dental hygienist could optimise the trainings. The practical part of the education 
sessions consisted of nurses brushing each other’s teeth. This ‘simple’ task was regarded 
as unpleasant but after the session many nurses changed their attitude towards the 
cleaning of teeth. 
Limitations 
The tools used in this study were specifically designed for this study and were not exten-
sively tested for their validity and reliability beforehand. However, the record test was 
based on expert validity and only two observers used the observation and the nursing 
record tool and they fine-tuned their interpretation to provide greater consistency. 
The follow-up data were collected one month after the education sessions so we do not 
know whether the same results would be obtained after 6 months or later. 
Our study included two wards of two different hospitals which, though similar in ad-
mission policy and patient demographics, will likely differ in other aspects. In addition, 
paired analysis was not possible because of the anonymity of the participants. The sam-
ple of nurses was different pre- and post-test which could have introduced bias into our 
study.
Generalizability is also limited as our study was conducted in only two haematology 
wards in the Netherlands. It is therefore not certain whether the results can be genera-
lized to haematology wards in other centres or general oncology wards and outpatient 
clinics here in the Netherlands or indeed elsewhere. None the less, the literature does 
suggest that similar problems and challenges exist elsewhere 7, 8, 20, 21, 26, 27.
Conclusion
Knowledge and skills improve when education in oral care is given to nurses. Baseline 
data showed a lack of knowledge and skills concerning oral care. These data gave direc-
tion to the need for and desired content of education sessions. Our education sessions 
met the need for oral care knowledge among nurses. 
Recommendations
Regular oral care education sessions to improve or refresh oral care knowledge, are 
72
Providing oral care in haematological oncology patients              Chapter 5
the most important recommendation from this study. Audits and feedback are likely to 
improve oral care skills in practice. Senior nursing staff should consider selecting inte-
rested and experienced nurses to become ‘resource nurses in oral care’. They can act as 
advisors, an information source and counsellor on oral care at the ward.  These nurses 
should be responsible for oral care education sessions and they can also supervise and 
teach oral assessment and care in clinical practice. 
Follow-up studies are necessary to validate our findings, and to determine the most 
effective training interval and type of instruction and research is needed to determine 
the impact of knowledge on patient outcomes. 
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Abstract
Oral mucositis (OM) is a serious consequence of some chemotherapy and radiotherapy 
regimens. A number of reliable instruments are available to assess OM, but none are 
universally accepted. A unique collaboration of multi-disciplinary experts from Europe 
was formed to make recommendations on OM assessment, based on a systematic lite-
rature review and the experts’ experience. The main recommendations are listed. There 
should be a comprehensive baseline assessment. OM should be frequently assessed 
using a standardised instrument, or a combination of instruments. Physical, functional 
and subjective changes should be measured. Subjective measures should be assessed 
prior to any physical examination. The use of pain scoring, in particular patient self-
reporting, should form part of any OM assessment. Any assessment instrument should 
be validated, easy to use and comfortable for the patient. Training of, and monitoring 
in, the use of the instrument is vital to successful monitoring of OM.
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Introduction
Oral mucositis (OM) is a frequently distressing, and sometimes serious, consequence 
of treatment with certain types of cancer therapies, with an incidence ranging from 
15% to 90%.1-3 OM is a multistage biological process that can cause erythema, swelling, 
bleeding and painful ulceration of the mucosal tissue.4
The impact of OM is generally under-rated, although patients often cite OM as one of 
the worst side effects of their treatment6,7.  Recent studies also show that severe OM is 
associated with inferior overall survival following haematopoietic stem cell transplan-
tation (HSCT)7. OM impacts on healthcare costs, due to increased length of in-patient 
stays and demands on resources8,9.  The prevention and palliation of OM is a priority 
for those involved in the management of these patients. The Multinational Association 
of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 
guidelines provide clinicians with a comprehensive assessment of OM prevention and 
treatment protocols and make recommendations for best clinical practice10,11.  Diagno-
sing and grading the severity of OM forms the basis of management and, accordingly, a 
number of validated and reliable instruments are available for this purpose12.
Their individual limitations, however, often lead investigators and clinicians to adapt 
existing scales or develop new ones. Unfortunately, there is a lack of consistency 
amongst these scales, and consequently, none are universally accepted1.  It is the ab-
sence of a universally accepted assessment scale, the lack of guidelines on best prac-
tice in OM assessment and the use of inconsistent and incompatible OM assessment 
instruments that continues to hinder progress in the measurement and management 
of this condition. 
Nursing, medical and dental experts from the European Group for Blood and Marrow 
Transplantation (EBMT) and the European Oncology Nursing Society (EONS) convened 
to form the Oral Mucositis Assessment Guidelines (OMAG) taskforce to generate guide-
lines for the use of tools in assessing OM in the adult patient with a malignancy. The 
aim of the taskforce was not to develop another tool, but to thoroughly analyse the 
assessment instruments currently available, their implementation and to formulate re-
commendations with which to address inconsistencies in the assessment of OM.
Methodology
Literature search
The methodology is similar to the one used in the recent guidelines from the United 
Kingdom Children’s Cancer Study Group (UKCCS) and the Paediatric Oncology Nurses 
Forum (PONF) Mouth Care Group (UKCCS-PONF guidelines)13 . 
Questions considered pertinent to OM assessment were defined by the EMBT/EONS 
OMAG taskforce (Appendix 1). Search terms were defined and MEDLINE, EMBASE and 
the Cochrane Library were searched electronically (Appendix 2). To be considered
relevant, the studies had to be phase II or III original clinical studies published in English 
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between 1st January 1990 and 31st January 2006, and involve patients ≥ 18 years of 
age. Studies were included if OM was a primary endpoint or if they compared OM  as-
sessment tools. Additional papers not identified in these electronic searches were sug-
gested by members of the taskforce. 
Relevant articles in press were identified by searching for abstracts on conference 
websites (Appendix 2). Abstracts that met the inclusion criteria were compared 
against papers already identified in the electronic literature search and papers recently
published through PUBMED. If data from the abstracts had not been published, the 
first author was contacted to see if the paper was in press and could be included in this 
analysis. 
Evidence assessment
A system for grading the quality of individual studies was adapted from frameworks 
of diagnostic test accuracy tools14-19.  Each study was graded according to the number 
of predefined sources of bias in the study design (Fig. 1). The quality of each study was 
then rated as good (Grade 1), adequate (Grades 2 and 3) or poor (Grades 4 and 5). 
 Figure 1: Studies were assessed for bias and graded accordingly
The papers were then reviewed for evidence to support or counter each of the task-
force’s questions and the overall evidence that answered each question was then rated, 
according to the following criteria:15-20 quantity – rated as a high (>10), moderate (3–10) 
or low (≤ 2) number of studies; consistency – the extent to which similar findings were 
reported, rated as good or poor; generalisability – how reasonable it is to apply the 
results of these studies to the target population, rated as good or poor; and clinical ap-
plicability – the potential clinical impact of the findings, rated as good or poor. Finally, 
the strength of the body of evidence behind each recommendation was deduced as 
shown in Table 1, and the recommendation was graded. 
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Table 1: Grading of evidence for recommendations 
The evidence for each recommendation is grouped, and the overall strength of the re-
commendation is graded according to the quality and quantity of studies providing 
evidence and the consistency, generalisability and clinical applicability of the body of 
evidence.
Definition of therapy
For the purposes of these guidelines, the term ‘therapy’ meant the administration of a 
cycle of radiotherapy (RT), chemotherapy (CT) or the period of conditioning treatment 
prior to stem cell transplantation. 
Results and discussion
Literature search
A total of 57 papers, most of which were research studies, met the inclusion criteria 
and addressed at least one of the questions (Appendix 1)7-12, 21-75.  The findings from the 
collation of evidence and the corresponding strength of evidence are covered for each 
recommendation below.
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Quality and quantity of Consistency, Strength of evidence Strength of
studies in body of evidence generalisability and  recommendation
 clinical applicability
 of evidence
High/moderate number of good-quality studies
or  All good  Strong  Strongly recommended
High number of adequate-quality studies
High/moderate number of good-quality studies
or  One or more are poor  Sufficient  Recommended
High number of adequate-quality studies
Moderate number of adequate-quality studies
or  All good  Sufficient  Recommended
Low number of good-quality studies   based on expert opinion
None of the above criteria met   Insufficient  Available studies
   do not provide
   sufficient evidence
   to formulate a guideline
The evidence for each recommendation is grouped, and the overall strength of the recommendation is graded according to the quality and 
quantity of studies providing evidence and the consistency, generalisability and clinical applicability of the body of evidence.
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Recommendation 1:
use of a standardised procedure for assessment
OM should be assessed using a standardised protocol. 
Evidence: strong/sufficient, therefore (strongly) recommended. 
Commentary on recommendation 1: use of a standardised procedure
Standardised procedures are defined here as OM assessment protocols that followed 
validated assessment tools (i.e. the tools and their validation studies were referenced in 
the paper), explicitly described the assessment procedure, or at the very least, outlined 
the frequency of assessment and defined the healthcare professionals involved. 
A total of 22 different assessment tools were used in the papers that provided evidence 
for this recommendation. Only two47,74  out of 57 eligible studies did not describe the 
OM assessment protocol in sufficient detail. Eleven studies12,23-29,40,43,55,64,73 used well-des-
cribed self-developed or modified instruments. Table 2 lists all the tools (excluding self-
developed scales except where the studies were for the express purpose of developing 
a scale), and the elements used in assessing OM. Pain, erythema and ulceration are the 
most commonly used measures across the tools. 
The World Health Organisation (WHO) scale was the most frequently used in the inclu-
ded studies (12 studies) 21,24,29,39,48,49,52,56,60,65,69,72. Of these studies, 10 were graded Grade 1 
or 2,21,24,29,39,48,49,52,60,65,69 showing that despite its simplicity, this scale does not limit study 
quality. 
The Oral Assessment Guide (OAG) scale was the second most frequently used. Although 
the Oral Mucositis Assessment Scale (OMAS) or Oral Mucositis Index (OMI)-based scales 
were specifically developed for OM staging, few studies in this analysis employed these 
tools, probably due to their complexity in clinical practice. 
Four studies compared two scales in parallel, particularly for validation purposes. 
Good correlations were found between OMAS and National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) scores41, and the Western Consortium for Cancer Nursing 
Research (WCCNR) and MacDibbs Mouth Assessment scales54. Donnelly and col-
leagues39 showed that a Daily Mucositis Score (DMS) achieved by adding scores for 
various elements of OM, was more successful than the WHO tool in monitoring OM 
through all its stages of development. Dodd and colleagues used several scales, and 
concluded that the tool must be chosen with the purpose of assessment in mind35. 
The taskforce recommends that this principle should be used when choosing the OM 
assessment tool.
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Recommendation 2:
routine assessment of OM
For a patient’s OM to be managed, routine assessments should take place. Patient self-
reporting should form an integrated part of the assessment. 
Evidence:  sufficient strength, therefore recommended. 
Commentary on recommendation 2: routine assessment of OM
A total of 13 studies (two high-quality52,64 and nine adequate-quality32,34,37,39,48,50,51,71,75 
provided evidence that frequent OM grading directed the active management of OM. 
In general, once OM scores passed certain thresholds, new, predetermined manage-
ment strategies were implemented9,37,60,71.  Interventions were usually initiated when 
OM was scored as moderate to severe. These studies used a total of nine assessment 
instruments, indicating that no single scale is particularly geared towards enabling 
clinical interventions. 
Eiler’s OAG was used in five of the 13 studies (Grades 2–4)34,36,51,70,75.  This instrument 
scores OM when changes to the mucosa are first observed, thus allowing early pre-
ventative or analgesic interventions. It is essential that risk factors of OM, or OM itself, 
are recognised at an early stage so that adequate measures can be implemented12. 
Authors using OAG note that the tool enables clinicians to document daily changes in 
oral status, plan appropriate interventions and follow trends75. The tool was found to 
be understandable, required only 3–4 min to complete and was clinically applicable for 
oncology nurses44. 
Several studies by Dodd and colleagues34,36,37  used an extension of the OAG, a thorough 
patient self-assessment programme (PRO-SELF Mouth Aware [PSMA] programme). The 
PSMA programme aims to support cancer patients with information on oral complica-
tions, self-care techniques and contact with nurses experienced in OM. Through this 
programme, patients learn the principles of good oral hygiene and how to thoroughly 
examine their mouth using assessment criteria based on the OAG77. 
It is the opinion of the taskforce that routine assessment of the oral cavity (both 
by patient and clinician) and information or educational programmes should ensure 
that the patient and healthcare professional are more aware of changes to the oral 
mucosa, the risks of OM and that patients are supported in improving their oral care 
practices34,36,37,77. 
Recommendation 3:
baseline oral assessments
A comprehensive baseline oral assessment should be made prior to treatment, where 
OM is expected. 
A further baseline assessment of OM should be taken as close to the administration of 
the first treatment dose as possible. 
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Evidence: sufficient/insufficient, supplemented by expert opinion, therefore recommen-
 ded based on expert opinion. 
Commentary on recommendation 3: baseline oral assessments
There is sufficient evidence that baseline assessments of the oral cavity should be made 
prior to any potentially damaging therapy. Only 17 papers7,12,22,25,30-32,46,53,56,62,68,70-73,75 did 
not specify baseline readings, in some cases because patients had already received CT 
or RT prior to study entry. 
The taskforce suggests two types of baseline assessment: one in preparation for the pro-
posed treatment and the second immediately before treatment administration. The first 
should be a comprehensive examination by dentists to identify, and if possible address, 
pre-existing conditions and OM risk factors (e.g. dental or oral infection, broken teeth, 
periodontal disease or poor oral hygiene). The examination and treatment of pre-existing 
problems should take place as early as possible prior to initiation of therapy78. 
The second baseline assessment, conducted immediately prior to treatment, establi-
shes a basis from which changes in the oral mucosa can be determined. In nine stu-
dies22,23,31,32,39,58,59,69,74. oral assessments only began on the day of stem cell administration, 
despite conclusive evidence that the onset of OM can occur during the conditioning 
phase of treatment1,7,39,72,79.  Similarly, the onset of OM following RT can be rapid: for 
some head and neck patients, symptoms can be observed as early as the first day of 
RT80-82.  It is therefore essential that baseline assessments are made before the onset of 
treatment. 
Recommendation 4:
frequency of assessment
4A – Frequent assessment of OM is recommended throughout the course of therapy, 
and especially for patients most at risk of developing OM. For outpatients, this will 
require some degree of self-assessment, although self-assessment for in-patients may 
also be beneficial. 
Evidence: sufficient, therefore recommended. 
4B – Assessment, whether by clinicians or patients, should take place on a daily basis 
during the period when OM is likely to first occur or be at its peak. Depending on the 
severity of baseline OM assessments and risk factors, assessments will need to continue 
at regular intervals (daily, every 2–3 days, weekly) as OM resolves. 
Evidence: insufficient, supplemented by expert opinion, therefore recommended based on
 expert opinion. 
Commentary on recommendation 4: frequency of assessment
One of the unresolved issues of OM is the frequency of its assessment. In this ana-
lysis, the frequency of examinations during treatment varied from a four-times-
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daily patient self-assessment34 to weekly, but none of the studies looked spe-
cifically at the timing of assessments. Five good-quality studies35,52,59,61,64 and 21 
adequate-quality studies7,21,23-25,28-30,33,37,41-44,49,55,56,58,60,68,73 support a frequency of a less 
than once-daily assessment compared with two good-quality65, 66 and 17 adequate-
quality studies7,12,22,31,32,39,42,46,50,51,57,62,68,69,72,74 favouring a daily assessment. 
The severity of OM can alter dramatically in 24–48 hours and symptoms can change 
depending on pain relief and other treatments; it seems prudent to conduct exami-
nations every one or two days, particularly at times when it is likely to arise or when it 
is particularly severe or painful. The taskforce believes that, where patients are unable 
to maintain their oral health or require pain relief, daily assessment, including pain as-
sessment, is essential. 
In practice, it may be difficult to have such frequent assessments, especially in the out-
patient setting where patients between treatment cycles may not be seen for several 
weeks. It is the opinion of the taskforce that all patients should be trained in self-assess-
ment and report typical signs/symptoms to the healthcare team. The PSMA program-
me34 is a good example of a self-assessment scheme that can be adapted for in- and 
outpatient use.
Recommendation 5:
post-treatment assessment
OM assessments should continue until OM is fully resolved or the trend to resolution is 
established. If OM has not resolved on discharge, follow-up of the patient is recommen-
ded. In the in-patient setting, assessment should continue until OM is resolved, which 
in most cases is approximately 2–4 weeks after treatment. 
Evidence:  sufficient to strong, therefore strongly recommended. 
Commentary on recommendation 5: post-treatment assessment
Once treatment is stopped, OM may continue to increase in severity before re-
solving1,3,72,76. Only 13 studies (one good-quality study,35 nine adequate-quali-
ty29,33,34,46,48,53,62,68,73 and three poor-quality36,38,70) covered post-treatment assessment in 
outpatients. Overall, the evidence favoured follow-up in outpatients post-RT and CT 
using self-assessment systems. 
For HSCT patients, the evidence also favours follow-up; three good-59,65,66 and se-
ven adequate-quality studies7,23,31,39,50,58,74 continued OM assessment between 18–28 
days following transplantation. A further 12 studies, all of good or adequate-quali-
ty12,22,25,30-32,42,43,57,69,72,75 specified follow-up OM assessments between 14 and 31 days. 
Few papers mentioned any follow-up after 28 days for inpatients, so it is unclear how 
patients who continued to show signs of OM were monitored. Studies are required to 
assess the risks of discharging patients with OM, the effect OM has on the patient’s 
quality of life (QoL) and what level of follow-up is appropriate. These questions must be 
addressed before the importance of long-term monitoring of OM can be determined. 
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Recommendation 6:
inclusion of patient-reported outcomes
6A – Patient-reported outcomes, for pain at the very least, should be included in all OM 
assessments. 
Evidence:  sufficient/strong, therefore strongly recommended. 
6B – Assessment of subjective measures should happen prior to any physical examina-
tion (including self-examination) of the mouth. 
Evidence:  insufficient, supplemented by expert opinion, therefore recommended based on
 expert opinion. 
Commentary on recommendation 6: inclusion of patient-reported outcomes
Thirty-three12,23,24,26-29,31-35,37-40,43,46,49-53,58,60,61,63-65,69,71,73 out of 57 papers supported the use 
of patient-reported outcomes for each OM assessment, whereas 11 papers 21,22,25,34,36,48,5
4,57,70,74,75 provided evidence that they were unnecessary. 
The degree of patient involvement varied considerably. In the studies using the NCI-
CTC and WHO scales (n = 22), minimal self-assessment requires patients to indicate pre-
sence or absence of pain only, but the majority of these studies were supplemented 
with a more comprehensive self-assessment. Nine studies out of the 33 used a visual 
analogue scale (VAS)12,23,24,29,32,40,61,64,69 and four studies28,50-52 used longer patient questi-
onnaires. 
Changes in subjective measures of OM, e.g. pain, can precede changes in objective exa-
minations.35 Furthermore, studies by Cella and Sonis and their respective colleagues 
show that patient-reported measures of OM correlated closely with clinical measu-
res28,64. Self-assessment may therefore allow healthcare teams to implement preven-
tative or palliative interventions at an early stage, which may help to reduce the peak 
severity and/or duration of OM. The taskforce recommends that patient self-reported 
outcomes should be included with OM assessments. Due to the pain involved in phy-
sical examination, the taskforce is of the opinion that self-assessments are best made 
prior to examination.64 
Recommendation 7: pain scoring
The use of pain scoring, and VAS tools in particular, should be used at each routine as-
sessment.
Evidence:  insufficient, supplemented by expert opinion, therefore recommended based on
 expert opinion. 
Commentary on recommendation 7: pain scoring
Subjective assessments of pain are included in the majority of scales, but are often li-
mited to the question ‘Do you have pain?’ without any indication of severity. For this 
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analysis, pain scoring is taken to be pain assessments that use either a VAS or scales 
that grade different intensities of pain according to specific descriptors, such as the 
Brief Pain Inventory. 
Pain scoring was reported in six good-quality40,52,61,64-66 and 18 adequate-quality stu-
dies12,23,24,28,29,31-33,37,39,46,50,53,60,69,71,73.  In four studies, pain scoring was added to instruments 
that did not include pain assessments23,50,51,61.  Nine studies using the WHO or NCI-CTC 
scales24,28,29,32,43,52,60 added scoring, even though a yes/no measure of pain is integral to 
these scales. 
There is now sufficient evidence that patient-reported outcomes for pain should be 
included in assessments (see Recommendation 6). It is the opinion of the taskforce that 
pain scores relate to changes in the oral mucosa and provide an indication of the course 
of OM and the effectiveness of interventions over time. In particular, a VAS is simple to 
use by patients and also easy to analyse by healthcare teams40.
Recommendation 8:
objective, subjective and functional measures of OM
8A – OM assessments should use instruments or a combination of suitable scales con-
taining elements covering physical changes in the oral mucosa, functional changes and 
subjective changes. 
Evidence: strong, therefore strongly recommended. 
8B – Where a selected instrument lacks one or more of these categories, a combination 
of scales should be adopted. The taskforce favours the combination of physical and 
functional grading and a VAS for patient pain and other subjective factors. 
Evidence:  insufficient, supplemented by expert opinion, therefore recommended based on
 expert opinion. 
Commentary on recommendation 8: objective, subjective and functional measures of OM
There is strong evidence (eight good-quality studies)35,40,52,54,61,64-66 and 39 adequate-
quality studies7,12,21-26,28-34,37,39,41-44,46,48-51,55-58,60,62,68,69,71-75 that the oral cavity should be exa-
mined to assess physical (objective) changes, using a good light source. Only one study 
graded OM purely on patient-reported pain, with no physical assessment53. 
In terms of functional changes (swallowing, voice and chewing), 41 studies supported 
their use in assessment21-24,26-29,31-41,43-46,49,51-53,55,57,60,62,64-72,75. There was also strong evidence 
to support the assessment of subjective measures of OM (pain, dryness and sensitivity); 
only eight studies did not include any subjective measure at all7,25,14,42,48,54,59,74. 
The evidence for combining tools was mixed, with 22 supporting 23,24,28,29,31-33,35,38,39,43,50-53,55,
60,61,65,69,71,73 and 35 not supporting7,12,21,22,25-27,30,34,36,37,40-42,44-49,54,56-59,62-64,66-68,70,72,74,75 a combi-
nation. In the studies that support a combination of assessment tools, most of them 
added a patient self-assessment element, often a VAS. It is the opinion of the taskforce 
that where OM assessments lack functional and/or subjective measures, patient-repor-
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ted assessments should be added to the routine assessment procedure. The MASCC 
guidelines highlight that objective, subjective and functional measures should be 
clearly differentiated in scales10,83.
Recommendation 9:
validity and reliability of tools
Validated assessment instruments should be used. If tools are modified, or new sca-
les are employed, they should be fully validated. Inter-rater reliability should be tested 
regularly. 
Evidence: insufficient, supplemented by expert opinion, therefore recommended based on
 expert opinion. 
Commentary on recommendation 9: validity and reliability of tools
The evidence for using validated tools was taken from studies that included a discussion 
of these issues, tested the tool’s validity or referenced an original paper that validated the 
tool in question. A high proportion of papers (n = 38) did not mention validity in any of 
these ways, including four studies that used their own assessment scales27,29,43,74. It is worth 
noting that the widely-used WHO scale has never undergone rigorous validation tests; its 
use is based upon the opinion of experts and nearly 30 years of accumulated experience. 
Several studies used scales developed for different settings or contexts, for example, 
the use of OMI to assess OM in leukaemia rather than HSCT patients51.  These findings 
raise the question whether investigators consider the appropriateness and limitations 
of particular instruments, or whether they choose a scale based on their own experi-
ence and expertise. In practice, it is likely that clinicians favour familiar instruments or 
scales that staff find easy to learn. 
Five good-quality studies52,54,61,64,65 and 12 adequate-quality studies12,23,31,34,37,44,50,51,55,58,62,71 
referred to the reliability of the tool, however, 39 studies did not consider reliability at 
all. In these cases, reliability may have been presumed by the authors, especially for the 
widely accepted tools. 
In clinical practice, the taskforce recommends that reliability should be regularly mo-
nitored. Whilst this testing may not be strictly necessary for tools of proven reliability, 
it ensures that OM monitoring remains consistent between personnel and highlights 
when training courses on OM assessment are required. 
Recommendation 10:
ease of use and patient comfort
Assessments should be easy to use by the clinician and be comfortable for the patient. 
Any physical examination of the oral cavity should take the minimum amount of time 
and be a minimally invasive procedure. 
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Evidence:  insufficient, supplemented by expert opinion, therefore recommended based on
 expert opinion. 
Commentary on recommendation 10: ease of use and patient comfort
Assessment of the oral cavity can be an uncomfortable experience for the patient; it is 
intrusive and many patients feel self-conscious about having their mouths examined. 
The examination itself may be painful and there is a risk of bleeding. 
A total of eight studies (two good-quality,54,64 six adequate-quality12,30,39,49,50,71) included 
discussions on ease of use and duration of assessment, but no studies specifically ad-
dressed these issues. There was also a lack of focus on patient comfort during assess-
ment, which may reflect the investigative nature of the papers. 
The WCCNR tool and the Oral Mucositis Nursing Instrument (OMNI) were found to be 
ideal for use in busy clinical practice, as they were quick and easy to use12,54 Similar ob-
servations were made regarding the OMAS tool1.
Excessive touching of the sensitive oral mucosa could induce greater damage and wor-
sen its condition. For this reason, the taskforce is of the opinion that physical exams 
should take the least amount of time, be minimally invasive but precise. The taskforce 
recommends that scales with extensive oral examination by trained personnel, such 
as the MacDibbs and OMI scales should only be used after careful consideration and 
elimination of all other alternatives. 
Recommendation 11: training
Clinicians assessing patients should be specifically trained in the application of the 
scale. Periodic inter-rater reliability should be used to monitor the need for staff training. 
Evidence:  insufficient, supplemented by expert opinion, therefore recommended based on
 expert opinion. 
Commentary on recommendation 11: training
For the purposes of these guidelines, where the investigators were described as expe-
rienced, or calibration procedures or inter-rater reliability tests were used, the studies 
were considered to have included training. A total of 22 studies mentioned formal trai-
ning of assessors12,23,31,33-38,43,50-54,58,64,65,69,71,74,75.
The taskforce recommends that examiners should be familiar and proficient in using 
the assessment tool in question. Several papers describe structured training such as the 
use of photographs to help maintain assessment standards23,31,61,71. The consistency and 
reliability of the tester and method should be monitored at regular intervals to deter-
mine the need for training and retraining amongst staff84. The PSMA programme34,36,37, 
effectively trains patients as well as staff. It is the opinion of the taskforce thorough 
training, as outlined in these studies, should be more widely adopted. 
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Summary
Table 3 shows a summary of the recommendations. The taskforce believes that this ana-
lysis points to some general principles for selecting OM assessment instruments.
Table 3: Summary of recommendations
Table 3.  
Summary of recommendations  
Recommendation No.
Strongly recommended  
OM should be assessed using a standardised protocol 1 
OM assessments should continue after the end treatment until OM is fully resolved or the trend to 
resolution is established 5 
Patient-reported outcomes should be included in all OM assessments 6A 
OM assessments should use instruments or a combination of suitable scales containing elements 
covering physical changes in the oral mucosa, functional changes and subjective changes 8A 
  
Recommended  
Routine assessments should take place 2 
Patient self-reporting should form an integrated part of the assessment  
Frequent assessment of OM is recommended throughout the course of any therapy, especially for 
patients who are most at risk of developing OM 4A 
  
Recommended based on expert opinion  
A comprehensive baseline oral assessment should be made prior to treatment, where OM is expected 3 
A further baseline assessment of OM should be taken as close to the administration of the first 
treatment dose as possible 4B 
Assessment for all patients should take place on a daily basis during the period when OM is likely to 
first occur, or be at its peak  
Depending on the severity of baseline OM assessments and risk factors,assessments will need to 
continue at regular intervals (daily, every 2–3 days, weekly) as OM resolves  
Assessment of subjective measures should happen prior to any physical examination (including self-
examination) of the mouth 6B 
The use of pain scoring, in relation to changes in the oral cavity,should form part of OM assessment 7 
Where a selected instrument lacks one or more of these categories a combination of scales should be 
adopted 8B 
Either validated assessment instruments should be used, or if tools are modified or new scales are to 
be employed they should be fully validated 9 
Inter-rater reliability should be tested on a regular basis  
Assessments should be easy to use by the clinician and to be comfortable for the patient. Any physical 
examination should take the minimum amount of time and be a minimally invasive procedure 10 
Clinicians assessing patients should be specifically trained in the application of the scale. Periodic inter-
rater reliability should be used to monitor the need for staff training 11 
Abbreviation: OM, oral mucositis. 
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In the out-patient setting emphasis should be placed on patient self-evaluation. The 
PSMA programme demonstrates that patients are capable of clinically-relevant assess-
ments which can be verified by a healthcare professional during patients’ visits to clinic. 
In the in-patient setting where the burden of assessment falls on nursing staff, instru-
ments should be quick and easy to implement while clinically effective. This analysis 
points to simple-to-use scales such as the WHO scale or the OAG, coupled with a VAS 
for pain. However, several instruments have been developed more recently and the 
taskforce calls for more studies into their clinical application (preferably head-to-head 
with the WHO and OAG).
The choice of instrument for the assessment of OM in the research setting requires care-
ful consideration; investigators must ensure that the instrument covers all elements of 
OM relevant to the study. The recommendations represent a consensus based on an 
interpretation of the recent literature identified in an extensive literature review, and 
the expert experience of the OMAG taskforce. Any clinician using these guidelines is 
expected to use their own experience to determine appropriate care for their patients.
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Appendix 1. 
Questions considered pertinent to OM assessment, defined prospectively by the
 taskforce
____________________________________________________________________________________
Question no. Question text____________________________________________________________________________________
Question 1.1 Is a standardised procedure used?____________________________________________________________________________________
Question 1.2 What elements are included in the procedure?____________________________________________________________________________________
Question 2 Is there evidence to suggest that routine assessment can affect:____________________________________________________________________________________
 a. the management of OM?____________________________________________________________________________________
 b. healthcare team reported outcomes?____________________________________________________________________________________
 c. patient reported outcomes?____________________________________________________________________________________
Question 3.1 In an inpatient setting,  is there evidence to support an OM assessment:____________________________________________________________________________________
 a. prior to initiating treatment?____________________________________________________________________________________
 b. during treatment?____________________________________________________________________________________
 c. post-treatment?____________________________________________________________________________________
Question 3.2 Was the OM assessment sufficient to meet study goals?____________________________________________________________________________________
Question 4.1 In an outpatient setting, is there evidence to support an OM assessment:____________________________________________________________________________________
 a. prior to initiating treatment?____________________________________________________________________________________
 b. during treatment?____________________________________________________________________________________
 c. post-treatment?____________________________________________________________________________________
Question 4.2 Was the OM assessment sufficient to meet study goals?____________________________________________________________________________________
Question 5.1 How often was an OM assessment carried out?____________________________________________________________________________________
 a. less than one daily?____________________________________________________________________________________
 b. once daily?____________________________________________________________________________________
 c. more than once daily?____________________________________________________________________________________
Question 5.2 Is there evidence that this frequency was sufficient to meet study goals?____________________________________________________________________________________
Question 6 Is there evidence to support patient reported outcomes (subjective assessment)
 in the assessment procedure?____________________________________________________________________________________
 a. before oral cavity examination?____________________________________________________________________________________
 b. with each assessment?____________________________________________________________________________________
 c. not at all?____________________________________________________________________________________
Question 7 Is there evidence to suggest that the patient’s oral intake was taken into account 
 during assessment?____________________________________________________________________________________
Question 8.1 Is there evidence to suggest that the patient’s pain score was taken into account 
 during assessment?____________________________________________________________________________________
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____________________________________________________________________________________
Question no. Question text____________________________________________________________________________________
Question 8.2 Was the pain score self reported,or reported by a healthcare professional?____________________________________________________________________________________
Question 9 Is there support for examination of the oral cavity for the following:____________________________________________________________________________________
  a. objective changes (e.g. erythema, lesions, oedema)?____________________________________________________________________________________
 b. subjective changes (e.g. pain, sensitivity, dryness)?____________________________________________________________________________________
 c. functional changes (e.g. voice, swallowing, chewing)?____________________________________________________________________________________
Question 10.1 Is there evidence to support one assessment scale over another?____________________________________________________________________________________
Question 10.2 Is there evidence to support a combination of assessment tools?____________________________________________________________________________________
Question 11 When deciding which tool to use, does the paper refer to the following factors:____________________________________________________________________________________
 a. validity?____________________________________________________________________________________
 b. reliability?____________________________________________________________________________________
 c. ease of use for the healthcare clinician?____________________________________________________________________________________
 d. time taken to use the tool?____________________________________________________________________________________
 e. comfort for the patient?____________________________________________________________________________________
Question 12 Was training given to the assessors prior to use of an assessment tool in OM?____________________________________________________________________________________
Abbreviation: OM, oral mucositis.
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Appendix 2.
Literature search terms
Published papers 
An electronic search of the Cochrane library and Medline and Embase databases used 
the following search terms: 
‘Oral mucositis’ OR oromucositis OR (‘mucosal cells’ AND (mouth OR oral)) OR ‘Stomati-
tis’ [MeSH] OR stomatitis 
AND 
((‘Radiotherapy’ [MeSH] OR ‘CT, Adjuvant’ [MeSH]) OR radiotherapy OR chemotherapy 
OR ‘Bone Marrow Transplation’ [MeSH] OR ‘Bone Marrow Transplantation’ OR ‘Bone Mar-
row Transpl’ OR ‘Bone Marrow Transplants’ OR ‘Stem Cell Transplantation’ [MeSH] OR 
‘Stem Cell Transplantation’ OR ‘Stem Cell Transplant’ OR ‘Stem Cell Transplants’) 
AND 
(assessment OR examination) 
Limits: All Adult: 19+ years, Publication Date from 1989/12/31, English, Humans. All the 
MeSH terms were exploded to capture anything that appealed below the term in the 
hierarchy and free text terms were used to ensure that all the relevant information was 
found. 
Abstracts 
Where available online at time of searching, abstracts from the following conferences 
were searched from 2003 to 2005: ASH (2005 only available), ESMO (2004), ECCO (2005 
only available), ASCO (2003–2005) and EBMT (2003–2005). Conference websites were 
searched with specific combinations of the following keywords: 
•	 Oral	mucositis	AND	assessment	OR	examination	OR	stomatitis	OR	radiotherapy	OR
chemotherapy OR bone marrow transplantation OR bone marrow transplant OR 
bone marrow transplants OR stem cell transplantation OR stem cell transplant OR 
stem cell transplants.
•	 Stomatitis	AND	assessment	OR	examination	OR	stomatitis	OR	radiotherapy	OR	che-
motherapy OR bone marrow transplantation OR bone marrow transplant OR bone 
marrow transplants OR stem cell transplantation OR stem cell transplant OR stem cell 
transplants.
•	 Mucosal	AND	assessment	OR	examination	OR	stomatitis	OR	radiotherapy	OR	chemo-
therapy OR bone marrow transplantation OR bone marrow transplant OR bone mar-
row transplants OR stem cell transplantation OR stem cell transplant OR stem cell 
transplants.
Identified abstracts were examined and those where OM was not a primary endpoint 
were discarded. For abstracts in which OM was a primary endpoint, the abstract was 
compared against papers already identified in the electronic literature search and 
against papers recently published through PubMed using the following combination 
of keywords: Author initial AND (Mucositis OR stomatitis). If the data were not publis-
hed, the first author of the abstract will be contacted to see if the paper is ‘in press’.
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Abstract
Daily chlorhexidine mouthwash is often recommended for preventing chemothera-
py-induced oral mucositis. Povidone-iodine, NaCl 0.9%, water salt soda solution and 
chamomile mouthwash are also recommended. However, the effectiveness of these 
mouthwashes is unclear. Therefore, we performed a systematic review to assess the 
effectiveness of mouthwashes in preventing and ameliorating chemotherapy-induced 
oral mucositis. Based on study quality, three out of five randomized controlled trials 
were included in a meta-analysis. The results failed to detect any beneficial effects of 
chlorhexidine as compared with sterile water, or NaCl 0.9%. Patients complained about 
negative side-effects of chlorhexidine, including teeth discoloration and alteration 
of taste in two of the five studies on chlorhexidine. The severity of oral mucositis was 
shown to be reduced by 30% using a povidone-iodine mouthwash as compared with 
sterile water in a single randomized controlled trial. These results do not support the 
use of chlorhexidine mouthwash to prevent oral mucositis.
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Introduction
Oral mucositis occurs in about 40% of patients who undergo cytostatic chemotherapy 
for malignancies1, 2. Virtually every patient who has undergone myeloablative therapy 
to prepare for a haematopoietic stem cell transplant (HSCT) develops mucositis, with 
67% developing severe oral mucositis3.
Damage to the mucous membranes (mucositis) can occur as a consequence of the di-
rect effects of cytostatic drugs on the rapidly dividing cells in the tissues in the mouth. 
The initial symptoms of mucositis usually present between the fourth and seventh day 
after chemotherapy4. White discoloration of the mucous membranes mostly precedes 
the redness, oedema and lesions. These lesions can develop into large painful ulcers 
that can seriously hinder eating and drinking5. Furthermore, the protective effect of 
saliva can be reduced – due to a decrease in the quality and quantity – increasing the 
chance of developing infection6, 7.
Severe mucositis results in a significant reduction in the quality of life, potential nutri-
tional deficit and even the postponement of chemotherapy8. A recent study among 92 
stem cell transplant recipients in eight centres in the United States, Canada and Europe 
demonstrated that the amount and severity of oral mucositis correlated with the num-
ber of days that patients required intravenous antibiotics, analgesics and parenteral 
feeding. The severity of mucositis among stem cell transplant recipients was also corre-
lated with the number of admissions and readmissions, hospital costs and mortality9.
The high incidence and severe consequences of mucositis among patients who un-
dergo chemotherapy underline the importance of good prevention.
Rinsing the mouth daily with chlorhexidine solution is a preventive measure frequently 
recommended by nurses. Solutions of sodium bicarbonate, chamomile and 0.9% saline 
are also often used in the Netherlands10. The extent to which these mouthwashes actu-
ally help to prevent mucositis is unclear. Clinical practice guidelines for the prevention 
and treatment of cancer therapy-induced oral and gastrointestinal mucositis have been 
produced11, but only two studies were used as evidence to support the use of chlorhexi-
dine although there are more studies available in the international literature. Moreover, 
there was no meta-analysis. There is also a review by Clarkson et al12. involving patients 
who received chemotherapy and/or radiotherapy. However, it is commonly known that 
mucositis induced by chemotherapy differs from that induced by radiation11. Therefore, 
we undertook to search the international literature afresh to ascertain whether these 
mouthwashes actually contribute to the prevention of oral mucositis among patients 
who undergo treatment with cytostatic chemotherapy.
Method
Search strategy
The Medline and Cinahl databases were searched for the relevant literature published 
from 1992 to the autumn of 2004. The search was restricted to these years in order to 
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obtain maximal validity in the light of oncology care today. The search terms ‘mucositis, 
‘stomatitis’ and ‘chemotherapy’ were used in combination with ‘prevention’, ‘mouthwa-
shes’, ‘antiseptic’, ‘oral infection’, ‘chlorhexidine’, ‘chamomile’, ‘PVP-iodine’ and ‘sodium bi-
carbonate’.
Selection criteria
All randomized studies of the effect of mouthwashes for the prevention and ameliora-
tion of oral mucositis in adult patients undergoing chemotherapy were eligible for this 
systematic literature study. Two independent assessors CP and RU selected the articles. 
The titles and/or abstracts were used to identify those that meet the inclusion criteria. 
Studies were selected if they involved using mouthwashes for oral mucositis, had a con-
trolled study design, involved adult patients with cancer who received chemotherapy 
and included an outcome measure of the severity of mucositis. If a difference of opinion 
arose, a third author was consulted before the article was included or excluded.
Study quality and analysis
The quality of a systematic review is related to the quality of the studies used with 
randomized controlled trials topping the hierarchy of evidence13. Quality assessment 
allows appraisal of the studies included and also aids data synthesis. The quality of stu-
dies was assessed for randomization, blinding and the intention-to-treat analysis. In 
randomized controlled trials, patients are randomly assigned to either a control or an 
experimental group. For blinding, a trial was classified as adequate if it was described 
as ‘double-blind’, a type of clinical trial in which neither the subject nor the investigator 
knows what treatment the patient is receiving. An intention-to-treat analysis specifies 
how to handle non-compliant patients in a randomized controlled trial. This analysis 
requires that patients be analysed in the groups into which they were randomized, re-
gardless of whether or not they complied with the treatment allocated14.
In a meta-analysis or statistical pooling, the data gathered in the framework of a syste-
matic review are statistically combined to estimate the effect of the intervention stu-
died in the research15.
The findings of the individual studies were analysed in a meta-analysis using the 
software Review Manager 4.216. In systematic reviews, homogeneity refers to the 
degree to which the results of studies included in a review are similar. A fixed effect 
model was allowed since homogeneity was found between the studies (Chi-squared
test: P < 0.1).
This is a statistical model that stipulates that the units under analysis (people in a trial 
or study in a meta-analysis) are the ones of interest, and thus constitutes the entire 
population of units. Only within-study variation is taken to influence the uncertainty 
of results (as reflected in the confidence interval) of a meta-analysis using a fixed effect 
model. Variation between the estimates of effect from each study (heterogeneity) does 
not effect the confidence interval in a fixed effect model.
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Results
The search term ‘mucositis or stomatitis’ provided 7589 hits using Medline and Cinahl 
for the period 1992–2004. When combined with ‘prevention’, there were still 905 ar-
ticles. After combining with ‘mouthwashes’, ‘antiseptic’, ‘oral infection’, ‘chlorhexidine’, 
‘chamomile’, ‘PVP-iodine’ or ‘sodium bicarbonate’, 20 articles remained (Fig. 1). Five
of these studies investigated chlorhexidine in a randomized controlled clinical trial 
(RCT)17-21. Three articles were found which investigated iodine solution as a mouthwash. 
However, further investigation revealed that these three articles were all reports of the 
same study. Hence only the most complete one is included in the review22.
One study determined the effects of chamomile solution23. The other 11 articles were 
excluded: five were not RCTs but tutor reviews, two investigated dental problems and 
two discussed guidelines for mucositis and were therefore excluded. One study investi-
gated micronized sucralfate versus salt and soda mouthwashes in head and neck can-
cer patients who received radiation therapy. This study was excluded because it dealt 
with radiation-induced mucositis and not chemotherapy-induced mucositis. Another 
study also investigated sodium bicarbonate, but did not use a randomized study de-
sign (clinical trial) and was therefore excluded.
No RCTs investigating sodium bicarbonate were found. However, three articles were 
found which investigated salt and soda, this solution is similar to sodium bicarbonate. 
In one study, where chlorhexidine was used as the intervention, the control group used 
a water, salt and soda solution. This study was included20.
Figure 1:  Selection of articles
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Figure 1  Selection of articles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Inclusion Exclusion 
Chlorhexidine    5  
Chamomile  1  
PVP-iodine 1 2 
Tutor reviews  5 
Guidelines  2 
Dental problems  2 
Head and neck cancer  1 
Clinical trial  1 
 
 
 
 
Cancer, neoplasm
                AND 
Chemotherapy  
                AND 
Mucositis OR stomatitis = 7589 
Prevention = 905
Mouthwashes or chlorhexidine OR chamomile OR PVP-iodine or sodium bicarbonate = 20 
AND 
AND 
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Study characteristic
The seven studies (Tables 1 and 2) included data from 863 adults with cancer with a mean 
age of 53.6, 72% of the patients in the studies received chemotherapy, only 6% of the pa-
tients received HSCT, for 22% of the patients it is unknown which treatment was received.
The World Health Organization instrument24 was used to score mucositis in three 
studies21-23: one study adapted this scale18, two studies19, 20 used the Oral Assessment 
Guide25 and one study employed a four-point scale developed by the investigator17. The 
frequency of assessing mucositis varied from once to twice a day, once weekly, and on 
three separate occasions during treatment.
Table 2:  Overview of the effect of mouthwashes other than chlorhexidine in preventing mucositis among 
 patients undergoing chemotherapy
Study quality
All studies randomly allocated subjects to either an intervention or a comparison group. 
Only one study assigned patients to one of the treatment groups by stratified block 
randomization21, the blocks being selected using a set of random sampling numbers. A 
double-blind study design was used in five studies, though the group assignment was 
revealed in one study at an early stage18. Another study had an open study design22 
and the last study did not report blinding at all17. The analysis was conducted on an 
intention-to-treat basis in four studies17, 21-23.
Compliance
The compliance of patients with treatment has an important effect on the results of 
different studies, and is therefore an important element to consider26. However, patient 
compliance was assessed in only three studies. Dodd et al.20 collected the mouth rinse 
bottles and measured the amounts remaining and compared this with what should 
have been used. Compliance in this study was very high (92%), although it is not known 
if patients disposed of their mouth rinses in another manner, but the investigators had 
no reason to believe that this occurred. However, Epstein et al.17 found less positive re-
sults regarding compliance with rinsing. In their study, assessment of compliance was 
based on medication records and on an interview at weekly assessment visits. Patients 
assigned to rinsing with Nystatin alone or in combination with chlorhexidine showed 
poor compliance, with only 47% of patients in the nystatin-chlorhexidine rinse group
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Table 2 Overview of the effect of mouthwashes other than chlorhexidine in preventing mucositis among patients undergoing chemotherapy 
 
Author / 
date 
Intervention Dose Control group Number of patients + Effect in terms of preventing 
mucositis 
Side effects Successful 
randomization / 
blinding / 
Intention-to-treat 
analysis  
Fidler/  
1996 
20 drops 
chamomile 
solution in 
100 ml water 
3x daily 
1 min rinse 
3 to 5x  
Mouthwash 
without 
chamomile 
Intervention group: 82
Control group: 82 
Power < 80 
Mucositis score * 
Physician: intv. 40% cont 45% 
Patient intv. 49% cont. 61%  
Chamomile was well 
tolerated with no increase in 
nausea and vomiting 
Yes / Complete / Yes 
 
Adamietz/
1998 
PVP-iodine 
betaisodona® 
3 min. rinse  
4x daily 
Sterile water Intervention group: 20
Control group: 20 
Power < 80 
Mucositis score * 
Intv. 70% 
Cont. 100% 
None: as long as the iodine 
was not swallowed as then 
there is a risk of 
hyperthyroidism  
Yes / no, open/ Yes 
 
+ Power calculation assuming α = 0.05, ∆ = 20% in frequencies or 20% of scale range 
* WHO scale                   ** Oral Assessment Guide (OAG) 
 
Figure 2  Forest plot mucositis 
 
Review: Chlorhexidine oral rinse
Comparison: 01 Chlorhexidine versus placebo                                                                               
Outcome: 02 mucositis                                                                                                  
Study  Treatment  Control  WMD (fixed)  Weight  WMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
Epstein 1992 A          18      2.61(1.63)          18      2.50(1.88)      13.11      0.11 [-1.04, 1.26]       
Epstein 1992 B          34      3.10(1.74)          16      2.95(1.49)     19.79     0.15 [-0.79, 1.09]       
Dodd 1996              112     14.10(3.08)         110     13.79(2.39)      33.00      0.31 [-0.41, 1.03]       
Dodd 2000 A             51     13.71(2.65)          48     13.21(2.39)      17.56     0.50 [-0.49, 1.49]       
Dodd 2000 B             51     13.71(2.65)          42     13.81(2.38)      16.54     -0.10 [-1.12, 0.92]       
Total (95% CI)    266                         234 100.00      0.22 [-0.20, 0.63]
Test for heterogeneity: Chi² = 0.80, df = 4 (P = 0.94), I² = 0%
Test for overall effect: Z = 1.03 (P = 0.31)
 -4  -2  0  2  4
 Favours treatment  Favours control  
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 using the rinse a 100% of the time, 78% of patients using chlorhexidine at all times, but 
89% of them using the saline solution group at all times.
Pitten et al.21 used brown glass bottles. On visiting the patients to assess mucositis, the 
clinician checked if the volume remaining in the bottle correlated with the number of 
rinses. The findings indicated that the patients had rinsed properly.
Chlorhexidine
Chlorhexidine is approved for use as an antibacterial mouthwash at a concentration of 
0.12% and 0.2% to prevent the build-up of dental plaque and to prevent gingivitis27. 
Its broad spectrum of antibacterial activity, minimal systemic absorption and ability to 
bind to oral surfaces led to use as prophylaxis in an attempt to prevent the develop-
ment of oral mucositis28.
Chlorhexidine has been tested in five randomized studies for its effects in preventing 
oral mucositis in patients undergoing chemotherapy (Table 1).
Epstein et al.17 investigated three different mouthwashes, chlorhexidine, nystatin and a 
combination of nystatin-chlorhexidine and compared these with rinsing using a saline 
solution. All patients (n=86) who received medical therapy that resulted in severe neu-
tropenia were included into the study. Fifty-six patients (65%) received aggressive chemo-
therapy for remission induction or consolidation. Thirty patients (35%) received HSCT. The 
patients were asked to rinse with the mouthwash after eating. Oral hygiene was assessed 
using the gingival index and plaque levels, and mucositis was assessed using a four-point 
scale specially developed for the study. Bacterial and fungal oral  cultures were done on a 
weekly basis. There was no difference in mucositis between the four groups although bac-
terial and fungal infections were found less often among the patients using chlorhexidine.
Rutkauskas and Davis18 investigated the effect of chlorhexidine versus a placebo in 
patients undergoing HSCT or remission-indication chemotherapy. The study showed 
chlorhexidine to be ineffective in preventing mucositis. Unfortunately, the data were 
also presented in a form that made it impossible to include them in the meta-analysis.
Dodd et al.19 investigated the effect of an instruction programme for the systematic 
oral care of 222 patients undergoing chemotherapy provided by nurses in combination 
with two mouthwashes (chlorhexidine and sterile water). The preventative effects of 
rinsing with chlorhexidine were no greater than those of rinsing with sterile water lea-
ding the investigators to recommend rinsing with water only.
Dodd et al.20 also compared the preventative effects of three mouthwashes (chlorhexi-
dine, salt and soda in water) and ‘magic mouthwash’ (containing Lidocaine, Benadryl 
and Maalox) in patients who received stomatotoxic chemotherapy at home and were 
monitored on an outpatient basis. Nurses used the Oral Assessment Guide for initial 
assessment, instructed patients on how to assess their own mouths, then phoned the 
patients every other day to note their oral status. No differences in the severity of muco-
sitis were found between the three groups nor were there any significant differences in 
the time taken for signs and symptoms of mucositis to subside. The first signs of muco-
sitis were seen within 6.6 days in the chlorhexidine group, within 7.0 days in the water/
salt/soda group and within 7.2 days in the ‘magic mouthwash’ group.
  111
Chapter 7            The effeciveness of commonly used mouthwashes 
Pitten et al.21 investigated chlorhexidine versus amine-stannous fluoride solution to 
investigate whether leucopenic patients who cannot clean their teeth mechanically 
might have clinical benefit from an antiseptic mouth rinse containing chlorhexidine. 
The statistical analysis showed that there was a significant decrease in the numbers of 
micro-organisms in the oral cavity during leucopenia among those in the chlorhexidine 
group compared with that in the control group. However, this did not translate into any 
measurable clinical benefit. Patients rinsing with chlorhexidine also indicated that the 
rinsing was unpleasant and even painful.
Power
None of the studies reported a power calculation, so we calculated this from the num-
bers of patients reported, assuming an alpha of 0.05 (two-sided) and a clinically rele-
vant effect size of 20% of the scale range for severity of mucositis in several studies, or 
a 20% difference in frequencies in studies with presence or absence of mucositis as the 
main outcome. Only the studies by Dodd et al.19, 20 had sufficient power (≥ 80%). The 
study by Fidler et a23 had an estimated power of 70%, whereas the power of the other 
studies was less.
Meta-analysis
Within the meta-analysis, the results from individual studies were weighted in inverse 
proportion to their variance, resulting in a weight proportional to the size of the studies.
Four out of five studies that investigated chlorhexidine mouthwash for preventing mu-
cositis were eligible for inclusion in the meta-analysis. Rutkauskas and Davis and Pitten 
et al.18, 21 did not state all of the necessary figures for this. The study by Epstein et al.17 
had a total of four groups and in the analysis was approached as two studies, namely 
chlorhexidine versus saline solution and chlorhexidinẹ nystatin versus nystatin.
The study by Dodd et al.20 was also entered as two studies (chlorhexidine vs. water/salt/ 
soda and chlorhexidine vs. ‘magic mouthwash’). All the information is contained within 
the forest plot graphical representation of the results in Figure 2.
Figure 2:  Forest plot mucositis
Taken together the results, the five studies showed no significant effect of chlorhexi-
dine mouthwash (Weighted mean differences 0.22; 95% confidence interval =−0.20, 
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Table 2 Overview of the effect of mouthwashes other than chlorhexidine in preventing mucositis among patients undergoing chemotherapy 
 
Author / 
date 
Intervention Dose Control group Number of patients + Effect in terms of preventing 
mucositis 
Side effects Successful 
randomization / 
blinding / 
Intention-to-treat 
a alysis  
Fidler/  
1996 
20 drops 
chamomile 
solution in 
100 ml water 
3x daily 
1 min rin e 
3 to 5x  
Mouthwash 
without 
chamomile 
Intervention group: 82
Control group: 82 
Power < 80 
Mucositis score * 
Physician: intv. 40% cont 45% 
Patient intv. 49% cont. 61%  
Chamomile was well 
tolerated with no incre se  
nausea and vomiting 
Yes / Complete / Yes 
 
Adamietz/
1998 
PVP-iodine 
betaisodona® 
3 min. rinse  
4x daily 
Sterile water Intervention group: 20
Control group: 20 
Power < 80 
Mucositis score * 
Intv. 70% 
Cont. 100% 
None: as long as the iodine 
was not swallowed as then 
there is a risk of 
hyperthyroidism  
Yes / no, open/ Yes 
 
+ Power calculation assuming α = 0.05, ∆ = 20% in frequencies or 20% of scale range 
* WHO scale                   ** Oral Assessment Guide (OAG) 
 
Figure 2  Forest plot mucositis 
 
Review: Chlorhexidine oral rinse
Comparison: 01 Chlorhexidine versus placebo                                                                               
Outcome: 02 mucositis                                                                                                  
Study  Treatment  Control  WMD (fixed)  Weight  WMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
Epstein 1992 A          18      2.61(1.63)          18      2.50(1.88)      13.11      0.11 [-1.04, 1.26]       
Epstein 1992 B          34      3.10(1.74)          16      2.95(1.49)      19.79      0.15 [-0.79, 1.09]       
Dodd 1996              112     14.10(3.08)         110     13.79(2.39)      33.00      0.31 [-0.41, 1.03]       
Dodd 2000 A             51     13.71(2.65)          48     13.21(2.39)      17.56      0.50 [-0.49, 1.49]       
Dodd 2000 B             51     13.71(2.65)          42     13.81(2.38)      16.54     -0.10 [-1.12, 0.92]       
Total (95% CI)    266                         234 100.00      0.22 [-0.20, 0.63]
Test for heterogeneity: Chi² = 0.80, df = 4 (P = 0.94), I² = 0%
Test for overall effect: Z = 1.03 (P = 0.31)
 -4  -2  0  2  4
 Favours treatment  Favours control  
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0.63). The test for heterogeneity and the test for overall effect are given at the bottom 
of the forest plot. It is important to remember that heterogeneity may be present when 
all or most studies indicate the same treatment effect, but the size of the effect differs or 
the trials are contradictory about the effect29. The results are considered homogenous 
when the effect sizes differ due to sampling errors.
Other mouthwashes
Table 2 provides an overview of randomized studies into the effect of mouthwashes other 
than chlorhexidine in preventing mucositis in patients undergoing chemotherapy.
Fidler et al.23 evaluated the effect of a chamomile solution in a group with a total of 164 
patients treated with 5-FU chemotherapy. After randomization, 82 patients received a 
mouthwash with a chamomile solution and 82 patients received a mouthwash without. 
All patients received oral cryotherapy for 30 min with each dose of 5-FU. Mucositis was 
scored by the physician (scale of 0–4). The patient also recorded his or her score on a 
daily basis. No differences were found between the chamomile group and the control 
group in either the incidence or severity of mucositis.
Adamietz et al.22 investigated the preventative effects of iodine solution as a mouthwash 
compared with rinsing with water in 40 patients given radiochemotherapy (n=20 for 
both groups). The World Health Organization criteria for mucositis (scale of 0–4) were 
used to estimate the severity and duration of the mucositis. The iodine group had a 
significantly less severe mucositis compared with the control group and the duration of 
the mucositis was shorter (2.8 weeks for the iodine group vs. 9.3 weeks for the control 
group). However, the study was too small to be confident that the difference observed 
was not simply a chance finding.
Conclusion
A systematic review was used to assemble and synthesize the evidence for the effect of 
commonly used mouthwashes on the prevention of chemotherapy-induced oral mu-
cositis. Comprehensive search methods were used to minimize any bias.
With the exception of iodine solution, none of the studies investigated were able to 
demonstrate an effect in preventing mucositis in patients undergoing chemotherapy.
Chlorhexidine
Chlorhexidine is widely used and has been investigated albeit in various small studies. 
Individually, the studies found chlorhexidine to be ineffective and increasing power 
through meta-analysis did not alter this. Studies done before 1992 found a positive 
effect of rinsing with chlorhexidine30-32 whereas those conducted in the period 1992–
2004 found either no effect or a negative effect. One possible explanation could be 
that bacterial infections were better controlled and managed after 1992 than before 
because of better antibiotics.
The discoloration of teeth, the bitter taste and the unpleasant sensation experienced 
.
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together with ineffectiveness are sufficient reasons for recommending sterile water, 
0.9% saline solution or sodium bicarbonate (water, salt and soda) rather than chlorhexi-
dine. Furthermore, these alternatives are less expensive and readily available in every-
day nursing practice.
Other mouthwashes
Most of the other formulations had no effect on the prevention of mucositis. The anti-
fungal drug nystatin, even in combination with chlorhexidine, was no exception17.
Even chamomile, which has an anti-inflammatory effect, proved ineffective33.
One study did demonstrate that iodine solution was effective as a mouthwash, but this 
finding must be treated with caution, due to the small sample sizes involved. Moreover, 
side-effects were not reported, though, when accidentally swallowed, iodine can cause 
hyperthyroidism.
The sample sizes varied from 21 to 222 and none of the studies indicated the power 
calculation based on a proposed treatment effect even though adequate statistical po-
wer is crucial to minimize type-II or beta errors34. This shortcoming was compensated 
to some extent by the meta-analysis supporting the negative conclusions for chlorhexi-
dine, which does not apply to other mouthwashes.
Patient compliance with the intervention has an important effect on the results and 
should always be considered26, yet only three studies did so17, 20, 21.
Based on our findings and those of others11, 12, the use of chlorhexidine as well as other 
mouthwash for preventing oral mucositis in patients undergoing chemotherapy can-
not be recommended. The use of an iodine solution could be promising, but should be 
investigated further.
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Abstract
The objective of this study was to identify and to assess the quality of evidence-based 
guidelines and systematic reviews. We used the case of oral mucositis to apply general 
quality criteria for the prevention and treatment of oral mucositis in patients receiving 
chemotherapy, radiotherapy or both. 
Literature searches were carried out in several electronic databases and websites. 
Publications were included if they concerned oral mucositis involving adults treated 
for cancer and had been published after January 1, 2000. As far as systematic reviews 
are concerned, the article had to report a search strategy, the search was minimally 
conducted in the databases PubMed or Medline and the articles included in the review 
were subjected to some kind of methodological assessment. 
The Appraisal of Guidelines for Research and Education (AGREE) instrument was used 
to assess the quality of the guidelines and the Overview Quality Assessment Question-
naire (OQAQ) was used for the quality of systematic reviews. 
Thirty one articles met the inclusion criteria of which eleven were guidelines and 20 
were systematic reviews. Nine of the eleven guidelines did not explicitly describe how 
they identified, selected and summarised the available evidence. Reviews suffered from 
lack of clarity, for instance in performing a thorough literature search. The quality varied 
among the different guidelines and reviews. 
Most guidelines and systematic reviews had serious methodological flaws. 
There is a need to improve the methodological quality of guidelines and systematic 
reviews for the prevention and treatment of oral mucositis if they are to be used in 
clinical practice.
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Introduction
Clinical guidelines are an important tool to provide effective and efficient care. They are 
‘systematically developed statements to assist practitioner decisions about appropriate 
health care for specific clinical circumstances’1.  To ensure high quality, the guidelines 
should be based on the best available scientific evidence 2.
Existing guidelines and protocols seem mostly based on tradition, subjective observa-
tion and incomplete evidence. This results in uncertainty among nurses about which 
advice or treatment is the best for their patients. The development of an evidence-
based guideline is essential for those taking care of patients. The development of such 
guidelines may promote uniformity of care both within a centre, as well as between 
centres and potentially increase the quality of care provided to patients. Clinicians use 
a variety of guidelines and protocols. These documents vary in the degree of detail and 
the evidence upon which these guidelines and protocols are based is unknown. Syste-
matic reviews can aid in guideline development because they involve searching for, se-
lecting, critically appraising and summarising the results of primary research. The more 
rigorous the review methods used and the higher the quality of the primary research 
that is synthesised, the more evidence-based the practice guideline is likely to be3.
In recent years, the number of available clinical practice guidelines has rapidly incre-
ased. This recent increase in the production of clinical practice guidelines has been ac-
companied by growing concern about the variations in guideline recommendations 
and quality. In fact, several studies suggested that many existing guidelines are of poor 
quality4, 5. To see whether these concerns about the quality of existing guidelines and 
systematic reviews are justified, we undertook a study to examine the quality of guide-
lines and systematic reviews using guidelines and systematic reviews developed for the 
prevention and treatment of oral mucositis.
Oral mucositis is a burdensome and potentially dangerous side effect of many antican-
cer therapies that include chemotherapeutic agents or ionising radiation6. Oral muco-
sitis plays a significant role in the physical and psychosocial aspects of patients under-
going cancer therapy and presents a larger problem than is currently recognised from 
a public health perspective.
Incidence as well as severity may vary from patient to patient and the likelihood of de-
veloping mucositis is dependent upon the cancer treatment. As the primary advocates 
for patients, nurses are central to recognising, preventing and managing oral mucositis 
to ameliorate its debilitating effects on patients. Nurses have three primary responsibi-
lities in managing oral mucositis:
(1) effective assessment and monitoring of the oral cavity as well as symptoms;
(2) disease management focusing on ensuring that appropriate intervention is
 available to patients; and
(3) patient education7.
A potential mechanism for improving outcomes in patients with oral mucositis would 
be to ensure that those patients are receiving evidence-based care. 
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Aims
The primary objective of the current study is to identify and assess the quality of avai-
lable guidelines and systematic reviews for prevention and treatment of oral mucositis. 
Rather than focussing on their content, we critically reviewed the methods employed 
and documented in writing the reviews and guidelines.
Materials and Methods 
Definitions
A systematic review uses a predefined, explicit methodology. The methods used in-
clude steps to minimise bias in all parts of the process: identifying relevant studies, 
selecting them for inclusion and collecting and combining their data. Studies should 
be sought regardless of their results8.
Guidelines are systematically developed statements to assist clinician and patient deci-
sions about appropriate health care specific clinical circumstances1. 
Search strategy
To identify the guidelines focused on prevention and treatment of oral mucositis, the 
websites of the main international institutions involved with prevention and treatment 
of cancer were explored as recommended by various authors9-14. Guidelines on the pre-
vention and treatment of oral mucositis published from 2000 to May 2006 were iden-
tified and downloaded. In addition, four computerised databases: PubMed, CINAHL 
(Cumulative Index of Nursing and Allied Health Literature); PiCarta (OCLC PICA system 
consisting the Dutch Central Catalogue and Online Content) and INVERT (Index of the 
Dutch nursing journal literature) were searched. All relevant English and Dutch web-
sites were searched with the keywords: guidelines, stomatitis, mucositis, oral care and 
mouth care.
Relevant systematic reviews were identified by searching 8 electronic databases of 
articles published from January 1, 2000 through May 31, 2006. These were: PubMed, 
Embase, CINAHL, PiCarta, INVERT, DARE, Cochrane Database of Systematic Reviews and 
Psychinfo. This publication time frame guaranteed data from systematic reviews con-
ducted in the recent past. Where one review clearly updated a previous review, only the 
most recent publication was used. To identify additional relevant studies the Science 
Citation Index was used to search for studies that cited located relevant papers.
Search strategies for electronic databases were developed sequentially, starting with 
PubMed, as this was expected to yield the highest number of relevant papers. The re-
view used a search strategy with Medical Subject Headings and text words (Box 1). Si-
milar search strategies were made for the other databases. There were no language 
restrictions applied.
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Box 1: Search strategy PubMed
(Oral Hygiene"[MeSH] OR "Stomatitis"[MeSH] OR "oral mucositis"[All Fields] OR "mouth 
care"[All Fields]) AND ("Radiation Oncology"[MeSH] OR "Medical Oncology"[MeSH] 
OR "Hematologic Neoplasms"[MeSH] OR "Oncologic Nursing"[MeSH] OR 
"Neoplasms"[MeSH] OR "chemotherapy"[All Fields] OR "radiotherapy"[All Fields] OR 
"cancer patients"[All Fields]) AND (review[pt] OR "meta-analysis"[pt] OR "quantita-
tive* overview*"[tw] OR "systematic* review*"[tw] OR "systematic* overview*"[tw] OR 
"methodologic* review*"[tw] OR "methodologic* overview*"[tw] OR "guideline"[pt] 
OR "practice guideline"[pt] OR "health planning guidelines"[mh] OR "consensus de-
velopment conference"[pt] OR "consensus development conference, nih"[pt] OR 
"consensus development conferences"[mh] OR "consensus development conferen-
ces, nih"[mh] OR "guidelines"[mh] OR "practice guidelines"[mh] OR (consensus[ti] 
AND statement[ti])
Selection criteria
Two reviewers (CP and PM) conducted independently screening of relevant studies for 
inclusion. Disagreements were resolved by discussion with a third member of the team 
(TvA). The first level of screening using titles, publication years and abstracts, was to 
include papers only if they concerned oral mucositis involving adults treated for cancer 
and had been published after January 1, 2000 and were probably a guideline or a sys-
tematic review 
The second level of screening was based on full text, with the same criteria as described 
above. As far as systematic reviews are concerned, publications were only included, ac-
cording to our definition of a systematic review. The article reported:  (1) a description 
of the search strategy (2) a minimal search in the databases PubMed or Medline and 
(3) the articles included in the review were subjected to some kind of methodological 
assessment.
Instruments to assess quality
Quality of guidelines was assessed with the Appraisal of Guidelines for Research and 
Evaluation (AGREE) instrument since it is internationally recognised, rigorously deve-
loped and a validated instrument that compares well with other instruments designed 
for this purpose15. Three reviewers (CP, PM and TvA) rated each guideline. The AGREE in-
strument instructs the reviewer to make a judgement as to the quality of the guideline, 
taking each of the appraisal criteria into consideration. The 23-item AGREE instrument 
is divided into the following six domains (see Box2): scope and purpose (three items); 
stakeholder involvement (four items); rigor of development (seven items); clarity and 
presentation (four items); applicability (three items); and editorial independence (two 
items)16.  Each item is rated on a 4-point scale ranging from 4 ‘Strongly Agree’ to 1 
‘Strongly Disagree’, with two midpoints: 3 ‘Agree’ and 2 ‘Disagree’. The scale measures 
the extent to which a criterion (item) has been fulfilled.  The score for each domain is 
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obtained by summing up all the scores of the individual items in a domain and then 
standardising as follows:
obtained score - minimum possible score
maximum possible score - minimum possible score
The maximum score for each domain would be the number of questions multiplied by 
the number of reviewers multiplied times 4 (ie, the score for strongly agree). The mini-
mum possible score for a domain would be the number of questions multiplied times 
the number of reviewers multiplied times 1 (ie, the score for strongly disagree). The final 
component of the AGREE instrument involves a recommendation regarding the use of 
the guidelines in practice as following;
1. ‘Strongly recommended,’ if the guideline rated high on the majority of items and
 most domain scores were 60%, indicating that the guideline had a high overall 
 quality and could be considered for use in practice without alterations; 
2. ‘Recommended’ with provisos or alterations if the guideline rated high or low on
 a similar number of items and most domain scores were 30%–60%, indicating that 
 the guideline had a moderate overall quality;
3. ‘Would not recommend’ if the guideline rated low on the majority of items and
 most domain scores were 30%, indicating that the guideline had a low overall
 quality and serious shortcomings and thus should not be recommended for use in
 practice; and finally, 
4. ‘Unsure’ if the guideline did not give sufficient information to enable to assess its
 quality17.
Quality of systematic reviews was assessed with The Overview Quality Assessment 
Questionnaire (OQAQ)18. This scale was selected because of its strong face validity and 
the availability of a published assessment of its construct validity. (see Box 3)  The validi-
ty of the scale has been thoroughly tested and clearly validated using several different 
measures19, 20. This instrument includes nine items pertaining to individual aspects in 
the reporting of a systematic review (e.g., were the search methods used to find evi-
dence on the primary question stated?). Each item is assessed using a three-point scale 
(i.e. no, partially/can't tell or yes). A final question elicits an overall scientific quality of 
the systematic review based on the previous items on a scale of 1-7, with 7 indicating 
superior quality and a score of  ≥ 5 indicating that the study has only minimal or minor 
flaws21. ‘The Review Appraisal Form’ was applied to each review independently by 2 
researchers and then judged by consensus.
Results 
Availability and quality of guidelines and reviews
After removal of duplicates, a total of 493 citations were identified from the electronic 
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searches (Figure 1). Two reviewers screened the titles and abstracts for further review. 
It was decided that 165 (34%) of the citations were potentially relevant based on the 
predetermined inclusion criteria. After reading the full text, the reviewers came to a 
consensus that 34 of these met the criteria for selection. 
Guidelines
Eleven of the 34 publications were guidelines. Six of the 11 guidelines were downloads 
from the Internet of which three were English and three were Dutch. The five remaining 
guidelines were publications in peer-reviewed journals. Each guideline was scored for 
each of the six domains of the AGREE-instrument, as shown in Table 2. 
A first finding is that none of the guidelines were of good overall quality. None of the 
guidelines had scores >60% in all domains and none had a score between 30% and 
60%, in all domains, indicating low overall quality for all guidelines according to the 
AGREE Instrument.  Almost all the guidelines were considered poor in the domains ‘ap-
plicability’ and ‘editorial independence’. 
Table 2: quality assessment guidelines
Applicability evaluates the likely organisational, behavioural and cost implications of 
applying the guideline, whereas editorial independence addressed potential conflicts 
of interest in guideline developers (e.g. due to sponsoring by companies selling pro-
ducts within the guideline scope). Nine of the eleven guidelines did not explicitly des-
cribe how they identified, selected and summarised the available evidence. Most of 
the guidelines did not provide an explicit link between the recommendations and the 
supporting evidence.
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Table 2 quality assessment guidelines 
Averaged AGREE scores by domain 
Author/year Scope and 
Purpose 
Stakeholder 
Involvement
Rigor of 
Development
Clarity and 
Presentation
Applicability Editorial 
Independence
(CBO 2004)28 93 44 56 61 48 22 
(Rubenstein et al. 2004a)6 59 39 56 61 22 72 
(Stricker 2003)29 56 50 38 56 11 11 
(Barasch et al. 2006)30 33 53 25 47 0 17 
(The Royal College of Surgeans of 
England 2004)31 
70 8 10 67 19 0 
(Milligan et al. 2001)32 33 19 8 28 11 28 
(Oncology Nursing Society 2001)33 26 14 16 47 15 6 
(LWVOC 2001a)34 22 6 5 58 19 0 
(West & Mitchell 2004)35 33 6 5 22 4 28 
(LWVOC 2001b)36 19 11 3 53 11 0 
(National Cancer Institute 200523 7 0 5 8 0 7 
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Systematic reviews
Only 23 of the 154 reviews were original systematic reviews. One review was an over-
view of two other included systematic reviews and in two of the reviews oral mucositis 
was not the primary topic, hence they were excluded.  A total of 20 systematic reviews 
remained in this study. Agreement was reached on the scoring of all component scores 
and the overall quality scores with the need for an additional independent reviewer in 
two cases, because two of the 20 reviews were written by co-authors involved in this 
review. 
Reviews suffered from lack of clarity, for instance in performing a thorough literature 
search, avoiding bias in the inclusion of studies and properly referring to the quality 
of the included studies. Table 3 shows the systematic reviews and contains the quality 
score of the 20 identified reviews. Interventions for preventing oral mucositis were des-
cribed in seven reviews, only one review was found describing interventions for treat-
ment of oral mucositis. All reviews made formal assessment of methodological quality 
of included randomised studies and most had included trials that were not double blin-
ded for the patient and assessor. None of the reviews excluded trials from analysis be-
cause of low quality through a small sample size. Most of the reviews were clear in what 
types of participants, intervention and outcome measures were included in the review. 
The total number of studies included in reviews ranged from 7-71 with a median of 25 
studies per review. Four of the 20 reviews conducted a meta-analysis. 
Discussion
For this study, guidelines and systematic reviews in the area of oral mucositis were used 
to assess their transparency and quality; however, the approach we used could be ap-
plied to any clinical topic.
This review shows that the quality of most of the guidelines and systematic reviews for 
prevention and treatment of oral mucositis was low. Although some guidelines seem 
to have been more rigorously developed than others, many methodological flaws were 
identified. The AGREE instrument for quality assessment was used in screening the 
guidelines. This questionnaire has been endorsed by the WHO and the European Com-
mission. The AGREE Instrument is a generic and validated questionnaire to assess both 
the quality of reporting and the methodological quality of some aspects of recommen-
dations. It provides an assessment of the predicted validity of a guideline, i.e. the likeli-
hood that it will achieve its intended use. It does not investigate, however, the accuracy 
of the recommendations within a guideline, nor its impact on patients’ outcomes22. This 
instrument was developed in 2003 before five of the eleven guidelines included in this 
study were developed. This suggests that provided that committees that are develo-
ping or updating guidelines use the AGREE recommendations, the quality of future 
guidelines will likely improve. In cases where no information was available on a certain 
topic, the AGREE instrument recommends the rating ‘strongly disagree’. This method 
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of operation is a conservative approach, because in such a case the quality of a guide-
line is possibly not rated as high as it actually is. It may be that many of the processes 
evaluated by the AGREE instrument were performed but not reported. In these cases 
transparency of methods is the issue whereas quality may be acceptable.  Although 
none of the guidelines scored well on all the domains, the guidelines of the National 
Cancer Institute23 scored relative low compared to the other ones. Important experts in 
the field developed this guideline, nevertheless an explicit description and justification 
of the process of developing the guideline was not given within the guideline.
Considering these results one could argue that perhaps the AGREE instrument is too 
strict. On the other hand however, one could question if guideline developers are awa-
re of the AGREE instrument and its criteria for transparency of guideline development. 
Given time, the AGREE criteria are likely to become more known and adopted as the 
need to distinguish between poor and good quality guidelines will increase.
Explicit and detailed information about the objectives and context of the guideline de-
velopment, including the methods used and the people and organisations involved in 
the development process are very important. Clinical practice guideline users will have 
more confidence in guidelines with these elements24, 25. Indeed, one could argue that 
large scale implementation of guidelines is not justified when guideline developers do 
not report their methods. Therefore, in our opinion, the AGREE instrument is a helpful 
tool in the process of guideline development and the assessment of guideline quality.
A limitation of this study is that although we used several methods to identify guide-
lines that were published, there is the possibility that we may have missed some. Ho-
wever, if guidelines were not published in major journals or readily available through 
the Internet, then most potential users would probably miss them as well. Another li-
mitation of the study is that in assessing the quality of guidelines only the guidelines 
themselves and relevant documents referred to in the guidelines were used and we did 
not systematically search for supplementary materials that may have been published 
elsewhere. However, if users lack clear references and easy access to such background 
documents, this would be problematic in itself.
The majority of the reviews were non-systematic literature reviews, often referred to as 
narrative reviews. Such literature reviews are almost always selective, in that they do 
not involve a systematic, rigorous and exhaustive search of all the relevant literature, 
using electronic and print media26 and therefore give only a subjective judgement of 
the included studies27. 
The 20 systematic reviews of prevention and treatment of oral mucositis published 
since 2000 represent what should be the highest level of evidence available. One of the 
major weaknesses of these reviews was that the search strategies reported were not 
always clear or adequate. The aim of a systematic review is to provide a comprehensive 
summary of current research evidence. To achieve this aim, a systematic review should 
employ a transparent and exhaustive search.  This may be due to the fact that such 
reports may not always reflect how the review was actually conducted but only what 
has been published. 
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The difficulty in interpreting results strengthens the argument that a systematic review 
should be a transparent process with the reader of the review being able to identify 
what has been done.
Conclusion
Although many guidelines on oral mucositis are classified as evidence-based, a pro-
found review of their quality applying the AGREE instrument revealed that none of 
the guidelines could be recommended. The majority of the guidelines are of middling 
quality. Also systematic reviews have methodological limitations despite their clinical 
relevance. 
Specific changes must be made at multiple levels by publishers, authors and readers 
of systematic reviews. First, journals should focus on accepting high-quality systematic 
reviews and on ensuring that the Methods sections outline the methods in a clearer 
manner21. 
Authors need to pay particular attention to methods used in systematic reviews, pre-
ferably before beginning on this research activity. Finally, readers need to become more 
familiar with critically appraising systematic reviews and developing a healthy skepti-
cism before incorporating the results into practice.
All the systematic reviews came to the same conclusion that it is important that more 
well designed, randomised controlled trials are conducted to investigate new treat-
ments for preventing and management of oral mucositis.  In line with this we conclude 
that there is also considerable room for improvement in formulating guidelines as well 
as systematic reviews for the prevention and treatment of oral mucositis.
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Box 2
AGREE Instrument
Response categories for each question are as follows: 
1. Strongly disagree 
2. Disagree 
3. Agree 
4. Strongly agree 
Scope and Purpose
•	 The	overall	objectives	of	the	guideline	are	specifically	described.	
•	 The	clinical	questions	covered	by	the	guideline	are	specifically	described.	
•	 The	patients	to	whom	the	guideline	is	meant	to	apply	are	specifically	described.	
Stakeholder Involvement
•	 The	guideline	development	group	includes	individuals	from	all	the	relevant	professional
 groups. 
•	 The	patients’	views	and	preferences	have	been	sought.	
•	 The	target	users	of	the	guideline	are	clearly	defined.	
•	 The	guideline	has	been	piloted	among	end-users.	
Rigor of Development
•	 Systematic	methods	were	used	to	search	for	evidence.	
•	 The	criteria	for	selecting	the	evidence	are	clearly	described.	
•	 The	methods	used	for	formulating	the	recommendations	are	clearly	described.	
•	 The	health	benefits,	side	effects,	and	risks	have	been	considered	in	formulating	the
 recommendations. 
•	 There	is	an	explicit	link	between	the	recommendations	and	the	supporting	evidence.	
•	 The	guideline	was	externally	reviewed	by	experts	prior	to	its	publication.	
•	 A	procedure	for	updating	the	guideline	is	provided.	
Clarity and Presentation
•	 The	recommendations	are	specific	and	unambiguous.	
•	 The	different	options	for	management	of	the	condition	are	clearly	presented.	
•	 Key	recommendations	are	easily	identifiable.	
•	 The	guideline	is	supported	with	tools	for	application.	
Applicability
•	 The	potential	organizational	barriers	in	applying	the	recommendations	have	been
 discussed. 
•	 The	potential	cost	implications	of	applying	the	recommendations	have	been	considered.	
•	 The	guideline	presents	key	review	criteria	for	monitoring	and/or	audit	purposes.	
Editorial Independence
•	 The	guideline	is	editorially	independent	from	the	funding	body.	
•	 Conflicts	of	interest	of	the	guideline	development	members	have	been	recorded. 
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Box 3
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Box 2 
Review Appraisal Form 
The Oxman and Guyatt’s index of the scientific quality of research overviews 
 
Reference:  
Reviewed by: 
  
1. Were the search methods used to find the evidence (original research) on the primary questions(s) stated? 
Yes /  Partially (Can't tell) /  No   
2. Was the search for evidence reasonably comprehensive? 
Yes /  Partially (Can't tell) /  No   
3. Were the criteria used for deciding which studies to include in the overview reported? 
Yes /  Partially (Can't tell) /  No   
4. Was bias in the selection of studies avoided? 
 Yes /  Partially (Can't tell) / No   
5. Were the criteria used for assessing the validity of the included studies reported?  
 Yes /  Partially (Can't tell) /  No   
6. Was the validity of all studies referred to in the text assessed using appropriate criteria (either in selecting 
studies for inclusion or in analysing the studies that are cited?) 
Yes /  Partially (Can't tell) /  No   
7. Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported? 
 Yes /  Partially (Can't tell) /  No   
8. Were the findings of the relevant studies combined appropriately relative to the primary question the 
overview addresses? 
Yes /  Partially (Can't tell) /  No   
9. Were the conclusions made by the author(s) supported by the data and/ or analysis reported in the 
overview? 
Yes /  Partially (Can't tell) /  No   
10. How would you rate the scientific quality of the overview? 
 
 
Extensive flaws 
 
 
 
Major flaws 
 
 
 
Minor flaws 
 
 
 
Minimal 
flaws 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7  
 
 
Chapter 8            Quality assessment of the methodology 
References
 1  Field M, Lohr K. Clinical Practice Guidelines: Directions for a New Program. Washington, DC,
  National Academy Press, 1990.
 2  Verkerk K, Van Veenendaal H, Severens JL, Hendriks EJ, Burgers JS. Considered judgement in
  evidence-based guideline development. Int J Qual Health Care 2006;18(5): 365-369.
 3  Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The Relation between Systematic Re-
  views and Practice Guidelines. Ann Intern Med 1997;127(3): 210-216.
 4  Burgers JS, van Everdingen JJ. Beyond the evidence in clinical guidelines. Lancet 
  2004;364(9432): 392-393.
 5  Raine R, Sanderson C, Hutchings A, Carter S, Larkin K, Black N. An experimental study of 
  determinants of group judgments in clinical guideline development. Lancet 2004;364
  (9432): 429-437.
 6  Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention 
  and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer
  2004;100(9 Suppl): 2026-2046.
 7  Stone R, Fliedner MC, Smiet AC. Management of oral mucositis in patients with cancer. Eur J
  Oncol Nurs 2005;9 Suppl 1(: S24-S32.
 8  The Cochrane Collaboration. The Cochrane Libray; Evidence for healthcare decision-making.
  http://www3 interscience wiley com/cgi-bin/mrwhome/106568753/WhatAreSystematic
  Reviews html 2007
 9  Graham ID, Harrison MB, Brouwers M, Davies BL, Dunn S. Facilitating the use of evidence in
  practice: evaluating and adapting clinical practice guidelines for local use by health care 
  organizations. J Obstet Gynecol Neonatal Nurs 2002;31(5): 599-611.
 10  Graham I, Lorimer K, Harrisson M, Pierscianowski T. Evaluating the Quality and Content of
  International Clinical Practice Guidelines for Leg Ulcers: Preparing for a Canadian Adapta-
  tion. CAET-Journal 2000;19(3): 15-31.
 11  Craig J. The evidence-based practice manual for nurses. London, Churchill Livingstone, 
  2002.
 12  Mistiaen P. Module onderzoek2, evidence based practice voor de Master Advanced Practice. 
  Diemen, School of Health. Hogenschool Inholland, 2004.
 13  van Everdingen JJE, Burgers JS, Assendelft WJJ, Swinkels JA, van Barneveld TA, van de Klun-
  dert JLM. Evidence-based richtlijnontwikkeling. 1 ed. Houten, Bohn Stafleu Van Loghum,
  2006.
 14  Cox K, de Louw D, Verhoef J, Kuiper C. Evidence-based practice voor verpleegkundigen.
  1 ed. Utrecht, Lemma BV, 2004.
 15  Graham ID, Calder LA, Hebert PC, Carter AO, Tetroe JM. A comparison of clinical practice 
  guideline appraisal instruments. Int J Technol Assess Health Care 2000;16(4): 1024-1038.
 16  The AGREE Collaboration. Development and validation of an international appraisal instru-
  ment for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf 
  Health Care 2003;12(1): 18-23.
 17  AGREE Collaboration . Appraisal of Guidelines for Research and Evaluation (AGREE) Training
  Manual. http://www agreecollaboration org/pdf/aitraining pdf 2003
132
Quality assessment of the methodology              Chapter 8
 18  Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin
  Epidemiol 1991;44(11): 1271-1278.
 19  Oxman AD, Guyatt GH, Singer J, et al. Agreement among reviewers of review articles. J Clin
  Epidemiol 1991;44(1): 91-98.
 20  Oxman AD. Systematic Reviews: Checklists for review articles. BMJ 1994;309(6955): 648-651.
 21  Jadad AR, McQuay HJ. Meta-analyses to evaluate analgesic interventions: a systematic
  qualitative review of their methodology. J Clin Epidemiol 1996;49(2): 235-243.
 22  AGREE Collaboration . Appraisal of Guidelines for Research and Evaluation (AGREE) Instru-
  ment. http://www agreecollaboration com 2007
 23  National Cancer Institute. Oral Complications of Chemotherapy and Head/Neck Radiation.
  http://www cancer gov/cancertopics/pdq/supportivecare/oralcomplications/health
  professional/allpages#Section_61 2005 August 20
 24  Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of clinical guide-
  lines that influence use of guidelines in general practice: observational study. BMJ 1998;
  317(7162): 858-861.
 25  Burgers JS, Grol RP, Zaat JO, Spies TH, van der Bij AK, Mokkink HG. Characteristics of effective
  clinical guidelines for general practice. Br J Gen Pract 2003;53(486): 15-19.
 26  Davies P. The Relevance of Systematic Reviews to Educational Policy and Practice. Oxford 
  Review of Education 2000;26(3&4): 365-378.
 27  Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews,
  meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 1999;28(1): 1-9.
 28  CBO. Richtlijn Mondholte en orofarynxcarcinoom. Nieuwegein, CBO, 2004.
 29  Stricker CT, Sullivan J. Evidence-based oncology oral care clinical practice guidelines: deve-
  lopment, implementation, and evaluation. Clin J Oncol Nurs 2003;7(2): 222-227.
 30  Barasch A, Elad S, Altman A, Damato K, Epstein J. Antimicrobials, mucosal coating agents, 
  anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support 
  Care Cancer 2006;14(6): 528-532.
 31  The Royal College of Surgeons of England. Clinical Guidelines: The oral management of
  oncology patients requiring Radiotherapy: Chemotherapy: Bone Marrow Transplant. http://
  www rcseng ac uk/fds/docs/oncolradio doc 2004
 32  Milligan S, McGill M, Sweeney MP, Malarkey C. Oral care for people with advanced cancer: an
  evidence-based protocol. Int J Palliat Nurs 2001;7(9): 418-426.
 33  Oncology Nursing Society. Chemotherapy and biotherapy: guidelines and recommen-
  dations for practice. Pittsburgh, ONS, 2001.
 34  LWVOC. Beschadigd mondslijmvlies. http://www oncoline nl/ 2001(1.1)
 35  West F, Mitchell SA. Evidence-based guidelines for the management of neutropenia
  following outpatient hematopoietic stem cell transplantation. Clin J Oncol Nurs 2004;8(6): 
  601-613.
 36  LWVOC. Beschadigd mondslijmvlies (verhoogd risico). http://www oncoline nl/ 2001(1.1)
 37  Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for
  patients with cancer receiving treatment. Cochrane Database Syst Rev 2006;(2): CD000978.
 38  Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients 
  with cancer receiving treatment. Cochrane Database Syst Rev 2004;(2): CD001973.
  133
Chapter 8            Quality assessment of the methodology 
 39  Sutherland SE, Browman GP. Prophylaxis of oral mucositis in irradiated head-and-neck can-
  cer patients: a proposed classification scheme of interventions and meta-analysis of rando-
  mized controlled trials. Int J Radiat Oncol Biol Phys 2001;49(4): 917-930.
 40  McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical 
  practice principles in the management of oral mucositis. Support Care Cancer 2006.
 41  Potting CMJ, Scholte op Reimer W, Smiet T, Van Achterberg T, Uitterhoeve RJ. De mond vol 
  van chloorhexidine.  Oncologica 2003;20(4): 188-192.
 42  Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or 
  treat oral mucositis. The Lancet Infectious Diseases 2003;3(7): 405-412.
 43  Bensadoun RJ, Schubert MM, Lalla RV, Keefe D. Amifostine in the management of radiation-
  induced and chemo-induced mucositis. Support Care Cancer 2006;14(6): 566-572.
 44  Migliorati CA, Oberle-Edwards L, Schubert M. The role of alternative and natural agents,
  cryotherapy, and/or laser for management of alimentary mucositis. Support Care Cancer 
  2006;14(6): 533-540.
 45  Lalla RV, Schubert MM, Bensadoun RJ, Keefe D. Anti-inflammatory agents in the manage-
  ment of alimentary mucositis. Support Care Cancer 2006;14(6): 558-565.
 46  Bultzingslowen IV, Brennan MT, Spijkervet FK, et al. Growth factors and cytokines in the pre-
  vention and treatment of oral and gastrointestinal mucositis. Support Care Cancer 2006.
 47  Gottschalck T, Dassen T, Zimmer S. [Assessment scales for nursing assessment of the mouth. 
  A literature review]. Pflege 2003;16(5): 273-282.
 48  Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR. Management of chemothera-
  py-induced adverse effects in the treatment of colorectal cancer. Drug Saf 2001;24(5):
  353-367.
 49  Kwong KK. Prevention and treatment of oropharyngeal mucositis following cancer therapy: 
  are there new approaches? Cancer Nurs 2004;27(3): 183-205.
 50  Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: 
  pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;
  100(9 Suppl): 1995-2025.
 51  Hendricks P. Orale cryotherapie: ijskoud het beste? Oncologica 2003;20(4): 193-197.
 52  Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating che-
  motherapy-induced oropharyngeal mucositis: A review of the literature. Oral Surg Oral Med
  Oral Pathol Oral Radiol Endod 2002;94(1): 39-44.
 53  Shih A, Miaskowski C, Dodd MJ, Stotts NA, MacPhail L. A research review of the current
  treatments for radiation-induced oral mucositis in patients with head and neck cancer.
  Oncol Nurs Forum 2002;29(7): 1063-1080.
 54  Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, che-
  motherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. 
  Head Neck 2003;25(12): 1057-1070.
 55  Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy,
  chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis.
  Head Neck 2004;26(1): 77-84.
 56  Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral 
  mucositis, and diarrhoea. Lancet Oncol 2005;6(2): 93-102.
134
AAppendixDevelopment and testing of the national guideline 
‘oral mucositis of patients with cancer’

Development and testing of the national guideline              Appendix
Background 
As the primary advocates for patients, nurses are central in preventing and managing 
oral mucositis and reducing its debilitating effects on patients with cancer. Develop-
ment of an evidence based guideline for oral mucositis will promote uniformity of care 
both within a centre, as well as between centres. Furthermore, it will potentially incre-
ase the quality of care provided to patients. To meet this challenge, Radboud University 
Nijmegen Medical Centre, the Dutch Expertise Centre for Nursing (LEVV), the Dutch 
Research Institute for Healthcare (NIVEL), and the Association of Comprehensive Cancer 
Centres (ACCC) cooperated to develop a national evidence based guideline. This guide-
line was based on the results of the study on quality assessment of the methodology 
used in guidelines and systematic reviews1. None of the guidelines met the quality as-
sessment criteria, but eight reviews had an overall Quality Assessment Questionnaire 
(OQAQ) 2 score ≥ 4  and were eligible for data extraction. 
Data extraction
A standardized excel template for data extraction was developed and pre-tested by the 
reviewers.
The template was based on the information necessary to answer the central questions 
for guideline development, and divided in three sections: prevention, screening and 
treatment.
Data were extracted on the general characteristics of the studies (authors, source, year, 
place, and language of publication); clinical issues (population, intervention and outco-
mes reviewed), methodological characteristics (language restrictions; number, format, 
design, and publication status of the studies included; data synthesis; heterogeneity 
testing; and methodological quality); and results and conclusions.
Analysis
To judge the quality of evidence and the strength of the recommendations of the syste-
matic reviews the GRADE (Grades of Recommendation Assessment, Development and 
Evaluation)3 system was used. GRADE proposes the following definitions: 
•	 The	quality	of	evidence;	indicates	the	extent	to	which	one	can	be	confident	that	an
 estimate of effect is correct. 
•	 The	strength	of	a	recommendation;	indicates	the	extent	to	which	one	can	be	confi-
 dent that adherence to the recommendation will do more good than harm.
The GRADE working group has developed criteria for assigning the grade of evidence 
see Box 14. The levels are broken down into four distinct groups: high, moderate, low 
and very low. 
According to the GRADE system high grade evidence is evidence that would not likely 
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be changed by any future research. Moderate evidence is evidence that may be affec-
ted and impacted by future research. This research may change the confidence in the 
estimate of the truth or may change that estimate altogether. Low grade evidence is 
evidence that will most likely be influenced and affected by future research and very 
low quality has an uncertain ability to estimate any effect. Limitations in study quality, 
important inconsistency of results, or uncertainty about the directness of the evidence 
can lower the grade of evidence. 
None of the guidelines had scores >60% in all domains and none had a score between 
30% and 60%, in all domains, indicating low overall quality for all guidelines according 
to the AGREE Instrument 5. As no good quality guidelines were identified systematic 
data extraction was not performed for guidelines and only systematic reviews were 
included for this purpose.
Box 1: Grade of evidence
Criteria for assigning grade of evidence
Type of evidence 
Randomised trial = high 
Observational study = low 
Any other evidence = very low 
Decrease grade if: 
•	 Serious	(-	1)	or	very	serious	(-	2)	limitation	to	study	quality
•	 Important	inconsistency	(-	1)
•	 Some	(-	1)	or	major	(-	2)	uncertainty	about	directness
•	 Imprecise	or	sparse	data	(-	1)
•		High	probability	of	reporting	bias	(-	1)
Increase grade if: 
•	 Strong	evidence	of	association—significant	relative	risk	of	>	2	(<	0.5)	based	on	consistent
 evidence from two or more observational studies, with no plausible confounders (+1)
•	 Very	strong	evidence	of	association—significant	relative	risk	of	>	5	(<	0.2)	based	on	direct
 evidence with no major threats to validity (+2)
•	 Evidence	of	a	dose	response	gradient	(+1)
•	 All	plausible	confounders	would	have	reduced	the	effect	(+1)
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Results
Table1 shows the study characteristics of the systematic reviews and contains informa-
tion describing the quality score of the eight identified systematic reviews, information 
source, quality assessment used in the reviews, and inclusion criteria for the trials. In-
terventions for preventing oral mucositis were described in seven reviews, only one 
review was found to describe interventions for treatment of oral mucositis. All eight 
reviews formally assessed the methodological quality of the randomised studies inclu-
ded, and few trials were both patient and assessor blinded. No review excluded trials 
from the analysis because of a too small sample size. Most of the reviews were clear in 
what types of participants, interventions and outcome measures were included in the 
review. The total number of studies included in reviews ranged from 7 to 71 with a me-
dian of 25 studies per review. Four of the ten reviews conducted a meta-analysis. 
Table 2 summarizes key data from 7 reviews of interventions for the prevention of oral 
mucositis. 44 Interventions divided into 11 groups varying from disinfectants to non-
pharmacological or natural agents were investigated. Most interventions failed to pre-
vent oral mucositis. Interventions with some evidence of a benefit in preventing or re-
ducing the severity of oral mucositis included povidone iodine, polymyxin tobramicin 
amphotericin (PTA) pastilles, benzoydamine, amifostine, cryotherapy, oral care, calcium 
phosphate rinse, sucralfate, and prostaglandin. However, benefits may be specific for 
certain types of cancer and its treatment.  
Treatment
Table 3 is a summary from the systematic review of Worthington 2006 6 on 12 inter-
ventions explored for treating oral mucositis of which 8 studies dealt with pain control. 
There is weak and unreliable evidence that allopurinol, polyvariant intramuscular im-
munoglobulin and human placental extract improves or eradicates mucositis. Oral mu-
cositis can cause severe pain. Given the lack of clear evidence for the treatment or pre-
vention of mucositis, pain control is of utmost importance. Opiates are often required 
for the relief of mucositis related pain. No evidence was found that patient controlled 
analgesia (PCA) was better than continuous infusion for controlling pain, despite the 
fact that less opiates were used per hour with PCA.
There was a considerable overlap across the reviews; for example chlorhexidine was 
discussed in 4 systematic reviews mostly of the same original studies even though all 
came to the same conclusion. This was not the case with povidone iodine as 4 reviews 
discussed this intervention but came to different conclusions.
The GRADE system was used to judge the quality of evidence and the strength of the 
recommendations of the systematic reviews. Although a very comprehensive method 
for assessing prevention and treatment modalities, the GRADE system is complicated 
and difficult to implement in reviews such as the one carried out here. Recommendati-
ons were often reached through discussion among the review team. 
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Expert meeting
To obtain consensus based recommendations where no evidence was available and to 
discuss the first concept of the guideline an expert group was formed. The group con-
sisted of 12 members: 4 nurses (oncology, haematology radiotherapy, and oncology 
outpatient clinic), 3 physicians (medical oncology, haematology, and head and neck), 
a dentist, a dental hygienist, a microbiologist, and two patients who had suffered from 
oral mucositis. The constitution of this group ensured that clinical experience and pa-
tient preferences were properly represented. The first concept guideline was written 
on the basis of the results of the systematic review. During the expert meeting, the 
proposed guideline was discussed and adapted and the first draft was then implemen-
ted in clinical practice to test its usability. Finally the results of the pilot implementation 
were discussed in the expert group, where necessary changes and key recommendati-
ons were made. 
Pilot implementation 
The concept guideline was tried out during a period of 3 months and evaluated for 
its usability by nurses and medical specialists, dentists and dental hygienists. Two uni-
versity hospitals and two general hospitals participated in the pilot implementation. 
Several haematological and oncology wards were involved as well as a radiotherapy 
ward and an outpatient clinic. Nurses on these wards are the potential users of the 
guideline. The pilot implementation began with an introductory meeting during which 
participants were given explanations of the guideline and its implementation as well as 
instructions on oral care. At the end of the period, a questionnaire was used to evaluate 
the guideline. 
Methodology and the content of the guideline
The guideline draft originating from the last expert meeting was presented to exter-
nal experts who were asked to fill in a form offering their opinion and judgement of 
the methodology and the content of the guideline. The external experts commented 
positively on both methodology and validity, and provided some additional remarks. 
The guideline was adapted and the final draft composed after discussing the external 
judgment within the project group. Key recommendations are listed in box 2.
This resulted in an evidence-based guideline for screening, preventing and treating oral 
mucositis of patients treated with chemotherapy with or without radiation therapy. The 
guideline was disseminated as a book and a summary card for daily use was made. The 
Dutch Nurses’ Association (V&VN oncology) is the owner of the guideline which can be 
found on digitally www.oncoline.nl.
The next step will be to implement the guideline in all the Dutch hospitals.
Development and testing of the national guideline              Appendix
Box 2: Key recommendations
Key recommendations oral mucositis guideline
Carrying out adequate oral care requires a multidisciplinary team  to be available consisting of 
nurses, physicians, dental professionals and other disciplines.
Before treatment, the oncology team  refers the patient to dental professionals to determine the 
status of the oral cavity and carry out any interventions that may be necessary.
•	 For	patients	treated	with	radiotherapy	for	head	and	neck	cancer	or	those	undergoing	haemato-
 poietic stem cell transplantation (HSCT) dental assessment should be performed 2 weeks be-
 fore cancer treatment
•	 For	patients	scheduled	to	undergo	other	cancer	therapies,	individual	considerations	for	dental
 assessment should be made.
Before cancer therapy, nurses should assess the oral cavity to determine the baseline situation so 
that individual advice can be given to the patient. The nurse takes a history of oral health and in-
spects the mouth.
Oral care should be carried out to prevent severe oral mucositis among patients treated with che-
motherapy, those receiving an HSCT and /or those given radiotherapy in the head and neck region. 
When necessary, ask for help from a dental hygienist.
The nurse should educate the patient on the importance of good oral care during cancer treatment. 
This should include: 
•	 An	explanation	of	the	relation	between	good	oral	hygiene	and	oral	complications.	
•	 Instructions	on	rinsing	the	mouth	frequently	to	remove	mucus	or	food	particles.	
•	 Plaque	prevention.	
•	 Prevention	of	mucosal	damage	by	avoiding	hot	and	spicy	food	and	by	being	careful	with
 dental prosthesis.
High-risk patients: oral assessment should be done on a daily basis beginning on the day of admis-
sion. If this is not possible, estimate oral mucositis by mouth inspection to see if changes of the 
mucous membrane are visible. Score accordingly.
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The nurse instructs the patient on the following aspects of good oral care: 
•	 Dental	cleaning		method	
•	 Frequency	of	cleaning:	2-4	times	a	day	
•	 Toothbrushes:	soft,	possibly	electronic	or	wet	gauzes	instead	of	a	brush	
•	 Toothpaste:	not		irritating,	with	fluoride,	possibly	menthol	free	toothpaste	
•	 Toothbrush		hygiene:	regular	renewal	of	the	toothbrush,	drying	the	toothbrush	with	the	brush
  upwards. 
•	 In	case	plaque	removal	by	 tooth	brushing	 is	not	possible,	alcohol-free	chlorhexidine	mouth
 rinse or spray is indicated. 
•	 Interdental	cleaning:	only	if	the	patient	is	accustomed	to	it	and	able	to	carry	out	the	cleaning
 without damaging the mucosa. 
•	 Frequent	rinsing	or	spraying	with	water	or	NaCl	0.9%	(radiotherapy	8-10	times	a	day	chemo-
 therapy 4-10 times a day). Rinsing or spraying is indicated after a bout of vomiting. Drinking
 cold water or sucking on an ice cube can relieve oral pain. 
•	 Lip	care:	cleaning	with	a	wet	gauze	and		moisturizing	with	a	tube	of	sterile	Vaseline	
•	 Care	of	dental	prosthesis:	not	wearing	the	prosthesis	at	night,	but	to	keeping	it	in	water.	In	case
 of oral mucositis dental prosthesis should not be worn. 
Provide adequate pain relief: give morphine to patients with pain due to oral mucositis. Use a Visual 
Analogue Scale (VAS) to determine.  Don’t use the WHO pain scale. Adjust the dose of morphine 
daily according to the level of pain 
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One of the aims of this thesis was to describe current nursing practice and practice 
improvement in relation to oral mucositis directed care in haematology nursing. This 
was achieved by a survey of European transplant centres, by developing and testing an 
assessment instrument and by investigating and attempting to improve nurses’ skills 
and knowledge regarding oral care.
The second aim was to evaluate available evidence and guidelines for the preventive 
care and treatment of oral mucositis in oncology patients in general. This aim was 
achieved by formulating recommendations for the use of oral mucositis assessment 
instruments, by investigating the quality of guidelines and systematic reviews for the 
prevention and treatment of oral mucositis and by developing a national guideline 
“Oral mucositis in patients with cancer”.
This chapter summarises the main findings of this thesis and describes the strengths 
and limitations of the studies. In addition main conclusions and recommendations for 
research and practice are given. 
Findings towards current practice improvement in
haematology nursing care
We surveyed nurses about their perceptions of oral care at European stem cell trans-
plantation centres as they play an important role in assessing and managing oral mu-
cositis (Chapter2). The nurses agreed that oral mucositis has a major influence on the 
quality-of-life and the costs of care in patients who undergo stem cell transplantation. 
However, the survey found inconsistencies in the treatment of oral mucositis across 
centres and identified the need for a more standardised approach. Not all centres pro-
vided treatment for patients with grade 4 oral mucositis, a debilitating condition. In 
contrast, other centres used early intervention and initiated treatment at the first ap-
pearance of oral ulcers. The nurses agreed that national evidence-based guidelines 
should be developed to help standardise the assessment, prevention, and treatment 
of oral mucositis in European transplantation centres. The results of the survey further 
demonstrated that fewer than half of the nurses who responded were aware of the 
newer therapies for oral mucositis.
To observe signs and symptoms of oral mucositis, nurses need assessment instru-
ments. A systematic review was undertaken to summarise the available assessment 
instruments before developing the Oral Mucositis Nursing Instrument (OMNI) (Chap-
ter3).  One of the main findings was that erythema, oedema, lesions, pain and saliva 
viscosity were the most commonly used items in the various instruments. These items 
were added together to generate the OMNI to monitor the development, progression 
and course of oral mucositis. The OMNI was then tested for reliability, usability and 
responsiveness. With the exception of oedema, the inter-observer Cohen’s weighted 
Kappa of all items was between 0.60 and 0.83. The internal consistency, measured with 
Cronbach’s alpha coefficient, was 0.729, indicating modest, but sufficient internal con-
sistency. Viscosity of saliva contributed little to the OMNI (Spearman’s rank-order 0.052) 
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and were therefore deleted. Usability of the OMNI was good when evaluated with a 
questionnaire (Chapter 4). Guyatt’s responsiveness index was 2.2 and the Receiver Ope-
rating Characteristic (ROC) curve was 0.89 for deterioration and 0.92 for improvement, 
indicating high sensitivity for detecting changes in oral mucositis over time. 
In an intervention study, knowledge and skills about oral care improved when educa-
tion in oral care was provided (Chapter 5). Nursing skills were assessed by reviewing 
nursing records and observing nurses in performing oral care. Knowledge tests at base-
line and follow-up gave an impression of the effect of the education sessions. After the 
oral care education sessions, knowledge and skills in oral care improved. 
Findings towards evidence and guidelines
in general oncology care
To guide the assessment of oral mucositis, eleven recommendations were developed 
based on a systematic review and expert opinion (Chapter 6).
The main recommendations are:
•	 Oral	mucositis	should	be	assessed	using	a	standardised	protocol.
•	 Oral	mucositis	assessment	should	continue	until	oral	mucositis	is	fully	resolved.	
•	 Patient	reported	outcomes	should	be	included	in	all	oral	mucositis	assessments.
•	 Oral	mucositis	 assessments	 should	 use	 instruments	 or	 combinations	 of	 suitable
 scales containing elements to cover the physical changes in the oral mucosa, func-
 tional changes and subjective changes.
In most of the guidelines for the prevention of oral mucositis, patients are advised to 
rinse their mouth with a mouthwash on a daily basis. A systematic review was perfor-
med to assess the effectiveness of commonly used mouthwashes for the prevention 
of oral mucositis (Chapter7). With the exception of iodine solution, none of the studies 
investigated were able to demonstrate an effect in preventing mucositis in patients 
undergoing chemotherapy. The results of all five studies investigating chlorhexidine 
mouthwashes, when taken together in the analysis, failed to show a significant benefi-
cial effect (Weighted mean differences 0.22; 95% confidence interval CI = -0.20, 0.63). In 
addition, tooth discolouration and the unpleasant bitter taste experienced by patients 
supported with the use of sterile water, 9% saline solution or sodium bicarbonate, ra-
ther than chlorhexidine. 
To identify and assess the quality of available guidelines and systematic reviews for 
the prevention and treatment of oral mucositis, a systematic review was performed 
(Chapter 8).  Although many guidelines on oral mucositis are classified as evidence-
based, a thorough review of their quality using the AGREE instrument revealed that 
none could be recommended. The majority of the guidelines were of mediocre qua-
lity and systematic reviews had important methodological limitations despite their 
clinical relevance. Consequently, a collaboration of different associations in the Ne-
therlands was established to develop a guideline on oral mucositis. The appendix
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with chapter 8 describes the realisation of the evidence based guideline for patients 
at risk of oral mucositis. The Grade system 1 was used for judging the quality of the 
evidence and the strength of the recommendations of the systematic reviews. An ex-
pert group was set up to obtain consensus recommendations when evidence was lac-
king. 
Strengths and limitations of the studies on
practice improvement in haematology nursing care.
Surveying haematology nurses of transplantation centres throughout Europe streng-
thened the generalisability of the results on current care. It provided a useful insight 
into the management of oral mucositis in European transplant centres. However, it was 
sometimes unclear if the answers given by nurses represented the opinion of the trans-
plant centre or their personal views. 
A systematic review and extensive testing of the OMNI on validity, reliability, usability 
and responsiveness are methodological strengths in the development of the assess-
ment instrument. To measure the responsiveness of the OMNI, special statistical tech-
niques had to be employed because the measurements took place on a day-to-day 
basis which is unique for this kind of instrument. A limitation of the responsiveness 
study is the small sample size; a larger study will provide more information about the 
instrument and its use. The instrument was tested in a cohort of haematopoietic stem 
cell transplant recipients but may be applicable to patients who receive other cancer 
therapies. Yet, the OMNI was not tested in more general oncology care. For the popu-
lation of stem cell transplant patients however, the OMNI is a practical instrument for 
daily nursing practice, and is tested more extensively on methodologically quality than 
other instruments. 
The study on the evaluation of nurses’ knowledge and skills in the management of oral 
care provided direction to the education sessions which met the nurses’ need for oral 
care knowledge. To measure the knowledge of nurses, we were obliged to construct a 
scale because none was available for our purpose. The clinical relevance of an increase 
of 50 points on a scale of 0 to 450 points could be debated.  However, an increase of ap-
proximately 10% could well mean marked improvement in the quality of daily practice. 
The study was limited by a small sample size, the lack of randomisation and the fact that 
different nurses participated at baseline and follow-up. 
Strengths and limitations towards evidence
and guidelines in general oncology care
In this thesis, we performed several systematic reviews (on assessment instruments, 
mouthwashes, systematic reviews and guidelines) to investigate the evidence for oral 
mucositis care. As with all systematic reviews, limitations need to be acknowledged. 
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The quality of the conclusions and recommendations in a systematic review depend on 
the quality of the studies or trials included. In many areas, the international literature 
still lacks well designed high quality studies. Despite the extensive search for studies 
to analyse existing assessment instruments and evidence based recommendations for 
their use, six out of the eleven recommendations for the assessment of oral mucositis 
still had to be based on expert opinion. A requirement for systematic reviews is an as-
sessment of the quality of the studies involved. In the study on assessment instruments 
we did not determine the quality of the studies. Instead, we assessed the quality of the 
instruments described in these studies. Validity, reliability and usability were the criteria 
that were used to give an impression of the quality of the instruments. In the review on 
mouthwashes we did not use a formal quality assessment scale. However, all studies 
were assessed for randomisation, blinding and intention to treat. 
The systematic review of guidelines and systematic reviews was performed in a most 
thorough manner. The Appraisal of Guidelines for Research and Education (AGREE) in-
strument was used to assess the quality of the guidelines and the Overview Quality 
Assessment Questionnaire (OQAQ) was used for the quality of systematic reviews. Both 
instruments are internationally recognised and validated. The quality of evidence and 
the strength of the recommendations of the systematic reviews were judged with the 
GRADE (Grades of Recommendation Assessment, Development and Evaluation) sys-
tem. The grade methodology was chosen because this was the only method where be-
sides the quality of the involved studies, a balance of advantages versus disadvantages 
is required. A limitation with the use of GRADE is that this method was not specifically 
developed for a review of systematic reviews. 
A general disadvantage of using systematic reviews is the delay between completion 
of the inclusion of studies in the review and the time to publication of the review in a 
journal, which can lead to results being out-of-date. A systematic review of systematic 
reviews, as carried out in this thesis, suffers even more from this delay. The performance 
of a meta-analysis was one of the strengths of the systematic review on mouthwashes 
which showed the ineffectiveness of chlorhexidine in the prevention of oral mucositis. 
This result was welcomed by nurses as it was in line with nursing practice according to 
national publications. This evidence is supported and recorded in our national guide-
line and an international guideline as well 2. 
The value of oral assessment in the light
of little evidence for interventions
The primary goal of nursing assessment of the oral cavity is to identify changes in the 
oral mucosa, recognise the presence of infection, and assess the effect that oral muco-
sitis has on patients’ functional status. Using systematic, timely oral assessments with a 
reliable and valid assessment instrument allows oncology nurses to better recognise, 
monitor, and document the progression of oral mucositis and institute interventions to 
ease patients’ experiences. 
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The relevance of systematic assessment could be debated in the face of little evidence 
for nursing interventions for prevention and treatment. However a lack of evidence is 
not proof of ineffectiveness of interventions such as oral care or patient education. The-
se and similar interventions especially lack good quality evaluations and could still be 
valuable and possibly supported by more evidence in the future. Also, despite the fact 
that there are no drugs available for the prevention of oral mucositis, the future is hope-
ful. A new treatment concept using Palifermin (rHu-KGF1), a keratinocyte growth factor 
receptor antibody, is now registered for prevention of oral mucositis in autologous he-
matopoietic stem-cell transplantation patients. A statistically significant improvement 
of oral mucositis was observed as a result of using Palifermin 3. Given the effectiveness 
of Palifermin in the autologous hematopoietic stem-cell transplantation setting, further 
research is necessary for other indications for the drug, including prevention and re-
duction of oral mucositis in patients with solid tumours.
As with prevention there is no well-known treatment for oral mucositis. However, 
nurses can play an active roll in symptom management during this stressful period by 
providing adequate pain relief, helping patients cope with viscous mucus, paying extra 
attention to food intake, and offering emotional support.
Validity of findings for subgroups of cancer patients
In the first part of this thesis we discussed several studies that were performed in a hae-
matological setting. It may not be unreasonable to assume, however, that the findings 
of these studies could be translated into other cancer nursing practices. The survey 
we undertook, for instance, was based on nurses’ perceptions of the management of 
oral mucositis in Europe and was only sent to transplantation centres. We do not know 
whether or not the survey is valid for cancer nursing in general.
In the development of the OMNI, a systematic review was undertaken to make an in-
ventory of scoring instruments. In reviewing the literature, there were no limitations in 
relation to specific patient groups. Therefore it can be assumed that the most relevant 
items or symptoms (lesions, erythema, oedema, pain, chewing or swallowing) are va-
lid for all patients who suffer from oral mucositis. We tested the OMNI for reliability, 
usability and responsiveness among HSCT recipients. Therefore, we do not know if the 
instrument is suitable for patients receiving other therapies for haematological malig-
nancies or other cancer types. 
In the second part of this thesis we investigated evidence and guidelines for oral muco-
sitis in general oncology care. There are a number of reliable instruments for evaluating 
oral mucositis available in the literature designed for various purposes and patients 
groups. None are universally accepted as they are used for different intentions and po-
pulations. However, the recommendations for the use of assessment instruments on 
oral mucositis are formulated in such a way that they are valid and useful for all patient 
populations and oral mucositis assessment instruments. By using these recommendati-
ons inconsistency will decrease and the quality of oral assessment will improve. 
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For the development of an evidence-based guideline for oral mucositis, we conducted 
a systematic review of systematic reviews and guidelines. The approach we used can 
be applied not only for guidelines and systematic reviews in the area of oral mucositis 
but for any clinical topic. Eight reviews of sufficient quality were used for data extrac-
tion and formed the basis for the national guideline. In searching the literature there 
were no restrictions regarding patient groups. This resulted in studies performed with 
various patient groups.  In the expert group for the development of a new guideline, 
most of the disciplines involved in the care for patients at risk of oral mucositis were 
represented, in order to deliver a guideline for all patients at risk of oral mucositis.  
Towards the systematic review on mouthwashes we included only studies where che-
motherapy was used as anti cancer treatment. We did not investigate if the recommen-
dations in this review are valid for patients treated with radiotherapy. We concluded 
that there is no additional value for using chlorhexidine mouth rinses for the preven-
tion of oral mucositis. However, sometimes patients are too sick or oral mucositis is too 
painful to tolerate tooth brushing 4 times daily. Consequently plaque removal does not 
take place. In this case an alcohol-free chlorhexidine mouth rinse or spray is could still 
be considered.
Main conclusions
The first aim of this thesis was to make an inventory of, and to evaluate different aspects 
of current haematology nursing practice. 
With regard to haematology nursing we conclude that nurses should be able to iden-
tify chemotherapy induced mucositis as early as possible so that they can intervene to 
help minimise its severity and evaluate the effectiveness of oral mucositis treatment. 
The OMNI is a valid, reliable, useable and responsive instrument for this purpose.  To 
optimise the daily assessment nurses must be trained in the use of such a valid, reliable 
instrument. Assessment of the oral cavity should be started before treatment, and con-
tinued after treatment until oral mucositis is fully resolved.  
Nurses’ knowledge and skills regarding oral mucositis determine the success of preven-
tion and treatment in patients. Regular base education sessions should be provided to 
nurses, as there is a lack in knowledge and skills. These sessions are probably effective 
for improving knowledge and skills in daily practice, though education does not auto-
matically result in improved documentation of oral care.  
The second aim of this thesis was to evaluate available evidence for preventive care and 
treatment of oral mucositis and to evaluate guidelines in general oncology care.
Although European oncology nurses believe oral mucositis has a large effect on the 
patient’s quality of life, oral care is not standardised and is inconsistent across Europe. 
Current evidence on the prevention and treatment of oral mucositis is incomplete and 
sometimes inconsistent. Yet, regular oral care is the most commonly mentioned inter-
vention for the prevention and treatment of oral mucositis.
Based on our guideline optimal oral care consists of:
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•	 Baseline	oral	examination	by	a	dentist	before	the	start	of	the	treatment
•	 Oral	assessment	on	a	regular	basis	
•	 Regular	tooth	brushing	and	rinsing	with	water	or	saline	solutions.
•	 Patient	education.
Although the evidence to support the performance of oral care is limited, the impor-
tance of oral care is not debated in practice or in the international literature and can be 
considered to be consensus based.
It is hoped that with the help of the guideline for oral mucositis prevention and treat-
ment, standardized oral care for patients at risk for oral mucositis will be realised.
Recommendations for future research and practice
Assessment is a primary nursing skill. Daily assessment of the oral cavity by nurses per-
mits early recognition of the first signs and symptoms of oral mucositis, interventing 
when necessary, and evaluating the effectiveness of oral mucositis treatment. Nursing 
intervention studies on oral mucositis require proper oral assessment with good inter-
and intra-observer reliability. Training is necessary to increase the inter- and intra-ob-
server reliability and to standardise the method of scoring. The OMNI should be tested 
in a group of patients who receive other cancer therapies than haematopoietic stem 
cell transplantation to determine its generalisability and usability. The OMNI was de-
signed to register the onset and duration of oral mucositis. The daily assessment of 
the patient’s cavity to detect day-to-day deterioration or improvement gives nurses an 
indication when interventions are needed. Detailed studies on the OMNI should help 
define the threshold which should trigger specific interventions. 
The use of evidence-based guidelines for managing oral mucositis will promote a more 
informed standard of care and potentially increase the quality of care provided to pa-
tients. The foundation of any oral care guideline is basic oral care. However, little evi-
dence can be found in relation to this topic. Therefore, there is a need for more research, 
investigating components of basic oral care and their effects on oral mucositis. This 
means there is a need for well designed clinical trials on the effects of patient education 
and the frequency and optimal nature of daily oral care. Clinical trials are missed in re-
lation to the effects of toothpastes and the use of electronic toothbrushes. There are a 
considerable number of studies on mouthwashes, yet still some of the most commonly 
used mouthwashes were not investigated (e.g.  there are no studies on NaCl 0.9% or 
sodium bicarbonate).
Most patients suffer from oral pain caused by mucositis. This pain can be severe, can 
hinder nutritional intake, cause psychosocial distress and restrict communication 4. Pa-
tients have cited oral pain as a major source of distress 5-7. The most commonly used 
pain-relief intervention is pain medication, especially narcotic analgesics. Despite the 
use of this sort of medications, a majority of patients report only partial relief of pain 4, 5. 
The lack of complete relief suggests an ongoing need for multiple strategies in mana-
ging patients’ pain. Various oral pain assessment strategies and combinations of phar-
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macological and non-pharmacological interventions should be investigated in pros-
pective studies. 
Standardised and evidence-based guidelines may contribute to a higher quality of nur-
sing care and lead to improved practice and more unambiguous care. Once guidelines 
are developed, regular updating is necessary to guarantee optimal care based on the 
latest available knowledge. 
Clinical research is consistently producing new findings that may contribute to effective 
and efficient patient care. The findings of such research will not change patients’ out-
comes unless health care professionals adopt them in daily clinical practice. Translating 
research into practice seems as simple as choosing an evidence-based intervention and 
telling nurses to act on it. To persuade nurses (or other heath- care providers) to start 
something new however may require different strategies from simply asking them to 
change their daily routine or to stop something they do frequently. Future research 
should not only focus on more nursing research but on implementation strategies as 
well. 
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In this thesis, oral mucositis was examined from a nursing perspective. Oral mucositis 
is a frequently occurring complication in cancer patients treated with chemotherapy or 
radiotherapy. 
The clinical signs of chemotherapy-induced oral mucositis include erythema, pain, blee-
ding, viscous or absent saliva and ulceration. Oral mucositis affects speech, the ability 
to eat or drink or to take oral medication. It can lead to a delay in treatment and has a 
negative impact on patients’ quality of life. Nurses are in the prime position to perform 
day to day care in patients at risk for oral mucositis, and are vital to its management. 
Moreover, they are the primary source of information on treatment options for patient. 
An inventory and an evaluation of different aspects of current nursing practice in the 
management of oral mucositis are reported in this thesis.
Chapter 1
In the general introduction, background information on the incidence of oral mucositis 
as a result of different anti-cancer treatments is given. To explain the mechanism by 
which mucositis occurs, the five phases of Sonis’ model of pathophysiology1 are descri-
bed and problem areas in current nursing care are discussed.
The aim of this thesis was to: 
•	 describe	 current	 nursing	 practice	 and	 practice	 improvement	 in	 relation	 to	 oral
 mucositis directed care in haematology nursing; 
•	 evaluate	available	evidence	for	preventive	care	and	treatment	of	oral	mucositis	and
 to evaluate guidelines in general oncology care.
Chapter 2
Oral mucositis is associated with substantial clinical, economic, and quality-of-life (QOL) 
consequences. The research subgroup of the European Blood and Marrow Transplanta-
tion (EBMT) Nurses Group surveyed nurses of transplantation centres for their thoughts 
about the clinical, QOL, and economic consequences of oral mucositis, the tools for 
assessing oral mucositis, strategies for preventing and treating oral mucositis and the 
need for the development and implementation of treatment guidelines. The responses 
from 46 centres in 16 countries indicated that most nurses (91%) believe oral mucositis 
has a large impact on patients’ wellbeing. Nurses are not very satisfied with current 
treatments for oral mucositis, but they believe discomfort is reduced by oral care pro-
tocols and mouthwashes. Oral mucositis is routinely and frequently assessed, however 
there are inconsistencies in how it is managed. Most centres (70%) treated all patients 
with grade 4 oral mucositis, but 9% of the centres did not treat any such patients. In 
contrast, 33% of the centres treated patients with early stages of oral mucositis at the 
first appearance of oral ulcers (grade 2 oral mucositis). Most centres used unpublished, 
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centre-specific guidelines, and the survey found that most nurses agreed that publis-
hed national guidelines would be valuable for standardising the assessment and ma-
nagement of oral mucositis.  
Chapter 3
Chapter 3 describes the development of a new scoring system for the assessment of 
oral mucositis. The objectives of this study were to summarise the assessment instru-
ments that are available, to develop a new Oral Mucositis Nursing Instrument (OMNI) 
and to evaluate this new instrument. 
A systematic review was undertaken, in which 21 instruments were reviewed and com-
pared. None of the instruments satisfied the criteria for validity and reliability that were 
established beforehand.
The six most common items from the systematic review were selected for the new in-
strument. To test the OMNI, pairs of experienced nurses independently assessed the 
oral cavity of 26 patients. Inter-observer reliability (Kappa), correlations between items 
(Spearman’s rank-order correlations) and internal consistency of the instrument (Cron-
bach’s alpha) were calculated. The usability was evaluated with a questionnaire. Co-
hen’s weighted Kappa’s were within an acceptable range. Nearly all correlations were 
statistically significant and in the predicted direction. The Cronbach’s alpha coefficient 
indicated sufficient internal consistency. 
All nurses found the OMNI user-friendly and suitable for day-to-day care.
We concluded that the OMNI can be used as a valid, reliable and usable instrument in 
nursing practice.
Chapter 4
The OMNI was further tested for responsiveness. Data came from a cohort of 32 reci-
pients of a haematopoietic stem cell transplant unit who had participated in a pros-
pective trial evaluating parenteral glutamine2. Evaluations of oral mucositis began 
between day 7 and 28 after conditioning. Responsiveness was operationalised using 
two strategies; Guyatt’s Responsiveness Index3 and the Receiver Operating Characte-
ristic (ROC)4, 5 curves. Guyatt’s responsiveness index for the OMNI instrument was 2.2, 
indicating good sensitivity for detecting changes in oral mucositis over time. The ability 
of the OMNI to detect day-to-day deterioration (or improvement) was expressed by 
the areas under the two corresponding ROC curves of 0.89 and 0.92 respectively. The 
responsiveness of the OMNI suggests it is an appropriate instrument for measuring oral 
mucositis on a daily basis. 
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Chapter 5
Good oral care is the most commonly recommended intervention for managing oral 
mucositis, assuming that nurses have sufficient knowledge and skills to perform oral 
care correctly. 
The aim of the study reported in chapter 5 was to investigate whether knowledge and 
skills about oral care improve when education in oral care is provided for nurses in char-
ge of patients who are at risk for oral mucositis.
This intervention study consisted of a baseline test on the knowledge and skills of 
nurses in haematology wards in two different hospitals, followed by oral care education 
sessions in one of the centres and a follow-up measurement in both centres. At base-
line as well as at follow-up, nursing records were examined and observations of nurses 
performing oral care were made. 
The results showed significant differences for scores on the knowledge test before and 
after the education session for nurses in the intervention setting, whereas there was no 
difference for the nurses who did not follow these sessions. The records test showed 
no differences at baseline or follow-up for the two groups. Observations showed that 
nurses who had attended an education session implemented the oral care protocol 
considerably better than nurses who did not attend.
The conclusion from the present study was that education in oral care has a positive 
influence on the knowledge and skills of nurses who care for patients at risk for oral 
mucositis, whereas documentation of oral care did not improve.
Chapter 6
To assess oral mucositis uniformly, recommendations for the use of assessment instru-
ments are needed.
To address this, a unique collaboration of multi-disciplinary experts from the Europe-
an group for Blood and Marrow Transplantation (EBMT) and the European Oncology 
Nursing Society (EONS) was formed. Recommendations were formulated based on a 
systematic literature review and the experts’ experience. Recommendations included 
a comprehensive baseline assessment and the use of a standardised instrument, or 
combination of instruments, on a regular basis. Also physical, functional and subjec-
tive changes should be measured and subjective measures should be assessed prior to 
any physical examination. The use of a pain score, in particular patient self-reporting, 
should be part of any oral mucositis assessment. Any assessment instrument should be 
validated, easy to use and comfortable for the patient. Finally, the expert group con-
cluded that training of and monitoring in the use of an instrument is vital to successful 
monitoring of oral mucositis.
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Chapter 7
In clinical practice, daily chlorhexidine mouthwash is often recommended to prevent 
chemotherapy induced oral mucositis6. Povidone-iodine, NaCL 0.9%, water salt soda 
solution and chamomile mouthwash are also recommended. However, the effective-
ness of these mouthwashes is unclear. Therefore, a systematic review was performed to 
assess the effect of mouthwashes on the prevention and severity of chemotherapy-in-
duced oral mucositis. After critical appraisal of study quality, three out of five randomi-
zed controlled trials were included in a meta-analysis. The results of the meta-analysis, 
however, failed to demonstrate a beneficial effect of chlorhexidine when compared 
to sterile water or NaCl 0.9%. Some patients also complained of tooth discoloration 
and altered taste. A beneficial effect on the severity of oral mucositis was found for 
povidone-iodine mouthwash, when compared to sterile water (70% vs. 100% mucositis 
respectively). 
Our results do not support the use of chlorhexidine mouthwash to prevent chemo-
therapy-induced oral mucositis. Beneficial effects of povidone-iodine mouthwash need 
further research, also into acceptability for patients.
Chapter 8
The objective of the study reported in chapter 8 was to identify and to assess the quality 
of evidence-based guidelines and systematic reviews on the prevention and treatment 
of oral mucositis in patients receiving chemotherapy, radiotherapy or both.
Literature searches were carried out using several electronic databases and websites. 
Publications were included if they concerned oral mucositis involving adults treated 
for cancer and if they had been published after January 1, 2000. As far as systematic 
reviews are concerned, the article had to report a search strategy, minimally conducted 
in the databases PubMed or Medline and the articles included in the review had to be 
subjected to some kind of methodological assessment.
The Appraisal of Guidelines for Research and Education7 instrument was used to as-
sess the quality of the guidelines and the Overview Quality Assessment Questionnaire 
(OQAQ)8 was used to assess the quality of systematic reviews. 
31 Articles met the inclusion criteria of which eleven were guidelines and 20 were sys-
tematic reviews. The overall quality varied among the different guidelines and reviews. 
Most guidelines and systematic reviews had serious methodological flaws. Nine of the 
eleven guidelines did not explicitly describe how they identified, selected and sum-
marised the available evidence. Reviews suffered from lack of clarity, for instance in 
performing a thorough literature search. 
We concluded that there is a need to improve the methodological quality of guidelines 
and systematic reviews for the prevention and treatment of oral mucositis if they are to 
be used in clinical practice.
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Appendix
Prevention and adequate treatment of oral mucositis is a common task for oncology 
nurses. The development of guidelines for oral mucositis is essential for nurses taking 
care of patients who are at risk for, or suffer from oral mucositis. An evidence based 
guideline will promote uniformity of care within a centre, as well as between centres, 
and potentially increases the quality of care provided to patients. Several Dutch or-
ganisations cooperated to develop such a guideline. This guideline was based on the 
results of the study on quality assessment of the methodology used in guidelines and 
systematic reviews 9.
The process of the development of the guideline consisted of several phases: 
•	 Data	extraction	from	eight	systematic	reviews;
•	 Expert	meetings,	to	obtain	consensus	on		recommendations	when	no	evidence	was
 available and to develop the guideline; 
•	 Pilot	 implementation,	 to	 test	 the	 utility	 of	 the	 guideline;	 nurses,	 physicians,	 oral
 hygienists and dentists in four hospitals used and evaluated the guideline;
•	 Appraisal	 of	 the	 methodology	 and	 the	 content	 of	 the	 guideline	 by	 external
 experts.
This resulted in a partly evidence-based and partly expert-consensus-based guideli-
ne for screening, prevention and treatment of oral mucositis in patients treated with 
chemo- and/or radiation therapy. Besides the guideline, a summary card was made for 
daily practice. The guideline can be found at www.oncoline.nl
Chapter 9
Chapter 9 summarises the main findings of this thesis and describes the strengths and 
limitations of the studies involved. It further presents the main conclusions that may be 
drawn and recommendations for further research 
The main conclusions are: 
•	 Nurses	should	assess	the	oral	cavity	on	daily	basis	with	the	help	of	a	standardised	
 protocol;
•	 The	OMNI	is	a	valid,	reliable	and	feasible	assessment	instrument	for	daily	nursing
 heamatologic practice;
•	 Regular	oral	care	education	sessions	are	effective	for	improvement	of	nurses	know-
 ledge and skills in the area of oral care;
•	 Patients	should	receive	oral	care	as	described	in	an	evidence	and	consensus-based
 guideline;
•	 The	quality	of	existing	guidelines	is	limited,	the	National	guideline	developed	from
 a collaboration in relation to this thesis is based on a more transparent and critical 
 development process and summarises current evidence in this area evidence.
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               Samenvatting
Ontsteking van het mondslijmvlies, orale mucositis, komt veelvuldig voor bij patiënten 
die worden behandeld met chemo- of radiotherapie. Schattingen van de incidentie 
van mucositis lopen uiteen van rond de 40 procent bij standaard chemotherapie tot 
meer dan 75 procent van de patiënten die een stamceltransplantatie ondergaan. Na-
genoeg alle patiënten die in het hoofd-halsgebied worden bestraald ontwikkelen orale 
mucositis.
Roodheid, zwelling en pijn zijn de eerste verschijnselen van orale mucositis. Uitein-
delijk kunnen er zweren ontstaan die zo pijnlijk zijn dat de patiënt moeite krijgt met 
spreken, eten en drinken en dus ook moeite heeft om medicijnen te slikken. Dit kan 
weer tot gevolg hebben dat de behandeling tijdelijk moet worden gestopt. De pijn 
die patiënten ervaren kan zo hevig zijn dat pijnbestrijding met morfine nodig is. Orale 
mucositis heeft een sterk negatief effect op de kwaliteit van leven voor deze ernstig 
zieke patiënten. 
Verpleegkundigen geven vierentwintiguurszorg. Zij kunnen dan ook een belangrijke 
bijdrage leveren aan het voorkomen van ernstige vormen van orale mucositis. Boven-
dien zijn de verpleegkundigen de eerste bron van informatie over preventie en behan-
delingsmogelijkheden voor de patiënt. 
Dit proefschrift onderzoekt orale mucositis vanuit verpleegkundig oogpunt. 
Hoofdstuk 1
In de algemene introductie wordt achtergrondinformatie over de incidentie van orale 
mucositis gegeven en wordt uitgelegd hoe orale mucositis ontstaat. Daarnaast wordt 
er beschreven hoe orale mucositis er uitziet en wat dit betekent voor de patiënt. Pro-
bleemgebieden in de verpleegkundige zorg worden bediscussieerd. Een goede mond-
inspectie, om veranderingen vast te stellen en de ernst van de orale mucositis te bepa-
len, is de eerste belangrijke stap in de behandeling van orale mucositis. Een obstakel 
hierin is dat er geen universeel geaccepteerd meetinstrument voor handen is om dit 
gestandaardiseerd uit te voeren. Daarnaast is er onduidelijkheid over de evidence voor 
preventieve maatregelen en de behandeling van orale mucositis. Bovendien zijn veel 
maatregelen geen verpleegkundige interventies, maar alleen te gebruiken op dokters-
advies. Het is onbekend welke zorg verpleegkundigen nu precies geven aan patiënten 
die risico lopen op orale mucositis. 
Het doel van dit proefschrift is tweeledig:
1. Een inventariseren en evalueren van de hematologische verpleegkundige praktijk 
 in relatie tot orale mucositis en het geven van aanbevelingen om deze te ver-
 beteren;
2. Het evalueren van bestaande evidence voor de preventie en behandeling van orale
 mucositis en het evalueren van richtlijnen in de algemene oncologische zorg.
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Hoofdstuk 2
De verpleegkundige onderzoekssubgroep van de European Group for Blood and 
Marrow Transplantation (EBMT) heeft onderzoek gedaan naar de mening van verpleeg-
kundigen over de verpleegkundige aspecten van orale mucositis (OM). In de vragenlijst 
werd gevraagd naar hun mening over de klinische en economische consequenties van 
OM en gevolgen die OM heeft voor de kwaliteit van leven van patiënten. Tevens werden 
er vragen gesteld over de gebruikte meetinstrumenten om de ernst van OM te registe-
ren, strategieën voor de preventie en behandeling van OM en de behoefte aan ontwik-
keling en implementatie van richtlijnen. Verpleegkundigen van 46 transplantatie centra 
uit 16 Europese landen hebben de vragenlijst ingevuld. De meeste verpleegkundigen 
(91%) vinden dat OM een grote impact heeft op het welbevinden van de patiënt. Ver-
pleegkundigen zijn niet tevreden met de bestaande behandelingsmogelijkheden, maar 
geloven wel dat het ongemak dat patiënten ervaren kan worden verminderd door het 
geven van goede mondverzorging en het gebruik van mondspoelmiddelen. Ondanks 
het feit dat OM vaak voorkomt, bestaan er diverse verschillen in de behandeling van 
OM. In de meeste centra (70%) ontvangen patiënten met ernstige OM (graad 4 WHO) 
een behandeling, maar in 9% van de centra gebeurt dat niet. Aan de andere kant start 
33% van de centra hun behandeling al bij de eerste verschijnselen van OM. De meeste 
centra gebruiken eigen, centra- specifieke richtlijnen. Verpleegkundigen uit deze cen-
tra zijn van mening dat meer algemene (nationale) richtlijnen voor OM de zorg en be-
handeling van de betreffende patiënten kunnen standaardiseren en verbeteren. 
Hoofdstuk 3
Hoofdstuk 3 beschrijft de ontwikkeling van een nieuw meetinstrument voor de beoor-
deling van orale mucositis. Allereerst werd er een systematisch literatuur onderzoek 
verricht naar bestaande meetinstrumenten. Hierbij werden 21 meetinstrumenten ge-
vonden en bekeken op validiteit, betrouwbaarheid en bruikbaarheid. Een op alle on-
derdelen geschikt meetinstrument werd niet gevonden. 
De Oral Mucositis Nursing Instrument (OMNI) werd vervolgens ontwikkeld op basis 
van de zes meest voorkomende items uit het literatuuronderzoek. De OMNI werd in 
een hematologische context getest door paarsgewijs ervaren verpleegkundigen on-
afhankelijk van elkaar de mond van 26 patiënten te laten beoordelen. De interrater 
betrouwbaarheid, correlatie tussen de items en de interne consistentie van het instru-
ment als geheel werden hierbij berekend. De bruikbaarheid van het instrument werd 
geëvalueerd met behulp van een vragenlijst. De betrouwbaarheid van het instrument 
bleek voor de diverse onderdelen voldoende tot goed . De verpleegkundigen vonden 
de OMNI gebruiksvriendelijk en bruikbaar voor de dagelijkse praktijk.
Hieruit kan geconcludeerd worden dat de OM een valide, betrouwbaar en bruikbaar 
meetinstrument is voor de verpleegkundige zorg bij hematologische patiënten.
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Hoofdstuk 4
Een meetinstrument moet responsief zijn, dat wil zeggen, een meetinstrument moet in 
staat zijn om klinische veranderingen te constateren.
Om de OMNI te testen op responsiviteit werd het instrument uitgetest bij 32 stam-
celtransplantatiepatiënten. De evaluatie van orale mucositis startte op dag 7 van de 
behandeling en stopte op dag 28. Gedurende al deze dagen werd het beloop van orale 
mucositis met de OMNI gevolgd. 
De responsiviteit werd afgezet tegen het beloop volgens de Daily Mucositis Score (DMS) 
en op 2 manieren berekend. De Guyatt’s Responsiveness Index voor de OMNI bleek 2.2 
te zijn, wat betekent dat het instrument gevoelig is om veranderingen in orale muco-
sitis in de loop van de tijd te detecteren. De mogelijkheid van de OMNI om van dag tot 
dag verslechteringen of verbeteringen van orale mucositis te constateren werd daar-
naast berekend met behulp van Receiver Operating Characteristic (ROC) curve. Ook de 
ROC curve toonde aan dat de OMNI veranderingen van dag tot dag detecteert. 
Geconstateerd kan worden dat de OMNI bij toepassing voor stamceltransplantatie-
patiënten een responsief instrument is.
Hoofdstuk 5
In de literatuur is de meest genoemde aanbeveling voor de preventie en behande-
ling van orale mucositis goede mondzorg, er van uitgaande dat verpleegkundigen vol-
doende kennis en vaardigheden hebben om deze zorg goed uit te voeren.
Het doel van de studie in hoofdstuk 5 was om te inventariseren of kennis en vaardig-
heden van verpleegkundigen met betrekking tot mondzorg verbeteren wanneer extra 
lessen in mondverzorging gegeven worden. Deze interventiestudie bestond uit een 
nulmeting van kennis en vaardigheden bij verpleegkundigen die werkten op hemato-
logische afdelingen in twee verschillende ziekenhuizen. De lessen in mondzorg wer-
den gegeven in één van de twee ziekenhuizen, de afdeling in het andere ziekenhuis 
fungeerde als vergelijkingsgroep. Vervolgens vond de nameting plaats in beide zieken-
huizen. De metingen bestonden uit een kennistest, observaties tijdens de uitvoering 
van mondzorg en dossieronderzoek. 
Er werd een significant verschil gevonden in de scores op de kennistest voor en na 
de mondzorglessen in de interventiegroep, terwijl er geen verschil gevonden werd in 
de groep verpleegkundigen die geen mondzorgles hadden gehad. De dossiercheck 
toonde geen verschil tussen de nulmeting en de nameting voor beide groepen. De 
observaties toonden aan dat verpleegkundigen die de lessen hadden gevolgd het 
mondverzorgingsprotocol beter uitvoerden dan verpleegkundigen geen les hadden 
gehad. 
De conclusie van deze studie is dan ook dat mondzorglessen een positieve invloed 
hebben op de kennis en vaardigheden van hematologieverpleegkundigen die zorgen 
voor patiënten die risico lopen op orale mucositis. 
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Hoofdstuk 6 
Om uniformiteit te verkrijgen in het evalueren en beoordelen van orale mucositis zijn 
er richtlijnen nodig die aangeven hoe meetinstrumenten gebruikt moeten worden. Om 
dit te bereiken werd een multidisciplinaire groep samengesteld die bestond uit experts 
van twee Europese organisaties: de European Group for Blood and Marrow Transplanta-
tion (EBMT) en de European Oncology Nursing Society (EONS). Aanbevelingen werden 
geformuleerd op basis van een systematisch literatuuronderzoek en op basis van de 
expertise van de experts. De aanbevelingen omvatten een uitgebreide basisevaluatie 
en het regelmatige gebruik van een gestandaardiseerd meetinstrument of een combi-
natie van meetinstrumenten. Het gebruikte meetinstrument moet de mogelijkheid ge-
ven tot het evalueren van objectieve, subjectieve en functionele veranderingen. Het in-
strument dient valide te zijn, eenvoudig in het gebruik en comfortabel voor de patiënt. 
Het beoordelen van de mate van pijn bij de patiënt hoort deel te zijn van elke meeting. 
Tenslotte concludeert de expertgroep dat training in het gebruik van een meetinstru-
ment van vitaal belang is om orale mucositis correct te evalueren. 
Hoofdstuk 7
In de klinische praktijk wordt het dagelijkse gebruik van chloorhexidine als mondspoel-
middel vaak aanbevolen voor de preventie van chemotherapiegeïndiceerde orale muco-
sitis. Ook jodiumoplossing, NaCl 0.9%, een oplossing van zout en soda en kamillemond-
spoelmiddel worden vaak aanbevolen. De effectiviteit van deze mondspoelmiddelen is 
echter niet duidelijk. Daarom werd in een systematisch literatuuronderzoek nagegaan 
of deze mondspoelmiddelen bijdragen aan de preventie van orale mucositis. 
Na een kritische beoordeling van de kwaliteit van de geïncludeerde studies kwamen 
drie van de vijf studies die chloorhexidine onderzochten ter preventie van mucositis in 
aanmerking voor opname in een meta-analyse. Het resultaat van de meta-analyse liet 
geen significant effect zien voor chloorhexidine ten opzichte van steriel water of NaCl 
0.9%. Een aantal patiënten in de studies klaagde over tandverkleuring en een onaange-
name bittere smaak bij gebruik van chloorhexidine. 
Onderzoek naar het gebruik van jodiumoplossingen is zeer beperkt, maar liet wel een 
positief effect zien voor dit middel. Op basis van onze bevindingen kan het gebruik van 
chloorhexidine als mondspoelmiddel ter preventie van chemotherapiegeïndiceerde 
orale mucositis niet worden aanbevolen. Het gebruik van jodiumoplossing verdient 
nader onderzoek. 
Hoofdstuk 8 
Het doel van de studie in hoofdstuk 8 was het identificeren en beoordelen van de kwaliteit 
van richtlijnen en systematische reviews gericht op de preventie en behandeling van orale 
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mucositis bij patiënten die behandeld worden met chemotherapie en/of radiotherapie.
Voor het zoeken van literatuur werden verschillende databases en websites geraad-
pleegd. Richtlijnen en systematic reviews werden geïncludeerd  wanneer het orale mu-
cositis betrof bij volwassen patiënten die behandeld werden voor kanker en wanneer 
deze gepubliceerd waren na 1 januari 2000. De systematische reviews moesten mini-
maal een zoekstrategie beschrijven, minimaal moest er gezocht zijn in de databases 
PubMed of Medline en de artikelen in de review moesten methodologisch beoordeeld 
zijn. Om de kwaliteit van de richtlijnen te beoordelen werd het Appraisal of Guidelines 
for Research and Education (AGREE) instrument gebruikt. Om de kwaliteit van de sys-
tematisch reviews te beoordelen werd de Overview Quality Assessment Questionnaire 
(OQAQ) gebruikt. 
31 Bronnen werden geïncludeerd waarvan 11 richtlijnen en 20 systematische reviews. 
De kwaliteit varieerde sterk tussen de verschillende richtlijnen en systematische reviews. 
De meeste richtlijnen en systematische reviews hadden serieuze methodologische
tekortkomingen. Negen van de elf richtlijnen beschreven bijvoorbeeld niet expliciet 
hoe zij de gevonden evidence hadden geïdentificeerd, geselecteerd en samengevat. 
Op basis van deze resultaten en andere resultaten kon worden geconcludeerd dat de 
methodologische kwaliteit van richtlijnen en systematische reviews voor de preventie 
en behandeling van orale mucositis sterk verbeterd kan worden. 
Appendix
Waar hoofdstuk 8 de kwaliteit van bestaande richtlijnen en systematic reviews kritisch 
belicht, wordt in het appendix toegelicht hoe op basis van de beoordeling van de ge-
vonden systematic reviews een nieuwe richtlijn voor de preventie en behandeling van 
orale mucositis werd ontwikkeld. Het nemen van preventieve maatregelen en het in-
zetten van adequate zorg voor de behandeling van orale mucositis behoren immers 
tot de taken van oncologieverpleegkundigen maar de studie in hoofdstuk 8 toonde 
ook aan dat een geaccepteerde, met actuele kennis onderbouwde richtlijn ontbreekt 
hiervoor ontbrak. Om een (landelijke) richtlijn tot stand te brengen werd er een multi-
disciplinaire werkgroep van experts samengesteld. 
De ontwikkeling van de richtlijn bestond uit een aantal fases:
•	 Data	extractie	van	acht	systematische	reviews
•	 Expertbijeenkomsten	 om	op	 consensus	 gebaseerde	 aanbevelingen	 te	 formuleren
 daar waar geen evidence voor handen was en om het eerste concept van de richtlijn
 te bediscussiëren.
•	 Pilot-implementatie	 om	 de	 bruikbaarheid	 van	 de	 richtlijn	 te	 testen.	Verpleegkun-
 digen, artsen, mondhygiënisten en tandartsen gebruikten en evalueerden de richtlijn.
•	 Beoordeling	van	de	methodologische	kwaliteit	en	de	 inhoud	van	de	richtlijn	door
 externe experts. 
Dit alles resulteerde in een evidence-based richtlijn voor de preventie en behandeling 
van orale mucositis. 
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Hoofdstuk 9 
In hoofdstuk 9 worden de algemene bevindingen van dit proefschrift samengevat, de 
sterke en de zwakke punten van de betrokken studies worden besproken. Daarnaast 
worden de belangrijkste conclusies beschreven en aanbevelingen voor toekomstig on-
derzoek gegeven.
De belangrijkste conclusies zijn:
•	 Verpleegkundigen	moeten	bij	patiënten	met	risico	op	orale	mucositis	dagelijks	een
 mondinspectie uitvoeren met behulp van een gestandaardiseerd protocol;
•	 Mondzorglessen	zijn	effectief	bij	het	verbeteren	van	kennis	en	vaardigheden	van	ver-
 pleegkundigen bij het uitvoeren van mondzorg;
•	 Patiënten	moeten	mondzorg	ontvangen	zoals	die	beschreven	is	in	evidence	en	con-
 sensus gebaseerde richtlijnen;
•	 De	kwaliteit	van	bestaande	richtlijnen	is	beperkt.	De	nieuwe	nationale	richtlijn,	die	in
 een samenwerkingsverband is ontwikkeld en is gebaseerd op een transparant en kri-
 tisch ontwikkelingsproces, beschrijft de bestaande evidence uitgebreid en nauw-
 keurig.
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Dankwoord
Ofschoon de laatste loodjes het zwaarst wegen, ben ik blij dat het einde in zicht is en 
met het schrijven van dit dankwoord begin ik dan echt met de afronding van mijn proef-
schrift. Zonder de hulp van anderen kan een proefschrift nooit tot stand komen. Ik ben 
dan ook heel wat personen dank verschuldigd voor hun grote en kleine bijdragen.
Allereerst wil ik mijn promotor Theo van Achterberg bedanken. Theo, ik ervaar het als 
een voorrecht dat ik als verpleegkundige bij jou mag promoveren. Door het vertrou-
wen en de steun die je aan mij gaf, kon ik me ontwikkelen als onderzoeker en werd 
dit proefschrift gerealiseerd. Je was altijd weer in staat om kritisch te kijken naar mijn 
artikelen en vertrouwen te geven op het moment dat ik het even niet zag zitten. Theo, 
heel erg bedankt voor je geduld, je begeleiding, je positieve inslag, de kopjes thee en 
je gezellige praatjes. 
Mijn copromotoren, Nicole Blijlevens en Peter Donnelly, wil ik bedanken. Wat een team! 
Jullie zijn gedreven, kundig, dynamisch, enthousiast en heel gezellig. Ik ben er trots op 
dat ik jullie eerste gezamenlijke promovendus ben. We hebben wat tijd nodig gehad 
om elkaar goed te leren kennen. Maar na een congresbezoek in St. Gallen was alles in 
orde. Nicole, zoals je ziet lijken onze boekjes op elkaar. Jij was immers mijn grote voor-
beeld. Heel erg bedankt voor jouw onvoorwaardelijke ondersteuning. Ik hoop dat we in 
de toekomst nog zeer productief zullen zijn. Peter, you are one of the kindest and nicest 
persons I know. It was an honour to work with such a dedicated scientist. Many thanks 
for all your help as a ‘native speaker’ correcting sometimes my terrible Dutch English. (It 
is obvious you didn’t correct this part).
Graag wil ik de leden van de leescommissie, prof. dr. Kaanders, prof. dr. De Wit en
prof. dr. Merkx, hartelijk danken voor hun kritische beoordeling van dit proefschrift.
Verder dank aan alle co-auteurs voor het lezen en becommentariëren van de artikelen 
en/of ondersteuning bij de analyses: Wilma Scholte op Reimer, Ruud Uitterhoeve, Ton 
Feuth, Else Poot, Patriek Mistiaen en Arno Mank.
I thank the co-authors Becky Stone, Simon Clark, Michelle Davies, Mary Uhlenhopp, 
Barry Quinn, Anita Margulies and Lena Sharp. It has been an honour and pleasure to 
work with all of you.
Ik dank mijn collega’s van de PhD groep en ik wens jullie veel succes met de afronding 
van jullie projecten.
Mieke Walenkamp, voormalig manager zorg van het CIS cluster, wil ik bedanken voor de 
steun, ruimte en gelegenheid die zij mij bood om verpleegkundig onderzoek te doen. 
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Graag wil ik Marie-José Jorna, voormalig hoofdverpleegkundige van de afdeling hema-
tologie, bedanken. Marie-José, jij nam zitting in de begeleidingsgroep om het proces 
te bewaken. Maar je deed veel meer. Je moedigde aan, streek oneffenheden glad en je 
had altijd een luisterend oor, maar bovenal je geloofde in mij als verpleegkundig onder-
zoeker en als persoon. Nog steeds vind ik het jammer dat je weg bent gegaan. 
Mijn (ex) kamergenoten Toine Smiet, Maarten van Vliet en Elles Strijbosch hebben mij 
gesteund waar ze konden. Toine vooral in het begin heb ik heel erg op je geleund. 
Ondanks dat we zo verschillend zijn, konden we het heel goed met elkaar vinden. Je 
reis door het oosten is bijna voorbij, als je terug bent moeten we snel en lang bijpra-
ten. Maarten bedankt voor je interesse en het meeleven met mijn proefschrift. Dit is je 
voorland, het zal jou ook lukken. Tot die tijd kunnen we het nog vaak over andere zaken 
hebben, zoals voetballen en dan in het speciaal over NEC. Wie weet krijg ik daar ook 
verstand van. Elles, bedankt voor je belangstelling en gezelligheid. 
Alle verpleegkundigen, verpleegassistenten, secretaresses en voedingsassistenten van 
de afdeling E00 wil ik bedanken. Onze afdeling is een inspirerende afdeling, ik heb veel 
van jullie geleerd.
Met bewondering zie ik hoe jullie elke dag met toewijding professionele zorg verlenen 
aan onze ernstig zieke patiënten.
Ik bedank mijn paranimfen, Han Repping en Ton Verswijveren. Het idee dat jullie bij de 
openbare verdediging mij bijstaan, maakt voor mij de last wat lichter.
Han we delen veel met elkaar. Onze loopbaan als verpleegkundig onderzoeker liep zo 
goed als parallel. We zijn samen ‘druk’ geweest met subsidieaanvragen. Ik, bij het KWF; 
jij bij het Reumafonds. We hebben het beide niet gekregen. Maar we gingen stug door, 
dan maar zonder geld. Lief en leed werd tijdens onze lunches uitgebreid besproken. 
Han, je leefde mee als ik weer eens stoom moest afblazen en je vierde mee als er weer 
een artikel geaccepteerd werd. Het zal je zeker lukken om ook dit jaar te promoveren.
Ton, je bent al jarenlang een ontzettend dierbare vriend met wie ik alles kan delen. 
Ik hoop dat we deze bijzondere vriendschap nog heel lang kunnen voortzetten. Heel 
erg bedankt voor de mooie tekening op de kaft. Ton, we gaan gewoon door met het 
uittesten van restaurants, ook al hebben we een gelegenheid gevonden waar we gaan 
feesten.
 
Mijn moeder overleed nog voordat ik met dit promotietraject begon. Mijn vader over-
leed 2 jaar geleden. Pap en mam, wat zouden jullie trots geweest zijn. Maar ik weet dat 
mijn broers en zussen plaatsvervangend trots zullen zijn.
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Carin Potting is geboren op 15 september 1956 te Meerssen. Na het behalen van haar 
HAVO diploma in 1975 op de scholengemeenschap Stella Maris te Maastricht startte zij 
met de inservice opleiding in het St. Radboud ziekenhuis te Nijmegen. Na de afronding 
(1979) behaalde zij de kinderaantekening en dialyse-aantekening. Vervolgens heeft zij 
als verpleegkundig teamleider 18 jaar op de afdeling kinderdialyse in het UMCN St. 
Radboud gewerkt. Tijdens deze periode was zij gedurende 6 jaar bestuurslid van de 
European Dialysis and Transplant Nurses Association/European Renal Care Association 
(EDTNA/ERCA). Daarnaast studeerde zij in deeltijd Gezondheidswetenschappen.
Na haar afstuderen werd Carin beleidsmedewerker functiedifferentiatie voor het Clus-
ter Inwendige Specialismen (CIS) en verpleegkundig onderzoeker op de afdeling he-
matologie in het UMCN St. Radboud.
De klinische afdeling hematologie heeft een onderzoekslijn Supportive Care. Het me-
disch onderzoek naar Mucosal Barrier Injury is hierbinnen een belangrijke peiler. Het 
verpleegkundig onderzoek naar orale mucositis is een waardevolle aanvulling. Naast 
het verzorgen van gastcolleges op de HAN en de complementmodule hematologie 
geeft zij presentaties op het gebied van orale mucositis op congressen. Carin is lid van 
het research sub-committee van de  European Group for Blood and Marrow Transplan-
tation Nurses Group. Daarnaast is zij is lid van de Nursing Advisory Board of the Myelo-
dysplastic Syndromes Foundation.





